BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Wu YL, Zhou C, Hu CP, Feng J, Lu S, Huang Y, Li W, Hou M, Shi JH, Lee KY, Xu CR, Massey D, Kim M, Shi Y, Geater SL. Afatinib versus cisplatin plus gemcitabine for first-line treatment of Asian patients with advanced non-small-cell lung cancer harbouring EGFR mutations (LUX-Lung 6): an open-label, randomised phase 3 trial. Lancet Oncol. 2014;15:213-222. [PMID: 24439929 DOI: 10.1016/s1470-2045(13)70604-1] [Cited by in Crossref: 1094] [Cited by in F6Publishing: 666] [Article Influence: 136.8] [Reference Citation Analysis]
Number Citing Articles
1 Guo L, Chen Z, Xu C, Zhang X, Yan H, Su J, Yang J, Xie Z, Guo W, Li F, Wu Y, Zhou Q. Intratumoral heterogeneity of EGFR-activating mutations in advanced NSCLC patients at the single-cell level. BMC Cancer 2019;19:369. [PMID: 31014278 DOI: 10.1186/s12885-019-5555-y] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 2.3] [Reference Citation Analysis]
2 de Biase D, Genestreti G, Visani M, Acquaviva G, Di Battista M, Cavallo G, Paccapelo A, Cancellieri A, Trisolini R, Degli Esposti R, Bartolini S, Pession A, Tallini G, Brandes AA. The percentage of Epidermal Growth Factor Receptor (EGFR)-mutated neoplastic cells correlates to response to tyrosine kinase inhibitors in lung adenocarcinoma. PLoS One 2017;12:e0177822. [PMID: 28520821 DOI: 10.1371/journal.pone.0177822] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
3 Isla D, De Castro J, Juan O, Grau S, Orofino J, Gordo R, Rubio-Terrés C, Rubio-Rodríguez D. Costs of adverse events associated with erlotinib or afatinib in first-line treatment of advanced EGFR-positive non-small cell lung cancer. Clinicoecon Outcomes Res 2017;9:31-8. [PMID: 28115857 DOI: 10.2147/CEOR.S121093] [Cited by in Crossref: 13] [Cited by in F6Publishing: 4] [Article Influence: 2.2] [Reference Citation Analysis]
4 Waliany S, Zhu H, Wakelee H, Padda SK, Das M, Ramchandran K, Myall NJ, Chen T, Witteles RM, Neal JW. Pharmacovigilance Analysis of Cardiac Toxicities Associated With Targeted Therapies for Metastatic NSCLC. J Thorac Oncol 2021;16:2029-39. [PMID: 34418561 DOI: 10.1016/j.jtho.2021.07.030] [Reference Citation Analysis]
5 Melosky B, Banerji S, Blais N, Chu Q, Juergens R, Leighl NB, Liu G, Cheema P. Canadian consensus: a new systemic treatment algorithm for advanced EGFR-mutated non-small-cell lung cancer. Curr Oncol 2020;27:e146-55. [PMID: 32489263 DOI: 10.3747/co.27.6007] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
6 Wang CC, Lai CH, Chang YP, Chang HC, Tseng CC, Huang KT, Lin MC. Comparing survival and treatment response of patients with acquired T790M mutation second-line osimertinib versus sequential treatment of chemotherapy followed by osimertinib: A real-world study. Thorac Cancer 2021;12:3263-72. [PMID: 34704378 DOI: 10.1111/1759-7714.14198] [Reference Citation Analysis]
7 Hirsh V, Singh J. Optimal sequencing strategies in the treatment of EGFR mutation-positive non-small cell lung cancer: Clinical benefits and cost-effectiveness. Am J Health Syst Pharm 2020;77:1466-76. [PMID: 32885829 DOI: 10.1093/ajhp/zxaa197] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
8 Zhou Z, Zhu L, Niu X, Shen S, Zhao Y, Zhang J, Ye J, Han-Zhang H, Liu J, Liu C, Lu S. Comparison of genomic landscapes of large cell neuroendocrine carcinoma, small cell lung carcinoma, and large cell carcinoma. Thorac Cancer 2019;10:839-47. [PMID: 30793508 DOI: 10.1111/1759-7714.13011] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 2.3] [Reference Citation Analysis]
9 Buonerba C, Iaccarino S, Dolce P, Pagliuca M, Izzo M, Scafuri L, Costabile F, Riccio V, Ribera D, Mucci B, Carrano S, Picozzi F, Bosso D, Formisano L, Bianco R, De Placido S, Di Lorenzo G. Predictors of Outcomes in Patients with EGFR-Mutated Non-Small Cell Lung Cancer Receiving EGFR Tyrosine Kinase Inhibitors: A Systematic Review and Meta-Analysis. Cancers (Basel) 2019;11:E1259. [PMID: 31466227 DOI: 10.3390/cancers11091259] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
10 Nie X, Zhang P, Gao JY, Cheng G, Liu W, Li L. Sarcopenia as a predictor of initial administration dose of afatinib in patients with advanced non-small cell lung cancer. Thorac Cancer 2021;12:1824-30. [PMID: 33951292 DOI: 10.1111/1759-7714.13934] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
11 Sekine I. Are there any differences in genomic characterization of non-small cell lung cancer between African Americans and Whites? J Thorac Dis 2016;8:E1517-9. [PMID: 28066648 DOI: 10.21037/jtd.2016.11.65] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
12 Lu S, Shih JY, Jang TW, Liam CK, Yu Y. Afatinib as First-Line Treatment in Asian Patients with EGFR Mutation-Positive NSCLC: A Narrative Review of Real-World Evidence. Adv Ther 2021;38:2038-53. [PMID: 33730350 DOI: 10.1007/s12325-021-01696-9] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
13 Corre R, Gervais R, Guisier F, Tassy L, Vinas F, Lamy R, Fraboulet G, Greillier L, Doubre H, Descourt R, Chouaid C, Auliac JB. Octogenarians with EGFR-mutated non-small cell lung cancer treated by tyrosine-kinase inhibitor: a multicentric real-world study assessing tolerance and efficacy (OCTOMUT study). Oncotarget 2018;9:8253-62. [PMID: 29492192 DOI: 10.18632/oncotarget.23836] [Cited by in Crossref: 14] [Cited by in F6Publishing: 11] [Article Influence: 3.5] [Reference Citation Analysis]
14 Carmichael JA, Wing-San Mak D, O'Brien M. A Review of Recent Advances in the Treatment of Elderly and Poor Performance NSCLC. Cancers (Basel) 2018;10:E236. [PMID: 30021993 DOI: 10.3390/cancers10070236] [Cited by in Crossref: 13] [Cited by in F6Publishing: 16] [Article Influence: 3.3] [Reference Citation Analysis]
15 Sakamoto H, Tanaka H, Shiratori T, Baba K, Ishioka Y, Itoga M, Taima K, Hasegawa Y, Takanashi S, Tasaka S. The efficacy of immune checkpoint inhibitors in advanced non-small cell lung cancer harboring driver mutations. Mol Clin Oncol 2019;10:610-4. [PMID: 31031976 DOI: 10.3892/mco.2019.1838] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
16 Chu CY, Choi J, Eaby-Sandy B, Langer CJ, Lacouture ME. Osimertinib: A Novel Dermatologic Adverse Event Profile in Patients with Lung Cancer. Oncologist 2018;23:891-9. [PMID: 29650685 DOI: 10.1634/theoncologist.2017-0582] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 3.5] [Reference Citation Analysis]
17 Passiglia F, Rizzo S, Di Maio M, Galvano A, Badalamenti G, Listì A, Gulotta L, Castiglia M, Fulfaro F, Bazan V, Russo A. The diagnostic accuracy of circulating tumor DNA for the detection of EGFR-T790M mutation in NSCLC: a systematic review and meta-analysis. Sci Rep 2018;8:13379. [PMID: 30190486 DOI: 10.1038/s41598-018-30780-4] [Cited by in Crossref: 33] [Cited by in F6Publishing: 36] [Article Influence: 8.3] [Reference Citation Analysis]
18 Wu L, Zhong W, Li A, Qiu Z, Xie R, Shi H, Lu S. Successful treatment of EGFR T790M-mutant non-small cell lung cancer with almonertinib after osimertinib-induced interstitial lung disease: a case report and literature review. Ann Transl Med 2021;9:950. [PMID: 34350265 DOI: 10.21037/atm-21-2823] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
19 Schuler M, Tan EH, O'Byrne K, Zhang L, Boyer M, Mok T, Hirsh V, Yang JC, Lee KH, Lu S, Shi Y, Kim SW, Laskin J, Kim DW, Arvis CD, Kölbeck K, Massey D, Märten A, Paz-Ares L, Park K. First-line afatinib vs gefitinib for patients with EGFR mutation-positive NSCLC (LUX-Lung 7): impact of afatinib dose adjustment and analysis of mode of initial progression for patients who continued treatment beyond progression. J Cancer Res Clin Oncol 2019;145:1569-79. [PMID: 30783814 DOI: 10.1007/s00432-019-02862-x] [Cited by in Crossref: 19] [Cited by in F6Publishing: 20] [Article Influence: 6.3] [Reference Citation Analysis]
20 Daoud A, Chu QS. Targeting Novel but Less Common Driver Mutations and Chromosomal Translocations in Advanced Non-Small Cell Lung Cancer. Front Oncol 2017;7:222. [PMID: 29034207 DOI: 10.3389/fonc.2017.00222] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.6] [Reference Citation Analysis]
21 Cao F, Zhang L, Wang S, Zhong D, Wang Y. [Effectiveness of EGFR-TKIs versus chemotherapy as first-line treatment for advanced non-small cell lung cancer: a meta-analysis]. Zhongguo Fei Ai Za Zhi 2015;18:146-54. [PMID: 25800570 DOI: 10.3779/j.issn.1009-3419.2015.03.04] [Cited by in F6Publishing: 3] [Reference Citation Analysis]
22 Hong W, Wu Q, Zhang J, Zhou Y. Prognostic value of EGFR 19-del and 21-L858R mutations in patients with non-small cell lung cancer. Oncol Lett 2019;18:3887-95. [PMID: 31516600 DOI: 10.3892/ol.2019.10715] [Cited by in Crossref: 3] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
23 Cejalvo JM, Jacob W, Fleitas Kanonnikoff T, Felip E, Navarro Mendivil A, Martinez Garcia M, Taus Garcia A, Leighl N, Lassen U, Mau-Soerensen M, Adessi C, Michielin F, James I, Ceppi M, Hasmann M, Weisser M, Cervantes A. A phase Ib/II study of HER3-targeting lumretuzumab in combination with carboplatin and paclitaxel as first-line treatment in patients with advanced or metastatic squamous non-small cell lung cancer. ESMO Open 2019;4:e000532. [PMID: 31423336 DOI: 10.1136/esmoopen-2019-000532] [Cited by in Crossref: 4] [Cited by in F6Publishing: 6] [Article Influence: 1.3] [Reference Citation Analysis]
24 Aggarwal C, Borghaei H. Treatment Paradigms for Advanced Non-Small Cell Lung Cancer at Academic Medical Centers: Involvement in Clinical Trial Endpoint Design. Oncologist 2017;22:700-8. [PMID: 28408617 DOI: 10.1634/theoncologist.2016-0345] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 1.2] [Reference Citation Analysis]
25 Liu Y, Ren Z, Wang J, Zhang S. Epidermal growth factor receptor-tyrosine kinase inhibitor therapy is especially beneficial to patients with exon 19 deletion compared with exon 21 L858R mutation in non-small-cell lung cancer: Systematic review and meta analysis. Thorac Cancer 2016;7:406-14. [PMID: 27385982 DOI: 10.1111/1759-7714.12343] [Cited by in Crossref: 12] [Cited by in F6Publishing: 16] [Article Influence: 2.0] [Reference Citation Analysis]
26 Melosky B, Hirsh V. Management of Common Toxicities in Metastatic NSCLC Related to Anti-Lung Cancer Therapies with EGFR-TKIs. Front Oncol 2014;4:238. [PMID: 25279350 DOI: 10.3389/fonc.2014.00238] [Cited by in Crossref: 31] [Cited by in F6Publishing: 36] [Article Influence: 3.9] [Reference Citation Analysis]
27 Prabhash K. Treatment of advanced nonsmall cell lung cancer: First line, maintenance and second line - Indian consensus statement update. South Asian J Cancer 2019;8:1-17. [PMID: 30766843 DOI: 10.4103/sajc.sajc_227_18] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 2.5] [Reference Citation Analysis]
28 Choi H, Chang J, Shin HJ, Park CK, Oh IJ, Kim KS, Kim YC. Clinically beneficial continued treatment with gefitinib after asymptomatic progression of lung adenocarcinoma. Thorac Cancer 2015;6:224-6. [PMID: 26273363 DOI: 10.1111/1759-7714.12171] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
29 Li X, Zhao X, Li C, Liu S, Yan F, Teng Y, Feng J, Miao D. Inhibitor of ghrelin receptor reverses gefitinib resistance in lung cancer. Hum Cell 2019;32:360-6. [PMID: 31020605 DOI: 10.1007/s13577-019-00245-5] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
30 Paz-Ares L, Tan EH, O'Byrne K, Zhang L, Hirsh V, Boyer M, Yang JC, Mok T, Lee KH, Lu S, Shi Y, Lee DH, Laskin J, Kim DW, Laurie SA, Kölbeck K, Fan J, Dodd N, Märten A, Park K. Afatinib versus gefitinib in patients with EGFR mutation-positive advanced non-small-cell lung cancer: overall survival data from the phase IIb LUX-Lung 7 trial. Ann Oncol 2017;28:270-7. [PMID: 28426106 DOI: 10.1093/annonc/mdw611] [Cited by in Crossref: 230] [Cited by in F6Publishing: 237] [Article Influence: 46.0] [Reference Citation Analysis]
31 Proto C, Imbimbo M, Gallucci R, Brissa A, Signorelli D, Vitali M, Macerelli M, Corrao G, Ganzinelli M, Greco FG, Garassino MC, Lo Russo G. Epidermal growth factor receptor tyrosine kinase inhibitors for the treatment of central nervous system metastases from non-small cell lung cancer: the present and the future. Transl Lung Cancer Res 2016;5:563-78. [PMID: 28149752 DOI: 10.21037/tlcr.2016.10.16] [Cited by in Crossref: 21] [Cited by in F6Publishing: 25] [Article Influence: 3.5] [Reference Citation Analysis]
32 Feng S, Wang Y, Cai K, Wu H, Xiong G, Wang H, Zhang Z. Randomized Adjuvant Chemotherapy of EGFR-Mutated Non-Small Cell Lung Cancer Patients with or without Icotinib Consolidation Therapy. PLoS One 2015;10:e0140794. [PMID: 26474174 DOI: 10.1371/journal.pone.0140794] [Cited by in Crossref: 10] [Cited by in F6Publishing: 18] [Article Influence: 1.4] [Reference Citation Analysis]
33 Chang IS, Jiang SS, Yang JC, Su WC, Chien LH, Hsiao CF, Lee JH, Chen CY, Chen CH, Chang GC, Wang Z, Lo FY, Chen KY, Wang WC, Chen YM, Huang MS, Tsai YH, Su YC, Hsieh WS, Shih WC, Shieh SH, Yang TY, Lan Q, Rothman N, Chen CJ, Chanock SJ, Yang PC, Hsiung CA. Genetic Modifiers of Progression-Free Survival in Never-Smoking Lung Adenocarcinoma Patients Treated with First-Line Tyrosine Kinase Inhibitors. Am J Respir Crit Care Med 2017;195:663-73. [PMID: 27669169 DOI: 10.1164/rccm.201602-0300OC] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 2.0] [Reference Citation Analysis]
34 Cheng WC, Shen YC, Chien CR, Liao WC, Chen CH, Hsia TC, Tu CY, Chen HJ. The optimal therapy strategy for epidermal growth factor receptor-mutated non-small cell lung cancer patients with brain metastasis: A real-world study from Taiwan. Thorac Cancer 2022. [PMID: 35394114 DOI: 10.1111/1759-7714.14423] [Reference Citation Analysis]
35 O'Kane GM, Leighl NB. Systemic Therapy of Lung Cancer CNS Metastases Using Molecularly Targeted Agents and Immune Checkpoint Inhibitors. CNS Drugs 2018;32:527-42. [PMID: 29799091 DOI: 10.1007/s40263-018-0526-4] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 2.7] [Reference Citation Analysis]
36 Pasello G, Vicario G, Zustovich F, Oniga F, Gori S, Rosetti F, Bonetti A, Favaretto A, Toso S, Redelotti R, Santo A, Bernardi D, Giovanis P, Oliani C, Calvetti L, Gatti C, Palazzolo G, Baretta Z, Bortolami A, Bonanno L, Basso M, Menis J, Corte DD, Frega S, Guarneri V, Conte P; Veneto Oncology Network. From Diagnostic-Therapeutic Pathways to Real-World Data: A Multicenter Prospective Study on Upfront Treatment for EGFR-Positive Non-Small Cell Lung Cancer (MOST Study). Oncologist 2019;24:e318-26. [PMID: 30846513 DOI: 10.1634/theoncologist.2018-0712] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.7] [Reference Citation Analysis]
37 Fouad M, Helvenstein M, Blankert B. Ultra High Performance Liquid Chromatography Method for the Determination of Two Recently FDA Approved TKIs in Human Plasma Using Diode Array Detection. J Anal Methods Chem 2015;2015:215128. [PMID: 26101692 DOI: 10.1155/2015/215128] [Cited by in Crossref: 16] [Cited by in F6Publishing: 12] [Article Influence: 2.3] [Reference Citation Analysis]
38 Passaro A, Leighl N, Blackhall F, Popat S, Kerr K, Ahn MJ, Arcila ME, Arrieta O, Planchard D, de Marinis F, Dingemans AM, Dziadziuszko R, Faivre-Finn C, Feldman J, Felip E, Curigliano G, Herbst R, Jänne PA, John T, Mitsudomi T, Mok T, Normanno N, Paz-Ares L, Ramalingam S, Sequist L, Vansteenkiste J, Wistuba II, Wolf J, Wu YL, Yang SR, Yang JCH, Yatabe Y, Pentheroudakis G, Peters S. ESMO expert consensus statements on the management of EGFR mutant Non-Small Cell Lung Cancer. Ann Oncol 2022:S0923-7534(22)00112-0. [PMID: 35176458 DOI: 10.1016/j.annonc.2022.02.003] [Reference Citation Analysis]
39 Otsuka T, Tanaka A, Azukizawa H, Sasaki S, Ishijima M, Matsuki T, Osa A, Nakatani T, Kuroyama M, Hirata H, Kijima T. Successful treatment with gefitinib after Stevens-Johnson syndrome associated with afatinib therapy in a patient with adenocarcinoma of the lung. Int Cancer Conf J 2017;6:38-41. [PMID: 31149467 DOI: 10.1007/s13691-016-0269-3] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
40 Kulkarni AA, Fujioka N, Reinhardt L, Patel MR, Kratzke RA. Exceptional response to afatinib in a patient with persistent G719A EGFR-mutant NSCLC. Lung Cancer Manag 2022;11:LMT54. [PMID: 35463918 DOI: 10.2217/lmt-2021-0001] [Reference Citation Analysis]
41 Liu Z, Ou W, Li N, Wang SY. Apatinib monotherapy for advanced non-small cell lung cancer after the failure of chemotherapy or other targeted therapy. Thorac Cancer 2018;9:1285-90. [PMID: 30126078 DOI: 10.1111/1759-7714.12836] [Cited by in Crossref: 10] [Cited by in F6Publishing: 14] [Article Influence: 2.5] [Reference Citation Analysis]
42 Prasad V, Kumar H, Mailankody S. Ethics of Clinical Trials in Low-Resource Settings: Lessons From Recent Trials in Cancer Medicine. J Glob Oncol 2016;2:1-3. [PMID: 28717675 DOI: 10.1200/JGO.2015.000885] [Cited by in Crossref: 6] [Cited by in F6Publishing: 2] [Article Influence: 0.9] [Reference Citation Analysis]
43 Wei M, Korotkov KV, Blackburn JS. Targeting phosphatases of regenerating liver (PRLs) in cancer. Pharmacol Ther 2018;190:128-38. [PMID: 29859177 DOI: 10.1016/j.pharmthera.2018.05.014] [Cited by in Crossref: 16] [Cited by in F6Publishing: 13] [Article Influence: 4.0] [Reference Citation Analysis]
44 Hu J, Chen Y, Zhu X, Ma Q, Zhang J, Jiang G, Zhang P. Surgical choice of non-small cell lung cancer with unexpected pleural dissemination intraoperatively. BMC Cancer 2021;21:445. [PMID: 33888088 DOI: 10.1186/s12885-021-08180-1] [Reference Citation Analysis]
45 Xu J, Zhang X, Yang H, Ding G, Jin B, Lou Y, Zhang Y, Wang H, Han B. Comparison of outcomes of tyrosine kinase inhibitor in first- or second-line therapy for advanced non-small-cell lung cancer patients with sensitive EGFR mutations. Oncotarget 2016;7:68442-8. [PMID: 27637087 DOI: 10.18632/oncotarget.12035] [Cited by in Crossref: 5] [Cited by in F6Publishing: 8] [Article Influence: 1.3] [Reference Citation Analysis]
46 Wang J, Bai H, Hong C, Wang J, Mei TH. Analyzing epidermal growth factor receptor mutation status changes in advanced non-small-cell lung cancer at different sampling time-points of blood within one day. Thorac Cancer 2017;8:312-9. [PMID: 28437026 DOI: 10.1111/1759-7714.12443] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 1.2] [Reference Citation Analysis]
47 Mazza V, Cappuzzo F. Treating EGFR mutation resistance in non-small cell lung cancer - role of osimertinib. Appl Clin Genet 2017;10:49-56. [PMID: 28794650 DOI: 10.2147/TACG.S103471] [Cited by in Crossref: 14] [Cited by in F6Publishing: 8] [Article Influence: 2.8] [Reference Citation Analysis]
48 Guo B, Wei J, Wang J, Sun Y, Yuan J, Zhong Z, Meng F. CD44-targeting hydrophobic phosphorylated gemcitabine prodrug nanotherapeutics augment lung cancer therapy. Acta Biomater 2022;145:200-9. [PMID: 35430336 DOI: 10.1016/j.actbio.2022.04.016] [Reference Citation Analysis]
49 Lan B, Wang Y, Wu J, Wang K, Wang P. The predictive and prognostic effects of PD-L1 expression on TKI treatment and survival of EGFR-mutant NSCLC: A meta-analysis. Medicine (Baltimore) 2021;100:e27038. [PMID: 34449486 DOI: 10.1097/MD.0000000000027038] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
50 Pignata M, Chouaid C, Le Lay K, Luciani L, McConnachie C, Gordon J, Roze S. Evaluating the cost-effectiveness of afatinib after platinum-based therapy for the treatment of squamous non-small-cell lung cancer in France. Clinicoecon Outcomes Res 2017;9:655-68. [PMID: 29123418 DOI: 10.2147/CEOR.S136657] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 1.6] [Reference Citation Analysis]
51 Yang G, Liu C, Hu J, Sun Y, Hu P, Liu L, Xu H, Li D, Li W, Yang Y, Sun N, He J, Wang Y. The Lifted Veil of Uncommon EGFR Mutation p.L747P in Non-Small Cell Lung Cancer: Molecular Feature and Targeting Sensitivity to Tyrosine Kinase Inhibitors. Front Oncol 2022;12:843299. [DOI: 10.3389/fonc.2022.843299] [Reference Citation Analysis]
52 O'Kane GM, Leighl NB. Are immune checkpoint blockade monoclonal antibodies active against CNS metastases from NSCLC?-current evidence and future perspectives. Transl Lung Cancer Res 2016;5:628-36. [PMID: 28149757 DOI: 10.21037/tlcr.2016.09.05] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 1.7] [Reference Citation Analysis]
53 Andrews Wright NM, Goss GD. Third-generation epidermal growth factor receptor tyrosine kinase inhibitors for the treatment of non-small cell lung cancer. Transl Lung Cancer Res 2019;8:S247-64. [PMID: 31857949 DOI: 10.21037/tlcr.2019.06.01] [Cited by in Crossref: 18] [Cited by in F6Publishing: 19] [Article Influence: 6.0] [Reference Citation Analysis]
54 Khaddour K, Jonna S, Deneka A, Patel JD, Abazeed ME, Golemis E, Borghaei H, Boumber Y. Targeting the Epidermal Growth Factor Receptor in EGFR-Mutated Lung Cancer: Current and Emerging Therapies. Cancers (Basel) 2021;13:3164. [PMID: 34202748 DOI: 10.3390/cancers13133164] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
55 Wang J, Wang B, Chu H, Yao Y. Intrinsic resistance to EGFR tyrosine kinase inhibitors in advanced non-small-cell lung cancer with activating EGFR mutations. Onco Targets Ther 2016;9:3711-26. [PMID: 27382309 DOI: 10.2147/OTT.S106399] [Cited by in Crossref: 47] [Cited by in F6Publishing: 36] [Article Influence: 7.8] [Reference Citation Analysis]
56 Vengoji R, Macha MA, Nimmakayala RK, Rachagani S, Siddiqui JA, Mallya K, Gorantla S, Jain M, Ponnusamy MP, Batra SK, Shonka N. Afatinib and Temozolomide combination inhibits tumorigenesis by targeting EGFRvIII-cMet signaling in glioblastoma cells. J Exp Clin Cancer Res 2019;38:266. [PMID: 31215502 DOI: 10.1186/s13046-019-1264-2] [Cited by in Crossref: 22] [Cited by in F6Publishing: 21] [Article Influence: 7.3] [Reference Citation Analysis]
57 Ando Y, Hayashi T, Ujita M, Murai S, Ohta H, Ito K, Yamaguchi T, Funatsu M, Ikeda Y, Imaizumi K, Kawada K, Yasuda K, Yamada S. Effect of renal function on pemetrexed-induced haematotoxicity. Cancer Chemother Pharmacol 2016;78:183-9. [PMID: 27286996 DOI: 10.1007/s00280-016-3078-7] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.8] [Reference Citation Analysis]
58 Wang S, Min X, Yang Y, Pei G, Liu Q, Liu J, Huang Y. [Comprehensive Treatment of An Advanced Lung Cancer Patient with 
EGFR Driver Gene Positive]. Zhongguo Fei Ai Za Zhi 2021;24:447-52. [PMID: 34157804 DOI: 10.3779/j.issn.1009-3419.2021.101.20] [Reference Citation Analysis]
59 Califano R, Tariq N, Compton S, Fitzgerald DA, Harwood CA, Lal R, Lester J, McPhelim J, Mulatero C, Subramanian S, Thomas A, Thatcher N, Nicolson M. Expert Consensus on the Management of Adverse Events from EGFR Tyrosine Kinase Inhibitors in the UK. Drugs 2015;75:1335-48. [PMID: 26187773 DOI: 10.1007/s40265-015-0434-6] [Cited by in Crossref: 60] [Cited by in F6Publishing: 56] [Article Influence: 10.0] [Reference Citation Analysis]
60 Reungwetwattana T, Rohatgi N, Mok TS, Prabhash K. Dacomitinib as first-line treatment for EGFR mutation-positive non-small cell lung cancer. Expert Review of Precision Medicine and Drug Development 2021;6:161-71. [DOI: 10.1080/23808993.2021.1909420] [Reference Citation Analysis]
61 Guo K, Shao C, Han L, Liu H, Ma Z, Yang Y, Feng Y, Pan M, Santarpia M, Carmo-Fonseca M, Silveira C, Lee KY, Han J, Li X, Yan X. Detection of epidermal growth factor receptor (EGFR) mutations from preoperative circulating tumor DNA (ctDNA) as a prognostic predictor for stage I-III non-small cell lung cancer (NSCLC) patients with baseline tissue EGFR mutations. Transl Lung Cancer Res 2021;10:3213-25. [PMID: 34430359 DOI: 10.21037/tlcr-21-530] [Reference Citation Analysis]
62 Vergoulidou M. More than a Decade of Tyrosine Kinase Inhibitors in the Treatment of Solid Tumors: What We Have Learned and What the Future Holds. Biomark Insights 2015;10:33-40. [PMID: 26483606 DOI: 10.4137/BMI.S22436] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 0.9] [Reference Citation Analysis]
63 Jiang X, Guan J, Xu Y, Ren H, Jiang J, Wudu M, Wang Q, Su H, Zhang Y, Zhang B, Zou Z, Hu Y, Sun X, Qiu X. Silencing of CASC8 inhibits non-small cell lung cancer cells function and promotes sensitivity to osimertinib via FOXM1. J Cancer 2021;12:387-96. [PMID: 33391435 DOI: 10.7150/jca.47863] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
64 Vyse S, Huang PH. Targeting EGFR exon 20 insertion mutations in non-small cell lung cancer. Signal Transduct Target Ther 2019;4:5. [PMID: 30854234 DOI: 10.1038/s41392-019-0038-9] [Cited by in Crossref: 81] [Cited by in F6Publishing: 81] [Article Influence: 27.0] [Reference Citation Analysis]
65 Akamatsu H, Ninomiya K, Kenmotsu H, Morise M, Daga H, Goto Y, Kozuki T, Miura S, Sasaki T, Tamiya A, Teraoka S, Tsubata Y, Yoshioka H, Hattori Y, Imamura CK, Katsuya Y, Matsui R, Minegishi Y, Mizugaki H, Nosaki K, Okuma Y, Sakamoto S, Sone T, Tanaka K, Umemura S, Yamanaka T, Amano S, Hasegawa K, Morita S, Nakajima K, Maemondo M, Seto T, Yamamoto N. The Japanese Lung Cancer Society Guideline for non-small cell lung cancer, stage IV. Int J Clin Oncol 2019;24:731-70. [PMID: 31049758 DOI: 10.1007/s10147-019-01431-z] [Cited by in Crossref: 33] [Cited by in F6Publishing: 40] [Article Influence: 11.0] [Reference Citation Analysis]
66 Zou B, Lee VHF, Chen L, Ma L, Wang DD, Yan H. Deciphering mechanisms of acquired T790M mutation after EGFR inhibitors for NSCLC by computational simulations. Sci Rep 2017;7:6595. [PMID: 28747773 DOI: 10.1038/s41598-017-06632-y] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 3.0] [Reference Citation Analysis]
67 Oser MG, Niederst MJ, Sequist LV, Engelman JA. Transformation from non-small-cell lung cancer to small-cell lung cancer: molecular drivers and cells of origin. Lancet Oncol. 2015;16:e165-e172. [PMID: 25846096 DOI: 10.1016/s1470-2045(14)71180-5] [Cited by in Crossref: 331] [Cited by in F6Publishing: 248] [Article Influence: 47.3] [Reference Citation Analysis]
68 Tran HT, Lam VK, Elamin YY, Hong L, Colen R, Elshafeey NA, Hassan ISA, Altan M, Blumenschein GR, Rinsurongkawong W, Rivera MJ, Vasquez ME, Carter BW, Byers LE, Tsao AS, Gibbons DL, Fossella F, Glisson BS, Zhang J, Heymach JV. Clinical Outcomes in Non-Small-Cell Lung Cancer Patients Treated With EGFR-Tyrosine Kinase Inhibitors and Other Targeted Therapies Based on Tumor Versus Plasma Genomic Profiling. JCO Precis Oncol 2021;5:PO. [PMID: 34377884 DOI: 10.1200/PO.20.00532] [Reference Citation Analysis]
69 Sellmann L, Fenchel K, Dempke WC. Improved overall survival following tyrosine kinase inhibitor treatment in advanced or metastatic non-small-cell lung cancer-the Holy Grail in cancer treatment? Transl Lung Cancer Res 2015;4:223-7. [PMID: 26207209 DOI: 10.3978/j.issn.2218-6751.2015.03.01] [Cited by in F6Publishing: 10] [Reference Citation Analysis]
70 Holleman MS, Al MJ, Zaim R, Groen HJM, Uyl-de Groot CA. Cost-effectiveness analysis of the first-line EGFR-TKIs in patients with non-small cell lung cancer harbouring EGFR mutations. Eur J Health Econ 2020;21:153-64. [PMID: 31541309 DOI: 10.1007/s10198-019-01117-3] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 3.7] [Reference Citation Analysis]
71 Gelatti ACZ, Drilon A, Santini FC. Optimizing the sequencing of tyrosine kinase inhibitors (TKIs) in epidermal growth factor receptor (EGFR) mutation-positive non-small cell lung cancer (NSCLC). Lung Cancer. 2019;137:113-122. [PMID: 31568888 DOI: 10.1016/j.lungcan.2019.09.017] [Cited by in Crossref: 40] [Cited by in F6Publishing: 42] [Article Influence: 13.3] [Reference Citation Analysis]
72 Serra-solé Ò, Pujol-riqué M, Camacho-cuartero L. Long progression-free survival with afatinib in a patient with heavily pretreated lung adenocarcinoma without common activating EGFR mutations. Lung Cancer Management 2015;4:263-9. [DOI: 10.2217/lmt.15.20] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
73 Bai Y, Chen X, Hou L, Qian J, Jiang T, Zhou C, Ciebiada M. PD-L1 expression and its effect on clinical outcomes of EGFR-mutant NSCLC patients treated with EGFR-TKIs. Cancer Biol Med 2018;15:434-42. [PMID: 30766753 DOI: 10.20892/j.issn.2095-3941.2018.0223] [Cited by in Crossref: 9] [Cited by in F6Publishing: 12] [Article Influence: 2.3] [Reference Citation Analysis]
74 Zhao B, Wang Y, Wang Y, Chen W, Zhou L, Liu PH, Kong Z, Dai C, Wang Y, Ma W. Efficacy and safety of therapies for EGFR-mutant non-small cell lung cancer with brain metastasis: an evidence-based Bayesian network pooled study of multivariable survival analyses. Aging (Albany NY) 2020;12:14244-70. [PMID: 32669477 DOI: 10.18632/aging.103455] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
75 Robichaux JP, Le X, Vijayan RSK, Hicks JK, Heeke S, Elamin YY, Lin HY, Udagawa H, Skoulidis F, Tran H, Varghese S, He J, Zhang F, Nilsson MB, Hu L, Poteete A, Rinsurongkawong W, Zhang X, Ren C, Liu X, Hong L, Zhang J, Diao L, Madison R, Schrock AB, Saam J, Raymond V, Fang B, Wang J, Ha MJ, Cross JB, Gray JE, Heymach JV. Structure-based classification predicts drug response in EGFR-mutant NSCLC. Nature 2021;597:732-7. [PMID: 34526717 DOI: 10.1038/s41586-021-03898-1] [Cited by in Crossref: 4] [Article Influence: 4.0] [Reference Citation Analysis]
76 Wen M, Xia J, Sun Y, Wang X, Fu X, Zhang Y, Zhang Z, Zhou Y, Li X. Combination of EGFR-TKIs with chemotherapy versus chemotherapy or EGFR-TKIs alone in advanced NSCLC patients with EGFR mutation. Biologics 2018;12:183-90. [PMID: 30555222 DOI: 10.2147/BTT.S169305] [Cited by in Crossref: 5] [Cited by in F6Publishing: 7] [Article Influence: 1.3] [Reference Citation Analysis]
77 Hong S, Fang W, Hu Z, Zhou T, Yan Y, Qin T, Tang Y, Ma Y, Zhao Y, Xue C, Huang Y, Zhao H, Zhang L. A large-scale cross-sectional study of ALK rearrangements and EGFR mutations in non-small-cell lung cancer in Chinese Han population. Sci Rep 2014;4:7268. [PMID: 25434695 DOI: 10.1038/srep07268] [Cited by in Crossref: 16] [Cited by in F6Publishing: 21] [Article Influence: 2.0] [Reference Citation Analysis]
78 Formisano L, Jansen VM, Marciano R, Bianco R. From Biology to Therapy: Improvements of Therapeutic Options in Lung Cancer. Anticancer Agents Med Chem 2018;18:1235-40. [PMID: 28901258 DOI: 10.2174/1871520617666170912123416] [Cited by in Crossref: 3] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
79 Shi Y, Sun Y, Yu J, Ding C, Wang Z, Wang C, Wang D, Wang C, Wang Z, Wang M, Zhi X, Lu Y, Feng J, Liu Y, Liu X, Liu W, Wu G, Li X, Li K, Li E, Li W, Chen G, Chen Z, Yu P, Wu N, Wu M, Xiao W, Zhang L, Zhang Y, Zhang S, Yang S, Song X, Lin D, Luo R, Shan L, Zhou C, Zhou Z, Zhao Q, Hu C, Hu Y, Guo Q, Chang J, Huang C, Zeng X, Han B, Han X, Jia B, Han Y, Huang Y. [China Experts Consensus on the Diagnosis and Treatment of Advanced Stage Primary Lung Cancer (2016 Version)]. Zhongguo Fei Ai Za Zhi 2016;19:1-15. [PMID: 26805732 DOI: 10.3779/j.issn.1009-3419.2016.01.01] [Cited by in F6Publishing: 14] [Reference Citation Analysis]
80 Yu KL, Tsai TH, Ho CC, Liao WY, Lin CK, Hsu CL, Shih JY. The value of radial endobronchial ultrasound-guided bronchial brushing in peripheral non-squamous non-small cell lung cancer. Sci Rep 2018;8:5837. [PMID: 29643378 DOI: 10.1038/s41598-018-24300-7] [Cited by in Crossref: 5] [Cited by in F6Publishing: 7] [Article Influence: 1.3] [Reference Citation Analysis]
81 Hayashi H, Nadal E, Gray JE, Ardizzoni A, Caria N, Puri T, Grohe C. Overall Treatment Strategy for Patients With Metastatic NSCLC With Activating EGFR Mutations. Clin Lung Cancer 2021:S1525-7304(21)00273-4. [PMID: 34865963 DOI: 10.1016/j.cllc.2021.10.009] [Reference Citation Analysis]
82 Leventakos K, Kipp BR, Rumilla KM, Winters JL, Yi ES, Mansfield AS. S768I Mutation in EGFR in Patients with Lung Cancer. J Thorac Oncol 2016;11:1798-801. [PMID: 27211795 DOI: 10.1016/j.jtho.2016.05.007] [Cited by in Crossref: 30] [Cited by in F6Publishing: 32] [Article Influence: 5.0] [Reference Citation Analysis]
83 Takayuki N, Keiko T, Junji U, Yoshiko K, Nobuyo T, Tadaaki Y, Koichi T. Advanced Non-Small-Cell Lung Cancer in Elderly Patients: Patient Features and Therapeutic Management. Biomed Res Int 2018;2018:8202971. [PMID: 29854794 DOI: 10.1155/2018/8202971] [Cited by in Crossref: 6] [Cited by in F6Publishing: 10] [Article Influence: 1.5] [Reference Citation Analysis]
84 Yip HYK, Papa A. Signaling Pathways in Cancer: Therapeutic Targets, Combinatorial Treatments, and New Developments. Cells 2021;10:659. [PMID: 33809714 DOI: 10.3390/cells10030659] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
85 Yang B, Ji HS, Zhou CS, Dong H, Ma L, Ge YQ, Zhu CH, Tian JH, Zhang LJ, Zhu H, Lu GM. 18F-fluorodeoxyglucose positron emission tomography/computed tomography-based radiomic features for prediction of epidermal growth factor receptor mutation status and prognosis in patients with lung adenocarcinoma. Transl Lung Cancer Res 2020;9:563-74. [PMID: 32676320 DOI: 10.21037/tlcr-19-592] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 2.5] [Reference Citation Analysis]
86 Hasegawa Y, Ando M, Maemondo M, Yamamoto S, Isa S, Saka H, Kubo A, Kawaguchi T, Takada M, Rosell R, Kurata T, Ou SH. The role of smoking status on the progression-free survival of non-small cell lung cancer patients harboring activating epidermal growth factor receptor (EGFR) mutations receiving first-line EGFR tyrosine kinase inhibitor versus platinum doublet chemotherapy: a meta-analysis of prospective randomized trials. Oncologist 2015;20:307-15. [PMID: 25657199 DOI: 10.1634/theoncologist.2014-0285] [Cited by in Crossref: 24] [Cited by in F6Publishing: 32] [Article Influence: 3.4] [Reference Citation Analysis]
87 Zhu J, Yang Q, Xu W. Iterative Upgrading of Small Molecular Tyrosine Kinase Inhibitors for EGFR Mutation in NSCLC: Necessity and Perspective. Pharmaceutics 2021;13:1500. [PMID: 34575576 DOI: 10.3390/pharmaceutics13091500] [Reference Citation Analysis]
88 Abdallah SM, Wong A. Brain metastases in non-small-cell lung cancer: are tyrosine kinase inhibitors and checkpoint inhibitors now viable options? Curr Oncol 2018;25:S103-14. [PMID: 29910653 DOI: 10.3747/co.25.3733] [Cited by in Crossref: 25] [Cited by in F6Publishing: 22] [Article Influence: 6.3] [Reference Citation Analysis]
89 Liu K, Zhang W, Tan Q, Jiang G, Jia J. Antibiotic use is a negative predictor of the efficacy and toxicity of epidermal growth factor receptor-targeted therapy in advanced non-small cell lung cancer. Oncol Lett 2019;18:2677-83. [PMID: 31404289 DOI: 10.3892/ol.2019.10481] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
90 Tan WL, Ng QS, Lim C, Tan EH, Toh CK, Ang MK, Kanesvaran R, Jain A, Tan DSW, Lim DW. Influence of afatinib dose on outcomes of advanced EGFR-mutant NSCLC patients with brain metastases. BMC Cancer 2018;18:1198. [PMID: 30509246 DOI: 10.1186/s12885-018-5110-2] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 2.0] [Reference Citation Analysis]
91 Brascia D, De Iaco G, Schiavone M, Panza T, Signore F, Geronimo A, Sampietro D, Montrone M, Galetta D, Marulli G. Resectable IIIA-N2 Non-Small-Cell Lung Cancer (NSCLC): In Search for the Proper Treatment. Cancers (Basel) 2020;12:E2050. [PMID: 32722386 DOI: 10.3390/cancers12082050] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
92 Anand K, Ensor J, Trachtenberg B, Bernicker EH. Osimertinib-Induced Cardiotoxicity: A Retrospective Review of the FDA Adverse Events Reporting System (FAERS). JACC CardioOncol 2019;1:172-8. [PMID: 34396179 DOI: 10.1016/j.jaccao.2019.10.006] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 2.7] [Reference Citation Analysis]
93 Spaans JN, Goss GD. Trials to Overcome Drug Resistance to EGFR and ALK Targeted Therapies - Past, Present, and Future. Front Oncol 2014;4:233. [PMID: 25221748 DOI: 10.3389/fonc.2014.00233] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 1.0] [Reference Citation Analysis]
94 Spicer J, Irshad S, Ang JE, Enting D, Kristeleit R, Uttenreuther-Fischer M, Pemberton K, Pelling K, Schnell D, de Bono J. A phase I study of afatinib combined with paclitaxel and bevacizumab in patients with advanced solid tumors. Cancer Chemother Pharmacol 2017;79:17-27. [PMID: 27872953 DOI: 10.1007/s00280-016-3189-1] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
95 Garinet S, Laurent-Puig P, Blons H, Oudart JB. Current and Future Molecular Testing in NSCLC, What Can We Expect from New Sequencing Technologies? J Clin Med. 2018;7. [PMID: 29890761 DOI: 10.3390/jcm7060144] [Cited by in Crossref: 32] [Cited by in F6Publishing: 29] [Article Influence: 8.0] [Reference Citation Analysis]
96 Wang H, Guo R, Zhang L. [TKI Resistance for T790M Mutation]. Zhongguo Fei Ai Za Zhi 2015;18:245-50. [PMID: 25936890 DOI: 10.3779/j.issn.1009-3419.2015.04.10] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
97 Santarpia M, Liguori A, Karachaliou N, Gonzalez-Cao M, Daffinà MG, D'Aveni A, Marabello G, Altavilla G, Rosell R. Osimertinib in the treatment of non-small-cell lung cancer: design, development and place in therapy. Lung Cancer (Auckl) 2017;8:109-25. [PMID: 28860885 DOI: 10.2147/LCTT.S119644] [Cited by in Crossref: 16] [Cited by in F6Publishing: 25] [Article Influence: 3.2] [Reference Citation Analysis]
98 Chukwueke UN, Brastianos PK. Precision Medical Approaches to the Diagnoses and Management of Brain Metastases. Curr Treat Options Oncol 2019;20:49. [PMID: 31062107 DOI: 10.1007/s11864-019-0649-y] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
99 Popat S, Jung HA, Lee SY, Hochmair MJ, Lee SH, Escriu C, Lee MK, Migliorino MR, Lee YC, Girard N, Daoud H, Märten A, Miura S. Sequential afatinib and osimertinib in patients with EGFR mutation-positive NSCLC and acquired T790M: A global non-interventional study (UpSwinG). Lung Cancer 2021;162:9-15. [PMID: 34649106 DOI: 10.1016/j.lungcan.2021.09.009] [Reference Citation Analysis]
100 Arrieta O, Carmona A, de Jesus Vega MT, Lopez-Mejia M, Cardona AF. Skin communicates what we deeply feel: antibiotic prophylactic treatment to reduce epidermal growth factor receptor inhibitors induced rash in lung cancer (the Pan Canadian rash trial). Ann Transl Med 2016;4:313. [PMID: 27668233 DOI: 10.21037/atm.2016.08.19] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
101 Rybarczyk-Kasiuchnicz A, Ramlau R, Stencel K. Treatment of Brain Metastases of Non-Small Cell Lung Carcinoma. Int J Mol Sci 2021;22:E593. [PMID: 33435596 DOI: 10.3390/ijms22020593] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
102 Davies RS, Smith C, Edwards G, Butler R, Parry D, Lester JF. Impact of Cytological Sampling on EGFR Mutation Testing in Stage III-IV Lung Adenocarcinoma. Lung Cancer Int 2017;2017:9614938. [PMID: 28367333 DOI: 10.1155/2017/9614938] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 0.4] [Reference Citation Analysis]
103 Dholaria B, Hammond W, Shreders A, Lou Y. Emerging therapeutic agents for lung cancer. J Hematol Oncol 2016;9:138. [PMID: 27938382 DOI: 10.1186/s13045-016-0365-z] [Cited by in Crossref: 51] [Cited by in F6Publishing: 59] [Article Influence: 8.5] [Reference Citation Analysis]
104 Saito Y, Matsui A, Michiyuki S, Morooka H, Ibi T, Yamauchi Y, Takahashi N, Shimizu Y, Ikeya T, Hoshi E, Sakao Y, Kawamura M. Loop-Mediated Isothermal Amplification as Point-of-Care Testing for EGFR-Mutated Lung Adenocarcinoma. Micromachines 2022;13:897. [DOI: 10.3390/mi13060897] [Reference Citation Analysis]
105 Kuo SW, Chen PH, Lu TP, Chen KC, Liao HC, Tsou KC, Tsai TM, Lin MW, Hsu HH, Chen JS. Primary Tumor Resection for Stage IV Non-small-cell Lung Cancer Without Progression After First-Line Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitor Treatment: A Retrospective Case-Control Study. Ann Surg Oncol 2022. [PMID: 35254583 DOI: 10.1245/s10434-022-11483-7] [Reference Citation Analysis]
106 Su PL, Chen CW, Wu YL, Lin CC, Su WC. First-line treatment with irreversible tyrosine kinase inhibitors associated with longer OS in EGFR mutation-positive non-small cell lung cancer. Thorac Cancer 2021;12:287-96. [PMID: 33336895 DOI: 10.1111/1759-7714.13462] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
107 Xu Z, Qin F, Yuan L, Wei J, Sun Y, Qin J, Deng K, Zheng T, Li S. EGFR DNA Methylation Correlates With EGFR Expression, Immune Cell Infiltration, and Overall Survival in Lung Adenocarcinoma. Front Oncol 2021;11:691915. [PMID: 34447695 DOI: 10.3389/fonc.2021.691915] [Reference Citation Analysis]
108 Tanaka F, Yoneda K. Adjuvant therapy following surgery in non-small cell lung cancer (NSCLC). Surg Today 2016;46:25-37. [PMID: 25925615 DOI: 10.1007/s00595-015-1174-7] [Cited by in Crossref: 18] [Cited by in F6Publishing: 22] [Article Influence: 2.6] [Reference Citation Analysis]
109 Li X, Xing S, Dong Q. Epidermal growth factor receptor-mutant lung cancer in Down syndrome: a case presentation and review of the literature. Oncotarget 2017;8:55760-5. [PMID: 28903458 DOI: 10.18632/oncotarget.17406] [Cited by in Crossref: 1] [Article Influence: 0.2] [Reference Citation Analysis]
110 Takahama T, Sakai K, Takeda M, Azuma K, Hida T, Hirabayashi M, Oguri T, Tanaka H, Ebi N, Sawa T, Bessho A, Tachihara M, Akamatsu H, Bandoh S, Himeji D, Ohira T, Shimokawa M, Nakanishi Y, Nakagawa K, Nishio K. Detection of the T790M mutation of EGFR in plasma of advanced non-small cell lung cancer patients with acquired resistance to tyrosine kinase inhibitors (West Japan oncology group 8014LTR study). Oncotarget 2016;7:58492-9. [PMID: 27542267 DOI: 10.18632/oncotarget.11303] [Cited by in Crossref: 44] [Cited by in F6Publishing: 48] [Article Influence: 11.0] [Reference Citation Analysis]
111 Isaka T, Ito H, Nakayama H, Yokose T, Saito H, Adachi H, Miura J, Shigefuku S, Kikuchi A, Rino Y. Effect of epidermal growth factor receptor gene mutation on the prognosis of pathological stage II-IIIA (8th edition TNM classification) primary lung cancer after curative surgery. Lung Cancer 2021;162:128-34. [PMID: 34775216 DOI: 10.1016/j.lungcan.2021.11.002] [Reference Citation Analysis]
112 Pasini L, Notarangelo M, Vagheggini A, Burgio MA, Crinò L, Chiadini E, Prochowski AI, Delmonte A, Ulivi P, D'Agostino VG. Unveiling mutational dynamics in non-small cell lung cancer patients by quantitative EGFR profiling in vesicular RNA. Mol Oncol 2021;15:2423-38. [PMID: 33942501 DOI: 10.1002/1878-0261.12976] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
113 Hopkins AM, Nguyen AM, Karapetis CS, Rowland A, Sorich MJ. Risk Factors for Severe Diarrhea with an Afatinib Treatment of Non-Small Cell Lung Cancer: A Pooled Analysis of Clinical Trials. Cancers (Basel) 2018;10:E384. [PMID: 30326638 DOI: 10.3390/cancers10100384] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.8] [Reference Citation Analysis]
114 Zhai H, Zhong W, Yang X, Wu YL. Neoadjuvant and adjuvant epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) therapy for lung cancer. Transl Lung Cancer Res 2015;4:82-93. [PMID: 25806348 DOI: 10.3978/j.issn.2218-6751.2014.11.08] [Cited by in F6Publishing: 17] [Reference Citation Analysis]
115 Zhang L, Chen B, Liu X, Song J, Fang M, Hu C, Dong D, Li W, Tian J. Quantitative Biomarkers for Prediction of Epidermal Growth Factor Receptor Mutation in Non-Small Cell Lung Cancer. Transl Oncol 2018;11:94-101. [PMID: 29216508 DOI: 10.1016/j.tranon.2017.10.012] [Cited by in Crossref: 42] [Cited by in F6Publishing: 41] [Article Influence: 8.4] [Reference Citation Analysis]
116 Takeda M, Nakagawa K. First- and Second-Generation EGFR-TKIs Are All Replaced to Osimertinib in Chemo-Naive EGFR Mutation-Positive Non-Small Cell Lung Cancer? Int J Mol Sci 2019;20:E146. [PMID: 30609789 DOI: 10.3390/ijms20010146] [Cited by in Crossref: 58] [Cited by in F6Publishing: 45] [Article Influence: 19.3] [Reference Citation Analysis]
117 Wang A, Zhang X, Yi J, Zhu M, Zhang Y. Successful treatment of advanced lung adenocarcinoma complicated with Lambert-Eaton myasthenic syndrome: A case report and literature review. Thorac Cancer 2020;11:1334-8. [PMID: 32154996 DOI: 10.1111/1759-7714.13385] [Reference Citation Analysis]
118 Lin JJ, Shaw AT. Resisting Resistance: Targeted Therapies in Lung Cancer. Trends Cancer 2016;2:350-64. [PMID: 27819059 DOI: 10.1016/j.trecan.2016.05.010] [Cited by in Crossref: 78] [Cited by in F6Publishing: 72] [Article Influence: 19.5] [Reference Citation Analysis]
119 Wu M, Pan X, Xu Y, Wu S, Wu X, Chen B. Methodological comparison of the allele refractory mutation system and direct sequencing for detecting EGFR mutations in NSCLC, and the association of EGFR mutations with patient characteristics. Oncol Lett 2018;16:1087-94. [PMID: 30061936 DOI: 10.3892/ol.2018.8775] [Cited by in F6Publishing: 3] [Reference Citation Analysis]
120 Tokudome N, Koh Y, Akamatsu H, Fujimoto D, Okamoto I, Nakagawa K, Hida T, Imamura F, Morita S, Yamamoto N. Differential significance of molecular subtypes which were classified into EGFR exon 19 deletion on the first line afatinib monotherapy. BMC Cancer 2020;20:103. [PMID: 32028909 DOI: 10.1186/s12885-020-6593-1] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
121 Wang S, Xing P, Yang K, Hao X, Ma D, Mu Y, Li J. Efficacy and safety of afatinib in a Chinese population with advanced lung adenocarcinoma with sensitive EGFR mutations. Thorac Cancer 2019;10:1461-8. [PMID: 31095895 DOI: 10.1111/1759-7714.13095] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.3] [Reference Citation Analysis]
122 Matsuo N, Azuma K, Sakai K, Hattori S, Kawahara A, Ishii H, Tokito T, Kinoshita T, Yamada K, Nishio K, Hoshino T. Association of EGFR Exon 19 Deletion and EGFR-TKI Treatment Duration with Frequency of T790M Mutation in EGFR-Mutant Lung Cancer Patients. Sci Rep 2016;6:36458. [PMID: 27811988 DOI: 10.1038/srep36458] [Cited by in Crossref: 46] [Cited by in F6Publishing: 48] [Article Influence: 7.7] [Reference Citation Analysis]
123 Niu FY, Zhong WZ, Zhou Q, Wu YL. Clinical trials for lung cancer in China. Transl Lung Cancer Res 2014;3:311-6. [PMID: 25806317 DOI: 10.3978/j.issn.2218-6751.2014.10.04] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
124 Nakao A, Hiranuma O, Uchino J, Sakaguchi C, Araya T, Hiraoka N, Ishizuka T, Takeda T, Kawasaki M, Goto Y, Imai H, Hattori N, Nakatomi K, Uramoto H, Uryu K, Fukuda M, Uchida Y, Yokoyama T, Akai M, Mio T, Nagashima S, Chihara Y, Tamiya N, Kaneko Y, Mouri T, Yamada T, Yoshimura K, Fujita M, Takayama K. Final Results from a Phase II Trial of Osimertinib for Elderly Patients with Epidermal Growth Factor Receptor t790m-Positive Non-Small Cell Lung Cancer That Progressed during Previous Treatment. J Clin Med 2020;9:E1762. [PMID: 32517152 DOI: 10.3390/jcm9061762] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
125 Fuggetta MP, Migliorino MR, Ricciardi S, Osman G, Iacono D, Leone A, Lombardi A, Ravagnan G, Greco S, Remotti D, Romano MCP. Prophylactic Dermatologic Treatment of Afatinib-Induced Skin Toxicities in Patients with Metastatic Lung Cancer: A Pilot Study. Scientifica (Cairo) 2019;2019:9136249. [PMID: 30838155 DOI: 10.1155/2019/9136249] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
126 Qin S, Yu H, Wu X, Luo Z, Wang H, Sun S, Huang M, Jin J, Tao Z, Qiao J, Feng Y, Wang J, Chang J. Weekly albumin-bound paclitaxel/cisplatin versus gemcitabine/cisplatin as first-line therapy for patients with advanced non-small-cell lung cancer: A phase II open-label clinical study. Chin J Cancer Res 2019;31:339-48. [PMID: 31156304 DOI: 10.21147/j.issn.1000-9604.2019.02.08] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
127 Ito K, Murotani K, Kubo A, Kunii E, Taniguchi H, Shindoh J, Asada K, Imaizumi K, Takahashi K, Karayama M, Okuno M, Inui N, Hataji O, Morikawa S, Hayai S, Suda T, Abe T, Tsuda T, Yamagichi T, Kimura T, Oya Y, Yoshida T, Hida T. Propensity score analysis of overall survival between first- and second-generation EGFR-TKIs using real-world data. Cancer Sci 2020;111:3705-13. [PMID: 32639668 DOI: 10.1111/cas.14560] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
128 Abdallah SM, Hirsh V. Irreversible tyrosine kinase inhibition of epidermal growth factor receptor with afatinib in EGFR activating mutation-positive advanced non-small-cell lung cancer. Curr Oncol 2018;25:S9-S17. [PMID: 29910643 DOI: 10.3747/co.25.3732] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 1.5] [Reference Citation Analysis]
129 Kuan FC, Kuo LT, Chen MC, Yang CT, Shi CS, Teng D, Lee KD. Overall survival benefits of first-line EGFR tyrosine kinase inhibitors in EGFR-mutated non-small-cell lung cancers: a systematic review and meta-analysis. Br J Cancer 2015;113:1519-28. [PMID: 26461059 DOI: 10.1038/bjc.2015.356] [Cited by in Crossref: 51] [Cited by in F6Publishing: 54] [Article Influence: 7.3] [Reference Citation Analysis]
130 Wang C, Li Y, Ke L, Cao L, Fan P, Wu Z, Wu Q. The Impact of Afatinib on Survival in Advanced Non-Small Cell Lung Cancer: A Meta-Analysis of Randomized Controlled Trials. J Cancer 2019;10:885-92. [PMID: 30854094 DOI: 10.7150/jca.27528] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.7] [Reference Citation Analysis]
131 Xu N, Fang W, Mu L, Tang Y, Gao L, Ren S, Cao D, Zhou L, Zhang A, Liu D, Zhou C, Wong KK, Yu L, Zhang L, Chen L. Overexpression of wildtype EGFR is tumorigenic and denotes a therapeutic target in non-small cell lung cancer. Oncotarget 2016;7:3884-96. [PMID: 26646697 DOI: 10.18632/oncotarget.6461] [Cited by in Crossref: 17] [Cited by in F6Publishing: 20] [Article Influence: 2.8] [Reference Citation Analysis]
132 Patil T, Mushtaq R, Marsh S, Azelby C, Pujara M, Davies KD, Aisner DL, Purcell WT, Schenk EL, Pacheco JM, Bunn PA, Camidge DR, Doebele RC. Clinicopathologic Characteristics, Treatment Outcomes, and Acquired Resistance Patterns of Atypical EGFR Mutations and HER2 Alterations in Stage IV Non-Small-Cell Lung Cancer. Clin Lung Cancer 2020;21:e191-204. [PMID: 31859066 DOI: 10.1016/j.cllc.2019.11.008] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
133 Park K, Wan-Teck Lim D, Okamoto I, Yang JC. First-line afatinib for the treatment of EGFR mutation-positive non-small-cell lung cancer in the 'real-world' clinical setting. Ther Adv Med Oncol 2019;11:1758835919836374. [PMID: 31019567 DOI: 10.1177/1758835919836374] [Cited by in Crossref: 12] [Cited by in F6Publishing: 17] [Article Influence: 4.0] [Reference Citation Analysis]
134 Ercan D, Choi HG, Yun CH, Capelletti M, Xie T, Eck MJ, Gray NS, Jänne PA. EGFR Mutations and Resistance to Irreversible Pyrimidine-Based EGFR Inhibitors. Clin Cancer Res 2015;21:3913-23. [PMID: 25948633 DOI: 10.1158/1078-0432.CCR-14-2789] [Cited by in Crossref: 202] [Cited by in F6Publishing: 119] [Article Influence: 28.9] [Reference Citation Analysis]
135 Mok TS, Wu Y-L, Ahn M-J, Garassino MC, Kim HR, Ramalingam SS, Shepherd FA, He Y, Akamatsu H, Theelen WS, Lee CK, Sebastian M, Templeton A, Mann H, Marotti M, Ghiorghiu S, Papadimitrakopoulou VA; AURA3 Investigators. Osimertinib or Platinum-Pemetrexed in EGFR T790M-Positive Lung Cancer. N Engl J Med. 2017;376:629-640. [PMID: 27959700 DOI: 10.1056/nejmoa1612674] [Cited by in Crossref: 1373] [Cited by in F6Publishing: 820] [Article Influence: 228.8] [Reference Citation Analysis]
136 Park JE, Hong MJ, Lee SY, Lee JH, Choi JE, Kang HG, Do SK, Jeong JY, Shin KM, Lee WK, Choi SH, Lee YH, Seo HW, Yoo SS, Lee J, Cha SI, Kim CH, Park JY. Nuclear Pore Glycoprotein 62 Genetic Variant rs9523 is Associated with Clinical Outcomes of Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Lung Adenocarcinoma Patients. Pharmgenomics Pers Med 2021;14:1291-302. [PMID: 34629889 DOI: 10.2147/PGPM.S329055] [Reference Citation Analysis]
137 Kurata T, Nakaya A, Yokoi T, Niki M, Kibata K, Takeyasu Y, Torii Y, Katashiba Y, Ogata M, Miyara T, Nomura S. Phase I/II study of erlotinib, carboplatin, pemetrexed, and bevacizumab in chemotherapy-naïve patients with advanced non-squamous non-small cell lung cancer harboring epidermal growth factor receptor mutation. Genes Cancer 2017;8:559-65. [PMID: 28740574 DOI: 10.18632/genesandcancer.145] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 0.4] [Reference Citation Analysis]
138 Suda K, Mitsudomi T. Drug Tolerance to EGFR Tyrosine Kinase Inhibitors in Lung Cancers with EGFR Mutations. Cells 2021;10:1590. [PMID: 34202566 DOI: 10.3390/cells10071590] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
139 Thomas R, Weihua Z. Rethink of EGFR in Cancer With Its Kinase Independent Function on Board. Front Oncol 2019;9:800. [PMID: 31508364 DOI: 10.3389/fonc.2019.00800] [Cited by in Crossref: 30] [Cited by in F6Publishing: 26] [Article Influence: 10.0] [Reference Citation Analysis]
140 Alshami J, Guiot MC, Owen S, Kavan P, Gibson N, Solca F, Cseh A, Reardon DA, Muanza T. Afatinib, an irreversible ErbB family blocker, with protracted temozolomide in recurrent glioblastoma: a case report. Oncotarget 2015;6:34030-7. [PMID: 26423602 DOI: 10.18632/oncotarget.5297] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 2.0] [Reference Citation Analysis]
141 Wang Y, Li RQ, Ai YQ, Zhang J, Zhao PZ, Li YF, He WJ, Xia YX, Li WH. Exon 19 deletion was associated with better survival outcomes in advanced lung adenocarcinoma with mutant EGFR treated with EGFR-TKIs as second-line therapy after first-line chemotherapy: a retrospective analysis of 128 patients. Clin Transl Oncol 2015;17:727-36. [PMID: 26041721 DOI: 10.1007/s12094-015-1300-4] [Cited by in Crossref: 12] [Cited by in F6Publishing: 14] [Article Influence: 1.7] [Reference Citation Analysis]
142 Tsironis G, Ziogas DC, Kyriazoglou A, Lykka M, Koutsoukos K, Bamias A, Dimopoulos MA. Breakthroughs in the treatment of advanced squamous-cell NSCLC: not the neglected sibling anymore? Ann Transl Med. 2018;6:143. [PMID: 29862232 DOI: 10.21037/atm.2018.02.18] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 1.3] [Reference Citation Analysis]
143 Shao D, Du D, Liu H, Lv J, Cheng Y, Zhang H, Lv W, Wang S, Lu L. Identification of Stage IIIC/IV EGFR-Mutated Non-Small Cell Lung Cancer Populations Sensitive to Targeted Therapy Based on a PET/CT Radiomics Risk Model. Front Oncol 2021;11:721318. [PMID: 34796106 DOI: 10.3389/fonc.2021.721318] [Reference Citation Analysis]
144 Nacchio M, Sgariglia R, Gristina V, Pisapia P, Pepe F, De Luca C, Migliatico I, Clery E, Greco L, Vigliar E, Bellevicine C, Russo A, Troncone G, Malapelle U. KRAS mutations testing in non-small cell lung cancer: the role of Liquid biopsy in the basal setting. J Thorac Dis 2020;12:3836-43. [PMID: 32802465 DOI: 10.21037/jtd.2020.01.19] [Cited by in Crossref: 20] [Cited by in F6Publishing: 16] [Article Influence: 10.0] [Reference Citation Analysis]
145 Jia Z, Wang Y, Cao L, Wang Y, Song Y, Yang X, Bing Z, Cao Z, Liu P, Zhang S, Chen Z, Huang M, Yu Y, Han-Zhang H, Song J, Christoph DC, Passaro A, Gridelli C, Hishida T, Liang N, Li S. First-line treatment selection with organoids of an EGFRm + TP53m stage IA1 patient with early metastatic recurrence after radical surgery and follow-up. J Thorac Dis 2020;12:3764-73. [PMID: 32802455 DOI: 10.21037/jtd-20-1882] [Reference Citation Analysis]
146 Chen H, Zhang Q, Zhang Y, Jia B, Zhang B, Wang C. Afatinib reverses ceritinib resistance (CR) in ALK/ROS1-positive non-small-cell lung cancer cell (NSCLC) via suppression of NRG1 pathway. Onco Targets Ther 2018;11:8201-9. [PMID: 30568455 DOI: 10.2147/OTT.S173008] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
147 Yao S, Zhi X, Wang R, Qian K, Hu M, Zhang Y. Retrospective study of adjuvant icotinib in postoperative lung cancer patients harboring epidermal growth factor receptor mutations. Thorac Cancer 2016;7:543-8. [PMID: 27766784 DOI: 10.1111/1759-7714.12365] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 0.8] [Reference Citation Analysis]
148 Tanaka H, Taima K, Itoga M, Ishioka Y, Baba K, Shiratori T, Sakamoto H, Tsuchiya J, Nakagawa H, Hasegawa Y, Yasugahira H, Okudera K, Takanashi S, Tasaka S. Real-world study of afatinib in first-line or re-challenge settings for patients with EGFR mutant non-small cell lung cancer. Med Oncol 2019;36:57. [PMID: 31089973 DOI: 10.1007/s12032-019-1278-9] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 2.7] [Reference Citation Analysis]
149 Pasini L, Ulivi P. Liquid Biopsy for the Detection of Resistance Mechanisms in NSCLC: Comparison of Different Blood Biomarkers. J Clin Med 2019;8:E998. [PMID: 31323990 DOI: 10.3390/jcm8070998] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 5.0] [Reference Citation Analysis]
150 Fu JY, Wan YL, Huang TY, Wu CF, Liu YH, Hsieh MJ, Wu YC, Wu CY. Correlation between image characteristics and pathologic findings in non small cell lung cancer patients after anatomic resection. PLoS One 2018;13:e0206386. [PMID: 30379929 DOI: 10.1371/journal.pone.0206386] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
151 Wu YL, Xu CR, Hu CP, Feng J, Lu S, Huang Y, Li W, Hou M, Shi JH, Märten A, Fan J, Peil B, Zhou C. Afatinib versus gemcitabine/cisplatin for first-line treatment of Chinese patients with advanced non-small-cell lung cancer harboring EGFR mutations: subgroup analysis of the LUX-Lung 6 trial. Onco Targets Ther 2018;11:8575-87. [PMID: 30584317 DOI: 10.2147/OTT.S160358] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 2.5] [Reference Citation Analysis]
152 Lee CS, Sharma S, Miao E, Mensah C, Sullivan K, Seetharamu N. A Comprehensive Review of Contemporary Literature for Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Non-Small Cell Lung Cancer and Their Toxicity. Lung Cancer (Auckl) 2020;11:73-103. [PMID: 33117017 DOI: 10.2147/LCTT.S258444] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
153 Jacobsen K, Bertran-Alamillo J, Molina MA, Teixidó C, Karachaliou N, Pedersen MH, Castellví J, Garzón M, Codony-Servat C, Codony-Servat J, Giménez-Capitán A, Drozdowskyj A, Viteri S, Larsen MR, Lassen U, Felip E, Bivona TG, Ditzel HJ, Rosell R. Convergent Akt activation drives acquired EGFR inhibitor resistance in lung cancer. Nat Commun 2017;8:410. [PMID: 28871105 DOI: 10.1038/s41467-017-00450-6] [Cited by in Crossref: 68] [Cited by in F6Publishing: 67] [Article Influence: 13.6] [Reference Citation Analysis]
154 Ng WW, Lin CC, Cheng CY, Jiang JS, Kao SJ, Yeh DY. Real-world outcomes of first- and second-generation tyrosine kinase inhibitors first-line in patients with epidermal growth factor receptor mutation-positive non-small cell lung cancer: A retrospective observational cohort study. PLoS One 2021;16:e0253335. [PMID: 34166400 DOI: 10.1371/journal.pone.0253335] [Reference Citation Analysis]
155 Belluomini L, Riva ST, Simbolo M, Nocini R, Trestini I, Avancini A, Tregnago D, Ferrara MG, Caldart A, Dodi A, Caliò A, Bria E, Scarpa A, Milella M, Menis J, Pilotto S. Anticipating EGFR Targeting in Early Stages of Lung Cancer: Leave No Stone Unturned. Cells 2021;10:2685. [PMID: 34685665 DOI: 10.3390/cells10102685] [Reference Citation Analysis]
156 Lee CS, Milone M, Seetharamu N. Osimertinib in EGFR-Mutated Lung Cancer: A Review of the Existing and Emerging Clinical Data. Onco Targets Ther 2021;14:4579-97. [PMID: 34471361 DOI: 10.2147/OTT.S227032] [Reference Citation Analysis]
157 Juan O, Popat S. Treatment choice in epidermal growth factor receptor mutation-positive non-small cell lung carcinoma: latest evidence and clinical implications. Ther Adv Med Oncol 2017;9:201-16. [PMID: 28344665 DOI: 10.1177/1758834016687262] [Cited by in Crossref: 19] [Cited by in F6Publishing: 19] [Article Influence: 3.8] [Reference Citation Analysis]
158 Zeng X, Wan X, Xu J, Wang H, Chen H, Zeng Q, Zhang W, Zhao B. Therapeutic options for advanced epidermal growth factor receptor (EGFR)-mutant non-small cell lung cancer: a Bayesian network secondary analysis. Aging (Albany NY) 2020;12:7129-62. [PMID: 32324592 DOI: 10.18632/aging.103066] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
159 Wang X, Goldstein D, Crowe PJ, Yang JL. Next-generation EGFR/HER tyrosine kinase inhibitors for the treatment of patients with non-small-cell lung cancer harboring EGFR mutations: a review of the evidence. Onco Targets Ther 2016;9:5461-73. [PMID: 27660463 DOI: 10.2147/OTT.S94745] [Cited by in Crossref: 30] [Cited by in F6Publishing: 11] [Article Influence: 5.0] [Reference Citation Analysis]
160 Pagliarini R, Shao W, Sellers WR. Oncogene addiction: pathways of therapeutic response, resistance, and road maps toward a cure. EMBO Rep. 2015;16:280-296. [PMID: 25680965 DOI: 10.15252/embr.201439949] [Cited by in Crossref: 132] [Cited by in F6Publishing: 118] [Article Influence: 18.9] [Reference Citation Analysis]
161 Arrieta O, De la Torre-Vallejo M, López-Macías D, Orta D, Turcott J, Macedo-Pérez EO, Sánchez-Lara K, Ramírez-Tirado LA, Baracos VE. Nutritional Status, Body Surface, and Low Lean Body Mass/Body Mass Index Are Related to Dose Reduction and Severe Gastrointestinal Toxicity Induced by Afatinib in Patients With Non-Small Cell Lung Cancer. Oncologist 2015;20:967-74. [PMID: 26173839 DOI: 10.1634/theoncologist.2015-0058] [Cited by in Crossref: 47] [Cited by in F6Publishing: 49] [Article Influence: 6.7] [Reference Citation Analysis]
162 Wang LY, Cui JJ, Guo AX, Yin JY. Clinical efficacy and safety of afatinib in the treatment of non-small-cell lung cancer in Chinese patients. Onco Targets Ther 2018;11:529-38. [PMID: 29416353 DOI: 10.2147/OTT.S136579] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
163 Chen C, Liu SM, Chen Y, Han M, Ou Q, Bao H, Xu L, Zhang Y, Zhang JT, Zhong W, Zhou Q, Yang XN, Shao Y, Wu YL, Liu SY, Li Y. Poor prognosis of intra-tumoural TRBV6-6 variants in EGFR-mutant NSCLC: Results from the ADJUVANT-CTONG1104 trial. Clin Transl Med 2022;12:e775. [PMID: 35452192 DOI: 10.1002/ctm2.775] [Reference Citation Analysis]
164 Pirker R. Systemic therapy of elderly patients with advanced non-small cell lung cancer-individualized treatment is key. Ann Transl Med 2019;7:S48. [PMID: 31032327 DOI: 10.21037/atm.2019.03.10] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
165 Melosky B, Leighl NB, Rothenstein J, Sangha R, Stewart D, Papp K. Management of egfr tki-induced dermatologic adverse events. Curr Oncol 2015;22:123-32. [PMID: 25908911 DOI: 10.3747/co.22.2430] [Cited by in Crossref: 40] [Cited by in F6Publishing: 33] [Article Influence: 5.7] [Reference Citation Analysis]
166 Tanaka H, Taima K, Tanaka Y, Itoga M, Ishioka Y, Nakagawa H, Baba K, Hasegawa Y, Takanashi S, Tasaka S. A phase I study of afatinib for patients aged 75 or older with advanced non-small cell lung cancer harboring EGFR mutations. Med Oncol 2018;35:34. [PMID: 29423683 DOI: 10.1007/s12032-018-1098-3] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.5] [Reference Citation Analysis]
167 Chen LY, You Q, Lv DZ, Li SH, Zhang SY. GPCR-mediated EGFR transactivation ameliorates skin toxicities induced by afatinib. Acta Pharmacol Sin 2022;43:1534-43. [PMID: 34552215 DOI: 10.1038/s41401-021-00774-6] [Reference Citation Analysis]
168 Miyashita Y, Ko R, Shimada N, Mitsuishi Y, Miura K, Matsumoto N, Asao T, Shukuya T, Shibayama R, Koyama R, Takahashi K. Impact of the generation of EGFR-TKIs administered as prior therapy on the efficacy of osimertinib in patients with non-small cell lung cancer harboring EGFR T790M mutation. Thorac Cancer 2021;12:329-38. [PMID: 33219754 DOI: 10.1111/1759-7714.13742] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
169 Haratake N, Takenoyama M, Edagawa M, Shimamatsu S, Toyozawa R, Nosaki K, Hirai F, Yamaguchi M, Taguchi K, Seto T, Ichinose Y. A case of different EGFR mutations in surgically resected synchronous triple lung cancer. J Thorac Dis 2018;10:E255-9. [PMID: 29850164 DOI: 10.21037/jtd.2018.03.105] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
170 Zhang Y, Sheng J, Yang Y, Fang W, Kang S, He Y, Hong S, Zhan J, Zhao Y, Xue C, Ma Y, Zhou T, Ma S, Gao F, Qin T, Hu Z, Tian Y, Hou X, Huang Y, Zhou N, Zhao H, Zhang L. Optimized selection of three major EGFR-TKIs in advanced EGFR-positive non-small cell lung cancer: a network meta-analysis. Oncotarget 2016;7:20093-108. [PMID: 26933807 DOI: 10.18632/oncotarget.7713] [Cited by in Crossref: 21] [Cited by in F6Publishing: 22] [Article Influence: 5.3] [Reference Citation Analysis]
171 Song Z, Yu X, Zhang Y. Clinicopathological characteristics and survival of ALK, ROS1 and RET rearrangements in non-adenocarcinoma non-small cell lung cancer patients. Cancer Biol Ther 2017;18:883-7. [PMID: 27635639 DOI: 10.1080/15384047.2016.1235660] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 1.3] [Reference Citation Analysis]
172 Chen YY, Yen YT, Lai WW, Huang WL, Chang CC, Tseng YL. Outcomes of salvage lung resections in advanced EGFR-mutant lung adenocarcinomas under EGFR TKIs. Thorac Cancer 2021;12:2655-65. [PMID: 34498378 DOI: 10.1111/1759-7714.13646] [Reference Citation Analysis]
173 Nguyen KSH, Neal JW, Wakelee H. Review of the current targeted therapies for non-small-cell lung cancer. World J Clin Oncol 2014; 5(4): 576-587 [PMID: 25302162 DOI: 10.5306/wjco.v5.i4.576] [Cited by in CrossRef: 47] [Cited by in F6Publishing: 40] [Article Influence: 5.9] [Reference Citation Analysis]
174 Hsu PC, Jablons DM, Yang CT, You L. Epidermal Growth Factor Receptor (EGFR) Pathway, Yes-Associated Protein (YAP) and the Regulation of Programmed Death-Ligand 1 (PD-L1) in Non-Small Cell Lung Cancer (NSCLC). Int J Mol Sci 2019;20:E3821. [PMID: 31387256 DOI: 10.3390/ijms20153821] [Cited by in Crossref: 36] [Cited by in F6Publishing: 36] [Article Influence: 12.0] [Reference Citation Analysis]
175 Liu L, Wang C, Li S, Bai H, Wang J. Tumor immune microenvironment in epidermal growth factor receptor-mutated non-small cell lung cancer before and after epidermal growth factor receptor tyrosine kinase inhibitor treatment: a narrative review. Transl Lung Cancer Res 2021;10:3823-39. [PMID: 34733631 DOI: 10.21037/tlcr-21-572] [Reference Citation Analysis]
176 Tsutani Y, Miyata Y, Masuda T, Fujitaka K, Doi M, Awaya Y, Kuyama S, Kitaguchi S, Ueda K, Hattori N, Okada M. Multicenter phase II study on cisplatin, pemetrexed, and bevacizumab followed by maintenance with pemetrexed and bevacizumab for patients with advanced or recurrent nonsquamous non-small cell lung cancer: MAP study. BMC Cancer 2018;18:1231. [PMID: 30526545 DOI: 10.1186/s12885-018-5146-3] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.8] [Reference Citation Analysis]
177 Seung SJ, Hurry M, Hassan S, Walton RN, Evans WK. Cost-of-illness study for non-small-cell lung cancer using real-world data. Curr Oncol 2019;26:102-7. [PMID: 31043811 DOI: 10.3747/co.26.4555] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 3.3] [Reference Citation Analysis]
178 Ding T, Zhou F, Chen X, Zhang S, Liu Y, Sun H, Ren S, Li X, Zhao C, Wang H, Zhou C. Continuation of gefitinib plus chemotherapy prolongs progression-free survival in advanced non-small cell lung cancer patients who get acquired resistance to gefitinib without T790M mutations. J Thorac Dis 2017;9:2923-34. [PMID: 29221264 DOI: 10.21037/jtd.2017.07.107] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 1.8] [Reference Citation Analysis]
179 Liu S, Zhang J, Zeng K, Wu Y. Perioperative targeted therapy for oncogene-driven NSCLC. Lung Cancer 2022. [DOI: 10.1016/j.lungcan.2022.05.007] [Reference Citation Analysis]
180 Carcereny E, Morán T, Capdevila L, Cros S, Vilà L, de Los Llanos Gil M, Remón J, Rosell R. The epidermal growth factor receptor (EGRF) in lung cancer. Transl Respir Med 2015;3:1. [PMID: 25810955 DOI: 10.1186/s40247-015-0013-z] [Cited by in Crossref: 17] [Cited by in F6Publishing: 14] [Article Influence: 2.4] [Reference Citation Analysis]
181 Liu WJ, Huang YX, Wang W, Zhang Y, Liu BJ, Qiu JG, Jiang BH, Liu LZ. NOX4 Signaling Mediates Cancer Development and Therapeutic Resistance through HER3 in Ovarian Cancer Cells. Cells 2021;10:1647. [PMID: 34209278 DOI: 10.3390/cells10071647] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
182 Sonehara K, Kobayashi T, Tateishi K, Morozumi N, Yoshiike F, Hachiya T, Ono Y, Takasuna K, Agatsuma T, Masubuchi T, Matsuo A, Tanaka H, Morikawa A, Hanaoka M, Koizumi T. Clinical analysis of EGFR-positive non-small cell lung cancer patients treated with first-line afatinib: A Nagano Lung Cancer Research Group. Thorac Cancer 2019;10:1078-85. [PMID: 31006178 DOI: 10.1111/1759-7714.13047] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
183 Zhao J, Gao J, Guo L, Hu X, Liu Q, Zhao J, Liu L, Jiang J, Wang M, Liang Z, Xu Y, Chen M, Zhang L, Li L, Zhong W. [EGFR and KRAS Gene Mutations in 754 Patients with Resectable Stage I-IIIa Non-small Cell Lung Cancer and Its Clinical Significance]. Zhongguo Fei Ai Za Zhi 2017;20:617-22. [PMID: 28935015 DOI: 10.3779/j.issn.1009-3419.2017.09.05] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
184 Normanno N, Fenizia F, Castiglione F, Barberis M, Taddei GL, Truini M, De Rosa G, Pinto C, Marchetti A. External quality assessment for EGFR mutations in Italy: improvements in performances over the time. ESMO Open 2017;2:e000160. [PMID: 29181190 DOI: 10.1136/esmoopen-2017-000160] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 1.6] [Reference Citation Analysis]
185 Nilsson RJ, Karachaliou N, Berenguer J, Gimenez-Capitan A, Schellen P, Teixido C, Tannous J, Kuiper JL, Drees E, Grabowska M, van Keulen M, Heideman DA, Thunnissen E, Dingemans AM, Viteri S, Tannous BA, Drozdowskyj A, Rosell R, Smit EF, Wurdinger T. Rearranged EML4-ALK fusion transcripts sequester in circulating blood platelets and enable blood-based crizotinib response monitoring in non-small-cell lung cancer. Oncotarget 2016;7:1066-75. [PMID: 26544515 DOI: 10.18632/oncotarget.6279] [Cited by in Crossref: 95] [Cited by in F6Publishing: 95] [Article Influence: 15.8] [Reference Citation Analysis]
186 Yao ZH, Liao WY, Ho CC, Chen KY, Shih JY, Chen JS, Lin ZZ, Lin CC, Chih-Hsin Yang J, Yu CJ. Real-World Data on Prognostic Factors for Overall Survival in EGFR Mutation-Positive Advanced Non-Small Cell Lung Cancer Patients Treated with First-Line Gefitinib. Oncologist 2017;22:1075-83. [PMID: 28507206 DOI: 10.1634/theoncologist.2016-0331] [Cited by in Crossref: 14] [Cited by in F6Publishing: 18] [Article Influence: 2.8] [Reference Citation Analysis]
187 Skupin-Mrugalska P, Minko T. Development of Liposomal Vesicles for Osimertinib Delivery to EGFR Mutation-Positive Lung Cancer Cells. Pharmaceutics 2020;12:E939. [PMID: 33008019 DOI: 10.3390/pharmaceutics12100939] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
188 Zhao S, Ma G, Guo J, Ding A, Wang S, Yu G, Chen L, Yuan Y, Xiao W. Outcomes of adjuvant epithelial growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) treatment for EGFR-mutant non-small-cell lung cancer: a propensity-score analysis. Sci Rep 2017;7:11528. [PMID: 28912511 DOI: 10.1038/s41598-017-11725-9] [Reference Citation Analysis]
189 Xiao D, Lu C, Zhu W, He Q, Li Y, Fu C, Zhou J, Liu S, Tao Y. Comparison of small biopsy specimens and surgical specimens for the detection of EGFR mutations and EML4-ALK in non-small-cell lung cancer. Oncotarget 2016;7:59049-57. [PMID: 27322143 DOI: 10.18632/oncotarget.10011] [Cited by in Crossref: 9] [Cited by in F6Publishing: 11] [Article Influence: 2.3] [Reference Citation Analysis]
190 Bylicki O, Guisier F, Monnet I, Doubre H, Gervais R, Janicot H, Perol M, Fournel P, Lamy R, Auliac JB, Chouaid C. Efficacy and safety of programmed cell-death-protein-1 and its ligand inhibitors in pretreated patients with epidermal growth-factor receptor-mutated or anaplastic lymphoma kinase-translocated lung adenocarcinoma. Medicine (Baltimore) 2020;99:e18726. [PMID: 32011450 DOI: 10.1097/MD.0000000000018726] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 4.5] [Reference Citation Analysis]
191 Calabrese F, Pezzuto F, Lunardi F, Fortarezza F, Tzorakoleftheraki S, Resi MV, Tiné M, Pasello G, Hofman P. Morphologic-Molecular Transformation of Oncogene Addicted Non-Small Cell Lung Cancer. IJMS 2022;23:4164. [DOI: 10.3390/ijms23084164] [Reference Citation Analysis]
192 Zhang XY, Cao R, Guo YJ, Zhen YH, Zheng JH, Huang LT, Zhang SL, Jing W, Sun L, Zhao JZ, Han CB, Ma JT. Impact of pulmonary interstitial lesions on efficacy and prognosis of EGFR-TKI-treated advanced non-small cell lung cancers. J Thorac Dis 2020;12:839-48. [PMID: 32274151 DOI: 10.21037/jtd.2019.12.128] [Reference Citation Analysis]
193 Kim Y, Lee SH, Ahn JS, Ahn MJ, Park K, Sun JM. Efficacy and Safety of Afatinib for EGFR-mutant Non-small Cell Lung Cancer, Compared with Gefitinib or Erlotinib. Cancer Res Treat 2019;51:502-9. [PMID: 29898592 DOI: 10.4143/crt.2018.117] [Cited by in Crossref: 27] [Cited by in F6Publishing: 31] [Article Influence: 6.8] [Reference Citation Analysis]
194 Hirashima T, Satouchi M, Hida T, Nishio M, Kato T, Sakai H, Imamura F, Kiura K, Okamoto I, Kasahara K, Uchida H, Vowler SL, Mitsudomi T. Osimertinib for Japanese patients with T790M-positive advanced non-small-cell lung cancer: A pooled subgroup analysis. Cancer Sci 2019;110:2884-93. [PMID: 31265163 DOI: 10.1111/cas.14120] [Cited by in Crossref: 10] [Cited by in F6Publishing: 12] [Article Influence: 3.3] [Reference Citation Analysis]
195 Wang T, Yang C, Li B, Xing Y, Huang J, Zhang Y, Bu S, Ge H. Identification of lncRNA-miRNA-mRNA Networks Linked to Non-small Lung Cancer Resistance to Inhibitors of Epidermal Growth Factor Receptor. Front Genet 2021;12:758591. [PMID: 34868237 DOI: 10.3389/fgene.2021.758591] [Reference Citation Analysis]
196 Batson S, Mitchell SA, Windisch R, Damonte E, Munk VC, Reguart N. Tyrosine kinase inhibitor combination therapy in first-line treatment of non-small-cell lung cancer: systematic review and network meta-analysis. Onco Targets Ther 2017;10:2473-82. [PMID: 28503070 DOI: 10.2147/OTT.S134382] [Cited by in Crossref: 22] [Cited by in F6Publishing: 16] [Article Influence: 4.4] [Reference Citation Analysis]
197 Pisapia P, Pepe F, Smeraglio R, Russo M, Rocco D, Sgariglia R, Nacchio M, De Luca C, Vigliar E, Bellevicine C, Troncone G, Malapelle U. Cell free DNA analysis by SiRe® next generation sequencing panel in non small cell lung cancer patients: focus on basal setting. J Thorac Dis 2017;9:S1383-90. [PMID: 29184677 DOI: 10.21037/jtd.2017.06.97] [Cited by in Crossref: 23] [Cited by in F6Publishing: 22] [Article Influence: 4.6] [Reference Citation Analysis]
198 Wu YP, Wu JJ, Tian SM, Jin T, Li C, Xie K. Apatinib with EGFR-TKIs in advanced wild gene-type NSCLC: A case report. Medicine (Baltimore) 2019;98:e13924. [PMID: 30608421 DOI: 10.1097/MD.0000000000013924] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
199 Kuan FC, Li SH, Wang CL, Lin MH, Tsai YH, Yang CT. Analysis of progression-free survival of first-line tyrosine kinase inhibitors in patients with non-small cell lung cancer harboring leu858Arg or exon 19 deletions. Oncotarget 2017;8:1343-53. [PMID: 27935868 DOI: 10.18632/oncotarget.13815] [Cited by in Crossref: 23] [Cited by in F6Publishing: 24] [Article Influence: 5.8] [Reference Citation Analysis]
200 Wang P, Li Y, Lv D, Yang L, Ding L, Zhou J, Hong W, Chen Y, Zhang D, He S, Zhou J, Wang K. Mefatinib as first-line treatment of patients with advanced EGFR-mutant non-small-cell lung cancer: a phase Ib/II efficacy and biomarker study. Signal Transduct Target Ther 2021;6:374. [PMID: 34719670 DOI: 10.1038/s41392-021-00773-3] [Reference Citation Analysis]
201 Bulbul A, Husain H. First-Line Treatment in EGFR Mutant Non-Small Cell Lung Cancer: Is There a Best Option? Front Oncol 2018;8:94. [PMID: 29755953 DOI: 10.3389/fonc.2018.00094] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 2.8] [Reference Citation Analysis]
202 Hirsh V. New developments in the treatment of advanced squamous cell lung cancer: focus on afatinib. Onco Targets Ther 2017;10:2513-26. [PMID: 28546756 DOI: 10.2147/OTT.S104177] [Cited by in Crossref: 17] [Cited by in F6Publishing: 17] [Article Influence: 3.4] [Reference Citation Analysis]
203 Ezeife DA, Melosky B, Tudor R, Lin S, Lau A, Panzarella T, Leighl NB. Afatinib in advanced pretreated non-small-cell lung cancer- a Canadian experience. Curr Oncol 2018;25:e385-90. [PMID: 30464688 DOI: 10.3747/co.25.3914] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
204 Kim T, Kim EY, Lee SH, Kwon DS, Kim A, Chang YS. Presence of mEGFR ctDNA predicts a poor clinical outcome in lung adenocarcinoma. Thorac Cancer 2019;10:2267-73. [PMID: 31647198 DOI: 10.1111/1759-7714.13219] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.7] [Reference Citation Analysis]
205 Nishio M, Kato T, Niho S, Yamamoto N, Takahashi T, Nogami N, Kaneda H, Fujita Y, Wilner K, Yoshida M, Isozaki M, Wada S, Tsuji F, Nakagawa K. Safety and efficacy of first-line dacomitinib in Japanese patients with advanced non-small cell lung cancer. Cancer Sci 2020;111:1724-38. [PMID: 32159882 DOI: 10.1111/cas.14384] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
206 Elbatanony RS, Parvathaneni V, Kulkarni NS, Shukla SK, Chauhan G, Kunda NK, Gupta V. Afatinib-loaded inhalable PLGA nanoparticles for localized therapy of non-small cell lung cancer (NSCLC)-development and in-vitro efficacy. Drug Deliv Transl Res 2021;11:927-43. [PMID: 32557351 DOI: 10.1007/s13346-020-00802-8] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
207 Zhang Y, Chen G, Chen X, Fang W, Gao F, Yang Y, Zhao Y, Ma Y, Hong S, Zhang Z, Miao S, Wu M, Huang X, Luo Y, Zhou C, Gong R, Huang Y, Chen L, Zhou N, Zhao H, Zhang L. The comparison of EGFR-TKI failure modes and subsequent management between exon 19 deletion and exon 21 L858R mutation in advanced non-small-cell lung cancer. J Cancer 2017;8:1865-71. [PMID: 28819384 DOI: 10.7150/jca.19867] [Cited by in Crossref: 1] [Cited by in F6Publishing: 4] [Article Influence: 0.2] [Reference Citation Analysis]
208 Yamaoka T, Ohba M, Ohmori T. Molecular-Targeted Therapies for Epidermal Growth Factor Receptor and Its Resistance Mechanisms. Int J Mol Sci 2017;18:E2420. [PMID: 29140271 DOI: 10.3390/ijms18112420] [Cited by in Crossref: 53] [Cited by in F6Publishing: 50] [Article Influence: 10.6] [Reference Citation Analysis]
209 Zhao D, Chen X, Qin N, Su D, Zhou L, Zhang Q, Li X, Zhang X, Jin M, Wang J. The prognostic role of EGFR-TKIs for patients with advanced non-small cell lung cancer. Sci Rep 2017;7:40374. [PMID: 28079142 DOI: 10.1038/srep40374] [Cited by in Crossref: 24] [Cited by in F6Publishing: 22] [Article Influence: 4.8] [Reference Citation Analysis]
210 He SY, Lin QF, Chen J, Yu GP, Zhang JL, Shen D. Efficacy of afatinib in a patient with rare EGFR (G724S/R776H) mutations and amplification in lung adenocarcinoma: A case report. World J Clin Cases 2021; 9(6): 1329-1335 [PMID: 33644199 DOI: 10.12998/wjcc.v9.i6.1329] [Cited by in CrossRef: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
211 Chen JA, Riess JW. Advances in targeting acquired resistance mechanisms to epidermal growth factor receptor tyrosine kinase inhibitors. J Thorac Dis 2020;12:2859-76. [PMID: 32642199 DOI: 10.21037/jtd.2019.08.32] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
212 West H. Prioritizing molecular markers to test for in the initial workup of advanced non-small cell lung cancer: wants versus needs. Ann Transl Med 2017;5:371. [PMID: 29057231 DOI: 10.21037/atm.2017.08.29] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
213 Ye J, Chen P, Chuang J, Lin M, Tsai T, Hsu H, Chen J. Treatment Effectiveness and Tolerability of Long-term Adjuvant First- and Second-Generation Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor at Different Doses in Patients With Stage IIA–IIIB Epidermal Growth Factor Receptor-Mutated Lung Adenocarcinoma: A Retrospective Study. Front Surg 2022;9:816018. [DOI: 10.3389/fsurg.2022.816018] [Reference Citation Analysis]
214 Sehgal K, Rangachari D, VanderLaan PA, Kobayashi SS, Costa DB. Clinical Benefit of Tyrosine Kinase Inhibitors in Advanced Lung Cancer with EGFR-G719A and Other Uncommon EGFR Mutations. Oncologist 2021;26:281-7. [PMID: 32969527 DOI: 10.1002/onco.13537] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
215 Liang SK, Lee MR, Liao WY, Ho CC, Ko JC, Shih JY. Prognostic factors of afatinib as a first-line therapy for advanced EGFR mutation-positive lung adenocarcinoma: a real-world, large cohort study. Oncotarget 2018;9:23749-60. [PMID: 29805772 DOI: 10.18632/oncotarget.25255] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 2.8] [Reference Citation Analysis]
216 Janning M, Süptitz J, Albers-Leischner C, Delpy P, Tufman A, Velthaus-Rusik JL, Reck M, Jung A, Kauffmann-Guerrero D, Bonzheim I, Brändlein S, Hummel HD, Wiesweg M, Schildhaus HU, Stratmann JA, Sebastian M, Alt J, Buth J, Esposito I, Berger J, Tögel L, Saalfeld FC, Wermke M, Merkelbach-Bruse S, Hillmer AM, Klauschen F, Bokemeyer C, Buettner R, Wolf J, Loges S. Treatment outcome of atypical EGFR mutations in the German National Network Genomic Medicine Lung Cancer (nNGM). Ann Oncol 2022:S0923-7534(22)00361-1. [PMID: 35263633 DOI: 10.1016/j.annonc.2022.02.225] [Reference Citation Analysis]
217 Chen M, Xu Y, Zhao J, Zhong W, Wang M. [Clinical Predictive Factors associated with First Line EGFR-TKI Efficacy 
in Advanced NSCLC Patients with EGFR Mutations]. Zhongguo Fei Ai Za Zhi 2019;22:99-104. [PMID: 30827326 DOI: 10.3779/j.issn.1009-3419.2019.02.04] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
218 Fujiwara A, Yoshida M, Fujimoto H, Nakahara H, Ito K, Nishihama K, Yasuma T, Hataji O, Taguchi O, D'Alessandro-Gabazza CN, Gabazza EC, Kobayashi T. A Retrospective Comparison of the Clinical Efficacy of Gefitinib, Erlotinib, and Afatinib in Japanese Patients With Non-Small Cell Lung Cancer. Oncol Res 2018;26:1031-6. [PMID: 29321093 DOI: 10.3727/096504018X15151523767752] [Cited by in Crossref: 10] [Cited by in F6Publishing: 7] [Article Influence: 2.5] [Reference Citation Analysis]
219 Lara MS, Holland WS, Chinn D, Burich RA, Lara PN Jr, Gandara DR, Kelly K, Mack PC. Preclinical Evaluation of MET Inhibitor INC-280 With or Without the Epidermal Growth Factor Receptor Inhibitor Erlotinib in Non-Small-Cell Lung Cancer. Clin Lung Cancer 2017;18:281-5. [PMID: 28038979 DOI: 10.1016/j.cllc.2016.11.006] [Cited by in Crossref: 24] [Cited by in F6Publishing: 20] [Article Influence: 4.0] [Reference Citation Analysis]
220 Kozuki T. Skin problems and EGFR-tyrosine kinase inhibitor. Jpn J Clin Oncol 2016;46:291-8. [PMID: 26826719 DOI: 10.1093/jjco/hyv207] [Cited by in Crossref: 42] [Cited by in F6Publishing: 40] [Article Influence: 7.0] [Reference Citation Analysis]
221 Liu X, Xu J. [Treatment of advanced NSCLC with unknown EGFR gene status
--TKI or chemotherapy?]. Zhongguo Fei Ai Za Zhi 2014;17:709-14. [PMID: 25342036 DOI: 10.3779/j.issn.1009-3419.2014.10.01] [Reference Citation Analysis]
222 Buffoni L, Vavalà T, Novello S. Adjuvant Therapy of Resected Non-small Cell Lung Cancer: can We Move Forward? Curr Treat Options Oncol 2016;17:54. [PMID: 27523606 DOI: 10.1007/s11864-016-0429-x] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 2.2] [Reference Citation Analysis]
223 Steuer CE, Ramalingam SS. Targeting EGFR in lung cancer: Lessons learned and future perspectives. Mol Aspects Med 2015;45:67-73. [PMID: 26022942 DOI: 10.1016/j.mam.2015.05.004] [Cited by in Crossref: 27] [Cited by in F6Publishing: 33] [Article Influence: 3.9] [Reference Citation Analysis]
224 Zhang X, Maity T, Kashyap MK, Bansal M, Venugopalan A, Singh S, Awasthi S, Marimuthu A, Charles Jacob HK, Belkina N, Pitts S, Cultraro CM, Gao S, Kirkali G, Biswas R, Chaerkady R, Califano A, Pandey A, Guha U. Quantitative Tyrosine Phosphoproteomics of Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitor-treated Lung Adenocarcinoma Cells Reveals Potential Novel Biomarkers of Therapeutic Response. Mol Cell Proteomics 2017;16:891-910. [PMID: 28331001 DOI: 10.1074/mcp.M117.067439] [Cited by in Crossref: 26] [Cited by in F6Publishing: 13] [Article Influence: 5.2] [Reference Citation Analysis]
225 Chen PY, Wang CC, Hsu CN, Chen CY. Association of EGFR Tyrosine Kinase Inhibitor Treatment With Progression-Free Survival Among Taiwanese Patients With Advanced Lung Adenocarcinoma and EGFR Mutation. Front Pharmacol 2021;12:720687. [PMID: 34434112 DOI: 10.3389/fphar.2021.720687] [Reference Citation Analysis]
226 Liu X, Hong L, Nilsson M, Hubert SM, Wu S, Rinsurongkawong W, Lewis J, Spelman A, Roth J, Swisher S, He Y, Jack Lee J, Fang B, Heymach JV, Zhang J, Le X. Concurrent use of aspirin with osimertinib is associated with improved survival in advanced EGFR-mutant non-small cell lung cancer. Lung Cancer 2020;149:33-40. [PMID: 32956986 DOI: 10.1016/j.lungcan.2020.08.023] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
227 Igawa S, Kasajima M, Ono T, Ozawa T, Kakegawa M, Kusuhara S, Sato T, Nakahara Y, Fukui T, Yokoba M, Kubota M, Mitsufuji H, Sasaki J, Naoki K. A Prospective Observational Study of Osimertinib for Chemo-Naive Elderly Patients with EGFR Mutation-Positive Non-Small Cell Lung Cancer. Cancer Manag Res 2021;13:8695-705. [PMID: 34849025 DOI: 10.2147/CMAR.S339891] [Reference Citation Analysis]
228 Hirsh V. Next-Generation Covalent Irreversible Kinase Inhibitors in NSCLC: Focus on Afatinib. BioDrugs 2015;29:167-83. [PMID: 26123538 DOI: 10.1007/s40259-015-0130-9] [Cited by in Crossref: 36] [Cited by in F6Publishing: 38] [Article Influence: 6.0] [Reference Citation Analysis]
229 Liu S, Yu J, Zhang H, Liu J. TP53 Co-Mutations in Advanced EGFR-Mutated Non-Small Cell Lung Cancer: Prognosis and Therapeutic Strategy for Cancer Therapy. Front Oncol 2022;12:860563. [PMID: 35444951 DOI: 10.3389/fonc.2022.860563] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
230 Lee KL, Lai TC, Wang YC, Shih PC, Yang YC, Tsao TC, Liu TC, Wen YC, Chang LC, Yang SF, Chien MH. Potential Impacts of Interleukin-17A Promoter Polymorphisms on the EGFR Mutation Status and Progression of Non-Small Cell Lung Cancer in Taiwan. Genes (Basel) 2021;12:427. [PMID: 33802737 DOI: 10.3390/genes12030427] [Reference Citation Analysis]
231 Arriola E, García Gómez R, Diz P, Majem M, Martínez Aguillo M, Valdivia J, Paredes A, Sánchez-Torres JM, Peralta Muñoz S, Barneto I, Gutierrez V, Andrade Santiago JM, Aparisi F, Isla D, Ponce S, Vicente Baz D, Artal A, Amador M, Provencio M. Clinical management and outcome of patients with advanced NSCLC carrying EGFR mutations in Spain. BMC Cancer 2018;18:106. [PMID: 29382302 DOI: 10.1186/s12885-018-4004-7] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
232 Bennati C, Paglialunga L, Ricciuti B, Metro G, Marcomigni L, Gili A, Crinò L. Targeting EGFR and ALK in NSCLC: current evidence and future perspective. Lung Cancer Manag 2016;5:79-90. [PMID: 30643552 DOI: 10.2217/lmt-2016-0005] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
233 Fang YH, Yang YH, Hsieh MJ, Hung MS, Lin YC. Concurrent proton-pump inhibitors increase risk of death for lung cancer patients receiving 1st-line gefitinib treatment - a nationwide population-based study. Cancer Manag Res 2019;11:8539-46. [PMID: 31572008 DOI: 10.2147/CMAR.S222278] [Cited by in Crossref: 9] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
234 Laganà M, Gurizzan C, Roca E, Cortinovis D, Signorelli D, Pagani F, Bettini A, Bonomi L, Rinaldi S, Berardi R, Filetti M, Giusti R, Pilotto S, Milella M, Intagliata S, Baggi A, Cortellini A, Soto Parra H, Brighenti M, Petrelli F, Bennati C, Bidoli P, Garassino MC, Berruti A. High Prevalence and Early Occurrence of Skeletal Complications in EGFR Mutated NSCLC Patients With Bone Metastases. Front Oncol 2020;10:588862. [PMID: 33282740 DOI: 10.3389/fonc.2020.588862] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
235 Cheema PK, Thawer A, Leake J, Cheng SY, Khanna S, Charles Victor J. Multi-disciplinary proactive follow-up algorithm for patients with advanced NSCLC receiving afatinib. Support Care Cancer 2019;27:1029-39. [PMID: 30116943 DOI: 10.1007/s00520-018-4392-x] [Cited by in Crossref: 2] [Article Influence: 0.5] [Reference Citation Analysis]
236 Zhang T, Wan B, Zhao Y, Li C, Liu H, Lv T, Zhan P, Song Y. Treatment of uncommon EGFR mutations in non-small cell lung cancer: new evidence and treatment. Transl Lung Cancer Res 2019;8:302-16. [PMID: 31367543 DOI: 10.21037/tlcr.2019.04.12] [Cited by in Crossref: 31] [Cited by in F6Publishing: 30] [Article Influence: 10.3] [Reference Citation Analysis]
237 Li M, Yang J, Zhang L, Tu S, Zhou X, Tan Z, Zhou W, He Y, Li Y. A low-molecular-weight compound exerts anticancer activity against breast and lung cancers by disrupting EGFR/Eps8 complex formation. J Exp Clin Cancer Res 2019;38:211. [PMID: 31118055 DOI: 10.1186/s13046-019-1207-y] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
238 Li M, Li C, Ke L, Zhan M, Cheng M. Significance of the epidermal growth factor receptor mutation status and differences among molecular subgroups in surgically resected lung microinvasive adenocarcinoma. Oncol Lett 2018;16:7057-67. [PMID: 30546439 DOI: 10.3892/ol.2018.9539] [Reference Citation Analysis]
239 An N, Wang H, Zhu H, Yan W, Jing W, Kong L, Zhang Y, Yu J. Great efficacy of afatinib on a patient with lung adenocarcinoma harboring uncommon EGFR delE709_T710insD mutations: a case report. Onco Targets Ther 2019;12:7399-404. [PMID: 31686847 DOI: 10.2147/OTT.S221638] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
240 König D, Savic Prince S, Rothschild SI. Targeted Therapy in Advanced and Metastatic Non-Small Cell Lung Cancer. An Update on Treatment of the Most Important Actionable Oncogenic Driver Alterations. Cancers (Basel) 2021;13:804. [PMID: 33671873 DOI: 10.3390/cancers13040804] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 7.0] [Reference Citation Analysis]
241 O'Brien MER, Sarker D, Bhosle J, Thillai K, Yap TA, Uttenreuther-Fischer M, Pemberton K, Jin X, Wiebe S, de Bono J, Spicer J. A phase I study to assess afatinib in combination with carboplatin or with carboplatin plus paclitaxel in patients with advanced solid tumors. Cancer Chemother Pharmacol 2018;82:757-66. [PMID: 30088048 DOI: 10.1007/s00280-018-3661-1] [Reference Citation Analysis]
242 Chang JW, Huang CY, Fang YF, Chang CF, Yang CT, Kuo CS, Hsu PC, Wu CE. Epidermal growth factor receptor tyrosine kinase inhibitors for de novo T790M mutation: A retrospective study of 44 patients. Thorac Cancer 2022. [PMID: 35633141 DOI: 10.1111/1759-7714.14272] [Reference Citation Analysis]
243 Zhang Y, Sheng J, Kang S, Fang W, Yan Y, Hu Z, Hong S, Wu X, Qin T, Liang W, Zhang L. Patients with exon 19 deletion were associated with longer progression-free survival compared to those with L858R mutation after first-line EGFR-TKIs for advanced non-small cell lung cancer: a meta-analysis. PLoS One 2014;9:e107161. [PMID: 25222496 DOI: 10.1371/journal.pone.0107161] [Cited by in Crossref: 84] [Cited by in F6Publishing: 96] [Article Influence: 10.5] [Reference Citation Analysis]
244 Reardon DA, Nabors LB, Mason WP, Perry JR, Shapiro W, Kavan P, Mathieu D, Phuphanich S, Cseh A, Fu Y, Cong J, Wind S, Eisenstat DD; BI 1200 36 Trial Group and the Canadian Brain Tumour Consortium. Phase I/randomized phase II study of afatinib, an irreversible ErbB family blocker, with or without protracted temozolomide in adults with recurrent glioblastoma. Neuro Oncol 2015;17:430-9. [PMID: 25140039 DOI: 10.1093/neuonc/nou160] [Cited by in Crossref: 33] [Cited by in F6Publishing: 60] [Article Influence: 4.1] [Reference Citation Analysis]
245 Gregg JP, Li T, Yoneda KY. Molecular testing strategies in non-small cell lung cancer: optimizing the diagnostic journey. Transl Lung Cancer Res 2019;8:286-301. [PMID: 31367542 DOI: 10.21037/tlcr.2019.04.14] [Cited by in Crossref: 20] [Cited by in F6Publishing: 21] [Article Influence: 6.7] [Reference Citation Analysis]
246 Díaz-Serrano A, Gella P, Jiménez E, Zugazagoitia J, Paz-Ares Rodríguez L. Targeting EGFR in Lung Cancer: Current Standards and Developments. Drugs 2018;78:893-911. [PMID: 29915896 DOI: 10.1007/s40265-018-0916-4] [Cited by in Crossref: 24] [Cited by in F6Publishing: 24] [Article Influence: 8.0] [Reference Citation Analysis]
247 Syed YY. therascreen® EGFR RGQ PCR Kit: A Companion Diagnostic for Afatinib and Gefitinib in Non-Small Cell Lung Cancer. Mol Diagn Ther 2016;20:191-8. [PMID: 26891729 DOI: 10.1007/s40291-016-0189-0] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 1.7] [Reference Citation Analysis]
248 Zhang M, Bao Y, Rui W, Shangguan C, Liu J, Xu J, Lin X, Zhang M, Huang X, Zhou Y, Qu Q, Meng H, Qian D, Li B. Performance of 18F-FDG PET/CT Radiomics for Predicting EGFR Mutation Status in Patients With Non-Small Cell Lung Cancer. Front Oncol 2020;10:568857. [PMID: 33134170 DOI: 10.3389/fonc.2020.568857] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
249 Ortega-Franco A, Calvo V, Franco F, Provencio M, Califano R. Integrating immune checkpoint inhibitors and targeted therapies in the treatment of early stage non-small cell lung cancer: a narrative review. Transl Lung Cancer Res 2020;9:2656-73. [PMID: 33489825 DOI: 10.21037/tlcr-20-546] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
250 Sala González MÁ. Prolonged survival with erlotinib followed by afatinib in a caucasian smoker with metastatic, poorly differentiated large cell carcinoma of the lung: a case report. Cancer Biol Ther 2015;16:1434-7. [PMID: 26186355 DOI: 10.1080/15384047.2015.1070993] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 0.6] [Reference Citation Analysis]
251 Zhang J, Zhang Y, Tang S, Liang H, Chen D, Jiang L, He Q, Huang Y, Wang X, Deng K, Jiang S, Zhou J, Xu J, Chen X, Liang W, He J. Evaluation bias in objective response rate and disease control rate between blinded independent central review and local assessment: a study-level pooled analysis of phase III randomized control trials in the past seven years. Ann Transl Med 2017;5:481. [PMID: 29299443 DOI: 10.21037/atm.2017.11.24] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
252 Ko EJ, Kwag EB, Park JH, Park SJ, Son JW, Yoon SH, Shin SH, Yoo HS. Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Exploratory Study to Evaluate the Efficacy and Safety of HAD-B1 for Dose-Finding in EGFR Mutation Positive and Locally Advanced or Metastatic NSCLC Subjects Who Need Afatinib Therapy. Integr Cancer Ther 2021;20:15347354211037917. [PMID: 34409891 DOI: 10.1177/15347354211037917] [Reference Citation Analysis]
253 Giusti R, Mazzotta M, Iacono D, Lauro S, Marchetti P. Complete Tumor Response with Afatinib 20 mg Daily in EGFR-Mutated Non-small Cell Lung Cancer: A Case Report. Clin Drug Investig 2017;37:581-5. [PMID: 28299582 DOI: 10.1007/s40261-017-0515-2] [Cited by in Crossref: 1] [Article Influence: 0.2] [Reference Citation Analysis]
254 Hiret S, Isambert N, Gomez-Roca C, Bennouna J, Sassi M, de Mont-Serrat H, Fan J, Schnell D, Delord JP. Phase I dose-escalation trial of afatinib, an irreversible ErbB family blocker, in combination with gemcitabine or docetaxel in patients with relapsed or refractory solid tumors. Invest New Drugs 2018;36:1044-59. [PMID: 29808308 DOI: 10.1007/s10637-018-0601-1] [Reference Citation Analysis]
255 Spagnuolo A, Muto M, Monaco F, Colantuoni G, Gridelli C. The optional approach of oncogene-addicted non-small cell lung cancer with brain metastases in the new generation targeted therapies era. Transl Lung Cancer Res 2019;8:1134-51. [PMID: 32010591 DOI: 10.21037/tlcr.2019.12.24] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
256 Zhang SR, Xu YS, Jin E, Zhu LC, Xia B, Chen XF, Li FZ, Ma SL. Capilliposide from Lysimachia capillipes inhibits AKT activation and restores gefitinib sensitivity in human non-small cell lung cancer cells with acquired gefitinib resistance. Acta Pharmacol Sin 2017;38:100-9. [PMID: 27840409 DOI: 10.1038/aps.2016.116] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 2.0] [Reference Citation Analysis]
257 Nan X, Xie C, Yu X, Liu J. EGFR TKI as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer. Oncotarget 2017;8:75712-26. [PMID: 29088904 DOI: 10.18632/oncotarget.20095] [Cited by in Crossref: 50] [Cited by in F6Publishing: 58] [Article Influence: 10.0] [Reference Citation Analysis]
258 Suda K, Bunn PA Jr, Rivard CJ, Mitsudomi T, Hirsch FR. Primary Double-Strike Therapy for Cancers to Overcome EGFR Kinase Inhibitor Resistance: Proposal from the Bench. J Thorac Oncol 2017;12:27-35. [PMID: 27642065 DOI: 10.1016/j.jtho.2016.09.003] [Cited by in Crossref: 18] [Cited by in F6Publishing: 17] [Article Influence: 3.0] [Reference Citation Analysis]
259 Wu CE, Chang CF, Huang CY, Yang CT, Kuo CS, Hsu PC, Chang JW. Feasibility and effectiveness of afatinib for poor performance status patients with EGFR-mutation-positive non-small-cell lung cancer: a retrospective cohort study. BMC Cancer 2021;21:859. [PMID: 34315431 DOI: 10.1186/s12885-021-08587-w] [Reference Citation Analysis]
260 Zou Y, Wei J, Xia Y, Meng F, Yuan J, Zhong Z. Targeted chemotherapy for subcutaneous and orthotopic non-small cell lung tumors with cyclic RGD-functionalized and disulfide-crosslinked polymersomal doxorubicin. Signal Transduct Target Ther 2018;3:32. [PMID: 30564464 DOI: 10.1038/s41392-018-0032-7] [Cited by in Crossref: 20] [Cited by in F6Publishing: 21] [Article Influence: 5.0] [Reference Citation Analysis]
261 Tamura K, Nukiwa T, Gemma A, Yamamoto N, Mizushima M, Ochai K, Ikeda R, Azuma H, Nakanishi Y. Real-world treatment of over 1600 Japanese patients with EGFR mutation-positive non-small cell lung cancer with daily afatinib. Int J Clin Oncol 2019;24:917-26. [PMID: 30953238 DOI: 10.1007/s10147-019-01439-5] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 2.7] [Reference Citation Analysis]
262 Sárosi V, Balikó Z, Smuk G, László T, Szabó M, Ruzsics I, Mezősi E. The Frequency of EGFR Mutation in Lung Adenocarcinoma and the Efficacy of Tyrosine Kinase Inhibitor Therapy in a Hungarian Cohort of Patients. Pathol Oncol Res 2016;22:755-61. [PMID: 27105879 DOI: 10.1007/s12253-016-0063-8] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
263 Chen Y, Mao B, Peng X, Zhou Y, Xia K, Guo H, Jiang H, Wang G, Zhuang W. A Comparative Study of Genetic Profiles of Key Oncogenesis-Related Genes between Primary Lesions and Matched Lymph Nodes Metastasis in Lung Cancer. J Cancer 2019;10:1642-50. [PMID: 31205520 DOI: 10.7150/jca.28266] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.7] [Reference Citation Analysis]
264 Mohindra NA, Patel JD. Towards manageable toxicities from targeted lung cancer treatment. Lung Cancer Management 2015;4:279-87. [DOI: 10.2217/lmt.15.30] [Reference Citation Analysis]
265 Hirano T, Yasuda H, Tani T, Hamamoto J, Oashi A, Ishioka K, Arai D, Nukaga S, Miyawaki M, Kawada I, Naoki K, Costa DB, Kobayashi SS, Betsuyaku T, Soejima K. In vitro modeling to determine mutation specificity of EGFR tyrosine kinase inhibitors against clinically relevant EGFR mutants in non-small-cell lung cancer. Oncotarget 2015;6:38789-803. [PMID: 26515464 DOI: 10.18632/oncotarget.5887] [Cited by in Crossref: 72] [Cited by in F6Publishing: 72] [Article Influence: 12.0] [Reference Citation Analysis]
266 Ma C, Zhang J, Tang D, Ye X, Li J, Mu N, Li Z, Liu R, Xiang L, Huang C, Jiang R. Tyrosine Kinase Inhibitors Could Be Effective Against Non-small Cell Lung Cancer Brain Metastases Harboring Uncommon EGFR Mutations. Front Oncol 2020;10:224. [PMID: 32195178 DOI: 10.3389/fonc.2020.00224] [Cited by in Crossref: 5] [Cited by in F6Publishing: 7] [Article Influence: 2.5] [Reference Citation Analysis]
267 Planchard D, Besse B, Groen HJ, Souquet PJ, Quoix E, Baik CS, Barlesi F, Kim TM, Mazieres J, Novello S. Dabrafenib plus trametinib in patients with previously treated BRAF(V600E)-mutant metastatic non-small cell lung cancer: an open-label, multicentre phase 2 trial. Lancet Oncol. 2016;17:984-993. [PMID: 27283860 DOI: 10.1016/s1470-2045(16)30146-2] [Cited by in Crossref: 399] [Cited by in F6Publishing: 218] [Article Influence: 66.5] [Reference Citation Analysis]
268 Min YJ. Anti-Cancer Therapy of Advanced Lung Cancer in Elderly Patients. Korean J Med 2014;87:537. [DOI: 10.3904/kjm.2014.87.5.537] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
269 Chiba M, Togashi Y, Bannno E, Kobayashi Y, Nakamura Y, Hayashi H, Terashima M, De Velasco MA, Sakai K, Fujita Y, Mitsudomi T, Nishio K. Efficacy of irreversible EGFR-TKIs for the uncommon secondary resistant EGFR mutations L747S, D761Y, and T854A. BMC Cancer 2017;17:281. [PMID: 28424065 DOI: 10.1186/s12885-017-3263-z] [Cited by in Crossref: 18] [Cited by in F6Publishing: 18] [Article Influence: 3.6] [Reference Citation Analysis]
270 Shi Z, Fan Y. [Optimal therapeutic strategy for non-small cell lung cancer with mutated epidermal growth factor receptor]. Zhongguo Fei Ai Za Zhi 2015;18:110-6. [PMID: 25676406 DOI: 10.3779/j.issn.1009-3419.2015.02.11] [Reference Citation Analysis]
271 Shin SH, Bode AM, Dong Z. Addressing the challenges of applying precision oncology. NPJ Precis Oncol 2017;1:28. [PMID: 29872710 DOI: 10.1038/s41698-017-0032-z] [Cited by in Crossref: 15] [Cited by in F6Publishing: 17] [Article Influence: 3.0] [Reference Citation Analysis]
272 Gan Y, Ren J, Xian J, Yu H, Jin J, Li D, Li W. Prognostic Value of Albumin-to-Alkaline Phosphatase Ratio for EGFR-Mutated Advanced Non-Small-Cell Lung Cancer Patients Treated with First-Line EGFR-TKIs: A Large Population-Based Study and Literature Review. IJGM 2022;Volume 15:3405-16. [DOI: 10.2147/ijgm.s348912] [Reference Citation Analysis]
273 Hotta K, Kato Y, Leighl N, Takigawa N, Gaafar RM, Kayatani H, Hirata T, Ohashi K, Kubo T, Tabata M, Tanimoto M, Kiura K. Magnitude of the benefit of progression-free survival as a potential surrogate marker in phase 3 trials assessing targeted agents in molecularly selected patients with advanced non-small cell lung cancer: systematic review. PLoS One 2015;10:e0121211. [PMID: 25775395 DOI: 10.1371/journal.pone.0121211] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 1.9] [Reference Citation Analysis]
274 Harvey RD, Adams VR, Beardslee T, Medina P. Afatinib for the treatment of EGFR mutation-positive NSCLC: A review of clinical findings. J Oncol Pharm Pract 2020;26:1461-74. [PMID: 32567494 DOI: 10.1177/1078155220931926] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
275 Suzawa K, Toyooka S, Sakaguchi M, Morita M, Yamamoto H, Tomida S, Ohtsuka T, Watanabe M, Hashida S, Maki Y, Soh J, Asano H, Tsukuda K, Miyoshi S. Antitumor effect of afatinib, as a human epidermal growth factor receptor 2-targeted therapy, in lung cancers harboring HER2 oncogene alterations. Cancer Sci 2016;107:45-52. [PMID: 26545934 DOI: 10.1111/cas.12845] [Cited by in Crossref: 50] [Cited by in F6Publishing: 48] [Article Influence: 7.1] [Reference Citation Analysis]
276 Huhn AJ, Guerra RM, Harvey EP, Bird GH, Walensky LD. Selective Covalent Targeting of Anti-Apoptotic BFL-1 by Cysteine-Reactive Stapled Peptide Inhibitors. Cell Chem Biol 2016;23:1123-34. [PMID: 27617850 DOI: 10.1016/j.chembiol.2016.07.022] [Cited by in Crossref: 44] [Cited by in F6Publishing: 38] [Article Influence: 7.3] [Reference Citation Analysis]
277 Ricciuti B, Mecca C, Cenci M, Leonardi GC, Perrone L, Mencaroni C, Crinò L, Grignani F, Baglivo S, Chiari R, Sidoni A, Paglialunga L, Currà MF, Murano E, Minotti V, Metro G. miRNAs and resistance to EGFR-TKIs in EGFR-mutant non-small cell lung cancer: beyond 'traditional mechanisms' of resistance. Ecancermedicalscience 2015;9:569. [PMID: 26435742 DOI: 10.3332/ecancer.2015.569] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 1.1] [Reference Citation Analysis]
278 Sato M, Watanabe S, Tanaka H, Nozaki K, Arita M, Takahashi M, Shoji S, Ichikawa K, Kondo R, Aoki N, Hayashi M, Ohshima Y, Koya T, Ohashi R, Ajioka Y, Kikuchi T. Retrospective analysis of antitumor effects and biomarkers for nivolumab in NSCLC patients with EGFR mutations. PLoS One 2019;14:e0215292. [PMID: 30978241 DOI: 10.1371/journal.pone.0215292] [Cited by in Crossref: 2] [Cited by in F6Publishing: 6] [Article Influence: 0.7] [Reference Citation Analysis]
279 Toschi L, Rossi S, Finocchiaro G, Santoro A. Non-small cell lung cancer treatment (r)evolution: ten years of advances and more to come. Ecancermedicalscience 2017;11:787. [PMID: 29225694 DOI: 10.3332/ecancer.2017.787] [Cited by in Crossref: 21] [Cited by in F6Publishing: 24] [Article Influence: 4.2] [Reference Citation Analysis]
280 Wang Y, Wei Y, Ma X, Ma X, Gong P. Association between advanced NSCLC T790 M EGFR-TKI secondary resistance and prognosis: A observational study. Medicine (Baltimore) 2018;97:e11346. [PMID: 29995771 DOI: 10.1097/MD.0000000000011346] [Cited by in Crossref: 8] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
281 Soares M, Antunes L, Redondo P, Borges M, Hermans R, Patel D, Grimson F, Munro R, Chaib C, Lacoin L, Daumont M, Penrod JR, O'Donnell JC, Bento MJ, Rocha Gonçalves F. Real-world treatment patterns and survival outcomes for advanced non-small cell lung cancer in the pre-immunotherapy era in Portugal: a retrospective analysis from the I-O Optimise initiative. BMC Pulm Med 2020;20:240. [PMID: 32912174 DOI: 10.1186/s12890-020-01270-z] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
282 Ellis PM, Coakley N, Feld R, Kuruvilla S, Ung YC. Use of the epidermal growth factor receptor inhibitors gefitinib, erlotinib, afatinib, dacomitinib, and icotinib in the treatment of non-small-cell lung cancer: a systematic review. Curr Oncol 2015;22:e183-215. [PMID: 26089730 DOI: 10.3747/co.22.2566] [Cited by in Crossref: 44] [Cited by in F6Publishing: 39] [Article Influence: 6.3] [Reference Citation Analysis]
283 Harvey RD, Aransay NR, Isambert N, Lee JS, Arkenau T, Vansteenkiste J, Dickinson PA, Bui K, Weilert D, So K, Thomas K, Vishwanathan K. Effect of multiple-dose osimertinib on the pharmacokinetics of simvastatin and rosuvastatin. Br J Clin Pharmacol 2018;84:2877-88. [PMID: 30171779 DOI: 10.1111/bcp.13753] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 3.0] [Reference Citation Analysis]
284 Ishikawa R, Yamazaki S, Mio T, Kawashima A, Masumoto A, Shiono A, Daito H, Yamaguchi O, Maeno Y, Okano T, Sakaguchi H, Murayama Y, Ishida H, Kato S, Hagiwara K, Kobayashi K. Carcinomatous meningitis and <i>EGFR</i> mutation. ACRT 2015;23:14-8. [DOI: 10.4993/acrt.23.14] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
285 Xiong L, Li R, Sun J, Lou Y, Zhang W, Bai H, Wang H, Shen J, Jing B, Shi C, Zhong H, Gu A, Jiang L, Shi J, Fang W, Zhao H, Zhang J, Wang J, Ye J, Han B. Erlotinib as Neoadjuvant Therapy in Stage IIIA (N2) EGFR Mutation-Positive Non-Small Cell Lung Cancer: A Prospective, Single-Arm, Phase II Study. Oncologist 2019;24:157-e64. [PMID: 30158288 DOI: 10.1634/theoncologist.2018-0120] [Cited by in Crossref: 22] [Cited by in F6Publishing: 29] [Article Influence: 5.5] [Reference Citation Analysis]
286 Moehler M, Maderer A, Ehrlich A, Foerster F, Schad A, Nickolay T, Ruckes C, Weinmann A, Sivanathan V, Marquardt JU, Galle PR, Woerns M, Thomaidis T. Safety and efficacy of afatinib as add-on to standard therapy of gemcitabine/cisplatin in chemotherapy-naive patients with advanced biliary tract cancer: an open-label, phase I trial with an extensive biomarker program. BMC Cancer 2019;19:55. [PMID: 30634942 DOI: 10.1186/s12885-018-5223-7] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 4.3] [Reference Citation Analysis]
287 Thongprasert S, Geater SL, Clement D, Abdelaziz A, Reyes-Igama J, Jovanovic D, Alexandru A, Schenker M, Sriuranpong V, Serwatowski P, Suresh S, Cseh A, Gaafar R. Afatinib in locally advanced/metastatic NSCLC harboring common EGFR mutations, after chemotherapy: a Phase IV study. Lung Cancer Manag 2019;8:LMT15. [PMID: 31807143 DOI: 10.2217/lmt-2019-0004] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 1.3] [Reference Citation Analysis]
288 Cadranel J. Osimertinib in first-line treatment-is a comparison not proof? Ann Transl Med 2018;6:57. [PMID: 29611546 DOI: 10.21037/atm.2017.12.13] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 0.8] [Reference Citation Analysis]
289 Park H, Sholl LM, Hatabu H, Awad MM, Nishino M. Imaging of Precision Therapy for Lung Cancer: Current State of the Art. Radiology 2019;293:15-29. [PMID: 31385753 DOI: 10.1148/radiol.2019190173] [Cited by in Crossref: 15] [Cited by in F6Publishing: 13] [Article Influence: 5.0] [Reference Citation Analysis]
290 Liu HL, Han G, Peng M, Weng YM, Yuan JP, Yang GF, Yu JM, Song QB. Efficacy of EGFR tyrosine kinase inhibitors in non-small cell lung cancer patients harboring different types of EGFR mutations: A retrospective analysis. J Huazhong Univ Sci Technolog Med Sci 2017;37:864-72. [PMID: 29270745 DOI: 10.1007/s11596-017-1819-4] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
291 Sui G, Qiu Y, Yu H, Kong Q, Zhen B. Interleukin-17 promotes the development of cisplatin resistance in colorectal cancer. Oncol Lett 2019;17:944-50. [PMID: 30655852 DOI: 10.3892/ol.2018.9645] [Cited by in Crossref: 7] [Cited by in F6Publishing: 12] [Article Influence: 1.8] [Reference Citation Analysis]
292 Castellanos EH, Horn L. Generations of Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors: Perils and Progress. Curr Treat Options Oncol 2015;16:51. [PMID: 26364032 DOI: 10.1007/s11864-015-0365-1] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
293 Bilgin B, Sendur MAN, Yucel S, Celik E, Ozyukseler DT, Ayhan M, Basoglu T, Ilhan A, Akdeniz N, Gulmez A, Dogan I, Aktas BY, Gurbuz M, Koca S, Paydas S, Tatli AM, Cinkir HY, Alan O, Erol C, Hizal M, Kut E, Menevse S, Sakalar T, Taskaynatan H, Deniz GI, Karaagac M, Avci O, Sen E, Karatas F, Akinci MB, Dede DS, Demir A, Demirkazık A, Oksuzoglu B, Kilickap S, Yumuk F, Yalcin B. Real-life comparison of the afatinib and first-generation tyrosine kinase inhibitors in nonsmall cell lung cancer harboring EGFR exon 19 deletion: a Turk Oncology Group (TOG) study. J Cancer Res Clin Oncol 2021;147:2145-52. [PMID: 33433657 DOI: 10.1007/s00432-020-03501-6] [Reference Citation Analysis]
294 Chen D, Jin Z, Zhang J, Xu C, Zhu K, Ruan Y, Zhang B, Chen B, Shen J. Efficacy and Safety of Neoadjuvant Targeted Therapy vs. Neoadjuvant Chemotherapy for Stage IIIA EGFR-Mutant Non-small Cell Lung Cancer: A Systematic Review and Meta-Analysis. Front Surg 2021;8:715318. [PMID: 34490338 DOI: 10.3389/fsurg.2021.715318] [Reference Citation Analysis]
295 Hsu CC, Yang AY, Chen JY, Tsai HH, Lin SH, Tai PC, Huang MH, Hsu WH, Lin AM, Yang JC. Lysine Deprivation Induces AKT-AADAT Signaling and Overcomes EGFR-TKIs Resistance in EGFR-Mutant Non-Small Cell Lung Cancer Cells. Cancers (Basel) 2021;13:E272. [PMID: 33450879 DOI: 10.3390/cancers13020272] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
296 Arrieta O, Cruz-Rico G, Soto-Perez-de-Celis E, Ramírez-Tirado LA, Caballe-Perez E, Martínez-Hernández JN, Martinez-Alvarez I, Soca-Chafre G, Macedo-Pérez EO, Astudillo-de la Vega H. Reduction in Hepatocyte Growth Factor Serum Levels is Associated with Improved Prognosis in Advanced Lung Adenocarcinoma Patients Treated with Afatinib: a Phase II Trial. Target Oncol 2016;11:619-29. [PMID: 27033062 DOI: 10.1007/s11523-016-0425-x] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 1.8] [Reference Citation Analysis]
297 Cheng Y, He Y, Li W, Zhang HL, Zhou Q, Wang B, Liu C, Walding A, Saggese M, Huang X, Fan M, Wang J, Ramalingam SS. Osimertinib Versus Comparator EGFR TKI as First-Line Treatment for EGFR-Mutated Advanced NSCLC: FLAURA China, A Randomized Study. Target Oncol 2021;16:165-76. [PMID: 33544337 DOI: 10.1007/s11523-021-00794-6] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 5.0] [Reference Citation Analysis]
298 Berz D, Raymond VM, Garst JH, Erlander MG. Non-invasive urine testing of EGFR activating mutation and T790M resistance mutation in non-small cell lung cancer. Exp Hematol Oncol 2015;5:24. [PMID: 27508108 DOI: 10.1186/s40164-016-0052-3] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 1.8] [Reference Citation Analysis]
299 Kobayashi K, Naoki K, Manabe T, Masuzawa K, Hasegawa H, Yasuda H, Kawada I, Soejima K, Betsuyaku T. Comparison of detection methods of EGFR T790M mutations using plasma, serum, and tumor tissue in EGFR-TKI-resistant non-small cell lung cancer. Onco Targets Ther 2018;11:3335-43. [PMID: 29922072 DOI: 10.2147/OTT.S161745] [Cited by in Crossref: 11] [Cited by in F6Publishing: 7] [Article Influence: 2.8] [Reference Citation Analysis]
300 Santos ES, Kaplan B, Kirshner E, Croft EF, Sequist LV, Chau M, Munley J, Oxnard GR. Osimertinib for Previously Treated Patients With Advanced EGFR T790M Mutation-Positive NSCLC: Tolerability and Diagnostic Methods From an Expanded Access Program. Oncol Ther 2018;6:45-58. [PMID: 32700141 DOI: 10.1007/s40487-018-0061-y] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
301 Jin Y, Chen M, Yu X. Differences among lesions with exon 19, exon 21 EGFR mutations and wild types in surgically resected non-small cell lung cancer. Sci Rep 2016;6:31636. [PMID: 27527915 DOI: 10.1038/srep31636] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
302 Ke EE, Wu YL. Afatinib in the first-line treatment of epidermal-growth-factor-receptor mutation-positive non-small cell lung cancer: a review of the clinical evidence. Ther Adv Respir Dis. 2016;10:256-264. [PMID: 26929305 DOI: 10.1177/1753465816634545] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 1.7] [Reference Citation Analysis]
303 Mizugaki H, Oizumi S, Fujita Y, Harada T, Nakahara Y, Takashina T, Ko R, Watanabe K, Hotta T, Minemura H, Saeki S, Asahina H, Nakamura K, Nakamura H, Hosoda F, Yagishita S, Hamada A. Pharmacokinetic and pharmacogenomic analysis of low-dose afatinib treatment in elderly patients with EGFR mutation-positive non-small cell lung cancer. Eur J Cancer 2022;160:227-34. [PMID: 34862083 DOI: 10.1016/j.ejca.2021.10.024] [Reference Citation Analysis]
304 Passaro A, de Marinis F. Looking for the high way in EGFR-positive non-small cell lung cancer through the evaluation of survival endpoints. Transl Lung Cancer Res 2019;8:S334-8. [PMID: 32038909 DOI: 10.21037/tlcr.2019.06.04] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
305 Zhang Y, Tang H, Li J, Li M. An active treatment of lung adenocarcinoma cancer with brain metastases: icotinib. Onco Targets Ther 2015;8:1351-4. [PMID: 26089684 DOI: 10.2147/OTT.S78925] [Cited by in Crossref: 2] [Cited by in F6Publishing: 6] [Article Influence: 0.3] [Reference Citation Analysis]
306 Okajima M, Miura S, Watanabe S, Tanaka H, Ito K, Ishida T, Makino M, Iwashima A, Matsumoto N, Sato K, Ichikawa K, Abe T, Yoshizawa H, Kikuchi T. A prospective phase II study of multimodal prophylactic treatment for afatinib-induced adverse events in advanced non-small cell lung cancer (Niigata Lung Cancer Treatment Group 1401). Transl Lung Cancer Res 2021;10:252-60. [PMID: 33569309 DOI: 10.21037/tlcr-20-649] [Reference Citation Analysis]
307 Dai L, Wang W, Li W, Wu Y, Qu K. Effect of Gefitinib Combined with Chemotherapy in Patients with Advanced NSCLC: A Retrospective Cohort Study. IJGM 2022;Volume 15:637-44. [DOI: 10.2147/ijgm.s342917] [Reference Citation Analysis]
308 Saida Y, Watanabe S, Abe T, Shoji S, Nozaki K, Ichikawa K, Kondo R, Koyama K, Miura S, Tanaka H, Okajima M, Terada M, Ishida T, Tsukada H, Makino M, Iwashima A, Sato K, Matsumoto N, Yoshizawa H, Kikuchi T. Efficacy of EGFR-TKIs with or without upfront brain radiotherapy for EGFR-mutant NSCLC patients with central nervous system metastases. Thorac Cancer 2019;10:2106-16. [PMID: 31507098 DOI: 10.1111/1759-7714.13189] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
309 Jiang W, Cai G, Hu PC, Wang Y. Personalized medicine in non-small cell lung cancer: a review from a pharmacogenomics perspective. Acta Pharm Sin B 2018;8:530-8. [PMID: 30109178 DOI: 10.1016/j.apsb.2018.04.005] [Cited by in Crossref: 32] [Cited by in F6Publishing: 27] [Article Influence: 8.0] [Reference Citation Analysis]
310 Hung MS, Chen IC, Lee CP, Huang RJ, Chen PC, Tsai YH, Yang YH. Statin improves survival in patients with EGFR-TKI lung cancer: A nationwide population-based study. PLoS One 2017;12:e0171137. [PMID: 28158206 DOI: 10.1371/journal.pone.0171137] [Cited by in Crossref: 31] [Cited by in F6Publishing: 34] [Article Influence: 6.2] [Reference Citation Analysis]
311 Kiura K, Yoh K, Katakami N, Nogami N, Kasahara K, Takahashi T, Okamoto I, Cantarini M, Hodge R, Uchida H. Osimertinib in patients with epidermal growth factor receptor T790M advanced non-small cell lung cancer selected using cytology samples. Cancer Sci 2018;109:1177-84. [PMID: 29363250 DOI: 10.1111/cas.13511] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
312 Santos ES, Hart L. Advanced Squamous Cell Carcinoma of the Lung: Current Treatment Approaches and the Role of Afatinib. Onco Targets Ther 2020;13:9305-21. [PMID: 33061419 DOI: 10.2147/OTT.S250446] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
313 Wang Y, Guo Z, Li Y, Zhou Q. Development of epidermal growth factor receptor tyrosine kinase inhibitors against EGFR T790M. Mutation in non small-cell lung carcinoma. Open Med (Wars) 2016;11:68-77. [PMID: 28352770 DOI: 10.1515/med-2016-0014] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.7] [Reference Citation Analysis]
314 De Mello RA, Escriu C, Castelo-Branco P, Cabral PL, Mountzios G, Lopes GL, Madureira P. Comparative outcome assessment of epidermal growth factor receptor tyrosine kinase inhibitors for the treatment of advanced non-small-cell lung cancer: a network meta-analysis. Oncotarget 2018;9:11805-15. [PMID: 29545937 DOI: 10.18632/oncotarget.23668] [Cited by in Crossref: 6] [Cited by in F6Publishing: 9] [Article Influence: 1.2] [Reference Citation Analysis]
315 Ko B, Paucar D, Halmos B. EGFR T790M: revealing the secrets of a gatekeeper. Lung Cancer (Auckl) 2017;8:147-59. [PMID: 29070957 DOI: 10.2147/LCTT.S117944] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 0.8] [Reference Citation Analysis]
316 Ma P, Fu Y, Chen M, Jing Y, Wu J, Li K, Shen Y, Gao JX, Wang M, Zhao X, Zhuang G. Adaptive and Acquired Resistance to EGFR Inhibitors Converge on the MAPK Pathway. Theranostics 2016;6:1232-43. [PMID: 27279914 DOI: 10.7150/thno.14409] [Cited by in Crossref: 23] [Cited by in F6Publishing: 26] [Article Influence: 3.8] [Reference Citation Analysis]
317 Lopez-Chavez A, Thomas A, Evbuomwan MO, Xi L, Chun G, Vidaurre T, Arrieta O, Oblitas G 3rd, Oton AB, Calvo AR, Rajan A, Raffeld M, Steinberg SM, Arze-Aimaretti L, Giaccone G. EGFR Mutations in Latinos From the United States and Latin America. J Glob Oncol 2016;2:259-67. [PMID: 28717712 DOI: 10.1200/JGO.2015.002105] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
318 Albaba H, Lim C, Leighl NB. Economic Considerations in the Use of Novel Targeted Therapies for Lung Cancer: Review of Current Literature. Pharmacoeconomics 2017;35:1195-209. [PMID: 28861770 DOI: 10.1007/s40273-017-0563-8] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 3.5] [Reference Citation Analysis]
319 Morgensztern D, Campo MJ, Dahlberg SE, Doebele RC, Garon E, Gerber DE, Goldberg SB, Hammerman PS, Heist RS, Hensing T, Horn L, Ramalingam SS, Rudin CM, Salgia R, Sequist LV, Shaw AT, Simon GR, Somaiah N, Spigel DR, Wrangle J, Johnson D, Herbst RS, Bunn P, Govindan R. Molecularly targeted therapies in non-small-cell lung cancer annual update 2014. J Thorac Oncol 2015;10:S1-63. [PMID: 25535693 DOI: 10.1097/JTO.0000000000000405] [Cited by in Crossref: 95] [Cited by in F6Publishing: 44] [Article Influence: 13.6] [Reference Citation Analysis]
320 Tsakonas G, Ekman S. Oncogene-addicted non-small cell lung cancer and immunotherapy. J Thorac Dis 2018;10:S1547-55. [PMID: 29951305 DOI: 10.21037/jtd.2018.01.82] [Cited by in Crossref: 17] [Cited by in F6Publishing: 17] [Article Influence: 4.3] [Reference Citation Analysis]
321 Tanaka H, Sakamoto H, Akita T, Ohyanagi F, Kawashima Y, Tambo Y, Tanimoto A, Horiike A, Miyauchi E, Tsuchiya-Kawano Y, Yanagitani N, Nishio M. Clinical efficacy of dacomitinib in rechallenge setting for patients with epidermal growth factor receptor mutant non-small cell lung cancer: A multicenter retrospective analysis (TOPGAN2020-02). Thorac Cancer 2022. [PMID: 35415873 DOI: 10.1111/1759-7714.14415] [Reference Citation Analysis]
322 Li Y, Appius A, Pattipaka T, Feyereislova A, Cassidy A, Ganti AK. Real-world management of patients with epidermal growth factor receptor (EGFR) mutation-positive non-small-cell lung cancer in the USA. PLoS One 2019;14:e0209709. [PMID: 30608948 DOI: 10.1371/journal.pone.0209709] [Cited by in Crossref: 12] [Cited by in F6Publishing: 14] [Article Influence: 4.0] [Reference Citation Analysis]
323 Frega S, Lorenzi M, Fassan M, Indraccolo S, Calabrese F, Favaretto A, Bonanno L, Polo V, Zago G, Lunardi F, Attili I, Pavan A, Rugge M, Guarneri V, Conte P, Pasello G. Clinical features and treatment outcome of non-small cell lung cancer (NSCLC) patients with uncommon or complex epidermal growth factor receptor (EGFR) mutations. Oncotarget 2017;8:32626-38. [PMID: 28427238 DOI: 10.18632/oncotarget.15945] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 2.3] [Reference Citation Analysis]
324 Ou SH, Soo RA. Dacomitinib in lung cancer: a “lost generation” EGFR tyrosine-kinase inhibitor from a bygone era? Drug Des Devel Ther. 2015;9:5641-5653. [PMID: 26508839 DOI: 10.2147/dddt.s52787] [Cited by in Crossref: 16] [Cited by in F6Publishing: 8] [Article Influence: 2.3] [Reference Citation Analysis]
325 You JHS, Cho WCS, Ming WK, Li YC, Kwan CK, Au KH, Au JS. EGFR mutation-guided use of afatinib, erlotinib and gefitinib for advanced non-small-cell lung cancer in Hong Kong - A cost-effectiveness analysis. PLoS One 2021;16:e0247860. [PMID: 33647045 DOI: 10.1371/journal.pone.0247860] [Reference Citation Analysis]
326 Byeon S, Ham JS, Sun JM, Lee SH, Ahn JS, Park K, Ahn MJ. Analysis of the benefit of sequential cranial radiotherapy in patients with EGFR mutant non-small cell lung cancer and brain metastasis. Med Oncol 2016;33:97. [PMID: 27447711 DOI: 10.1007/s12032-016-0811-3] [Cited by in Crossref: 24] [Cited by in F6Publishing: 26] [Article Influence: 4.0] [Reference Citation Analysis]
327 Aguiar PN Jr, Haaland B, Park W, San Tan P, Del Giglio A, de Lima Lopes G Jr. Cost-effectiveness of Osimertinib in the First-Line Treatment of Patients With EGFR-Mutated Advanced Non-Small Cell Lung Cancer. JAMA Oncol 2018;4:1080-4. [PMID: 29852038 DOI: 10.1001/jamaoncol.2018.1395] [Cited by in Crossref: 53] [Cited by in F6Publishing: 63] [Article Influence: 17.7] [Reference Citation Analysis]
328 Malapelle U, Rossi A, Bria E. Relationship between performance status or younger age and osimertinib therapy in T790M-positive NSCLC: are the available data convincing? J Thorac Dis 2019;11:S1837-40. [PMID: 31632763 DOI: 10.21037/jtd.2019.08.99] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
329 Enewold L, Thomas A. Real-World Patterns of EGFR Testing and Treatment with Erlotinib for Non-Small Cell Lung Cancer in the United States. PLoS One 2016;11:e0156728. [PMID: 27294665 DOI: 10.1371/journal.pone.0156728] [Cited by in Crossref: 38] [Cited by in F6Publishing: 41] [Article Influence: 6.3] [Reference Citation Analysis]
330 Chen JY, Cheng YN, Han L, Wei F, Yu WW, Zhang XW, Cao S, Yu JP. Predictive value of K-ras and PIK3CA in non-small cell lung cancer patients treated with EGFR-TKIs: a systemic review and meta-analysis. Cancer Biol Med 2015;12:126-39. [PMID: 26175928 DOI: 10.7497/j.issn.2095-3941.2015.0021] [Cited by in F6Publishing: 12] [Reference Citation Analysis]
331 Hirsh V, Blais N, Burkes R, Verma S, Croitoru K. Management of diarrhea induced by epidermal growth factor receptor tyrosine kinase inhibitors. Curr Oncol 2014;21:329-36. [PMID: 25489260 DOI: 10.3747/co.21.2241] [Cited by in Crossref: 49] [Cited by in F6Publishing: 41] [Article Influence: 6.1] [Reference Citation Analysis]
332 Keating GM. Afatinib: A Review in Advanced Non-Small Cell Lung Cancer. Target Oncol 2016;11:825-35. [PMID: 27873136 DOI: 10.1007/s11523-016-0465-2] [Cited by in Crossref: 12] [Cited by in F6Publishing: 16] [Article Influence: 2.4] [Reference Citation Analysis]
333 Wang Y, Zheng C, Lu W, Wang D, Cheng Y, Chen Y, Hou K, Qi J, Liu Y, Che X, Hu X. Bioinformatics-Based Identification of HDAC Inhibitors as Potential Drugs to Target EGFR Wild-Type Non-Small-Cell Lung Cancer. Front Oncol 2021;11:620154. [PMID: 33763356 DOI: 10.3389/fonc.2021.620154] [Reference Citation Analysis]
334 Castellano GM, Pine SR. Liquid biopsies in non-small cell lung cancer management: what can we learn from methylation status and mutant allele frequencies? Transl Lung Cancer Res 2020;9:951-5. [PMID: 32953473 DOI: 10.21037/tlcr.2020.04.05] [Reference Citation Analysis]
335 Tamiya M, Tamiya A, Okamoto N, Taniguchi Y, Nishino K, Atagi S, Hirashima T, Imamura F, Kumagai T, Suzuki H. The ratio of T790M to EGFR-activating mutation predicts response of osimertinib in 1st or 2nd generation EGFR-TKI-refractory NSCLC. Sci Rep 2021;11:9629. [PMID: 33953280 DOI: 10.1038/s41598-021-89006-9] [Reference Citation Analysis]
336 Deeks ED, Keating GM. Afatinib in advanced NSCLC: a profile of its use. Drugs Ther Perspect 2018;34:89-98. [PMID: 29540977 DOI: 10.1007/s40267-018-0482-6] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 2.3] [Reference Citation Analysis]
337 Lu S. Development of treatment options for Chinese patients with advanced squamous cell lung cancer: focus on afatinib. Onco Targets Ther 2019;12:1521-38. [PMID: 30863118 DOI: 10.2147/OTT.S188296] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.7] [Reference Citation Analysis]
338 Jotte RM, Spigel DR. Advances in molecular-based personalized non-small-cell lung cancer therapy: targeting epidermal growth factor receptor and mechanisms of resistance. Cancer Med 2015;4:1621-32. [PMID: 26310719 DOI: 10.1002/cam4.506] [Cited by in Crossref: 28] [Cited by in F6Publishing: 28] [Article Influence: 4.0] [Reference Citation Analysis]
339 Puliafito I, Esposito F, Raciti G, Giuffrida P, Caltavuturo C, Colarossi C, Munao S, Sciacca D, Giuffrida D. Metabolic complete tumor response in a patient with epidermal growth factor receptor mutant non-small cell lung cancer treated with a reduced dose of afatinib. J Int Med Res 2022;50:3000605211058864. [PMID: 35291829 DOI: 10.1177/03000605211058864] [Reference Citation Analysis]
340 Huang YH, Hung JY, Ko HW, Su PL, Lai CL, Chang HC, Hsia TC, Lin SH, Wu KL, Yang CT, Su WC, Chu YC, Wang CC, Liao WY, Lin YT, Lin CH, Lin MC, Hsu KH, Tseng JS, Yang TY, Chen KC, Lee MH, Yu SL, Ho CC, Chang GC. The relative importance of predictive factors for single first-generation EGFR-TKI use for more than 5 years in patients with advanced non-small cell lung cancer: Taiwan multicenter TIPS-5 study. Ther Adv Med Oncol 2021;13:17588359211018022. [PMID: 34093743 DOI: 10.1177/17588359211018022] [Reference Citation Analysis]
341 Han F, He J, Li F, Yang J, Wei J, Cho WC, Liu X. Emerging Roles of MicroRNAs in EGFR-Targeted Therapies for Lung Cancer. Biomed Res Int 2015;2015:672759. [PMID: 26273639 DOI: 10.1155/2015/672759] [Cited by in Crossref: 21] [Cited by in F6Publishing: 26] [Article Influence: 3.0] [Reference Citation Analysis]
342 Minuti G, D'Incecco A, Cappuzzo F. Current and Emerging Options in the Management of EGFR Mutation-Positive Non-Small-Cell Lung Cancer: Considerations in the Elderly. Drugs Aging 2015;32:907-16. [PMID: 26446154 DOI: 10.1007/s40266-015-0305-6] [Cited by in Crossref: 8] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
343 Levantini E, Maroni G, Del Re M, Tenen DG. EGFR signaling pathway as therapeutic target in human cancers. Semin Cancer Biol 2022:S1044-579X(22)00096-7. [PMID: 35427766 DOI: 10.1016/j.semcancer.2022.04.002] [Reference Citation Analysis]
344 Schremser K, Rogowski WH, Adler-Reichel S, Tufman AL, Huber RM, Stollenwerk B. Cost-Effectiveness of an Individualized First-Line Treatment Strategy Offering Erlotinib Based on EGFR Mutation Testing in Advanced Lung Adenocarcinoma Patients in Germany. Pharmacoeconomics 2015;33:1215-28. [PMID: 26081300 DOI: 10.1007/s40273-015-0305-8] [Cited by in Crossref: 18] [Cited by in F6Publishing: 17] [Article Influence: 3.0] [Reference Citation Analysis]
345 Wu WS, Chen YM. Re-Treatment with EGFR-TKIs in NSCLC Patients Who Developed Acquired Resistance. J Pers Med 2014;4:297-310. [PMID: 25563355 DOI: 10.3390/jpm4030297] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 1.3] [Reference Citation Analysis]
346 Iwama E, Sakai K, Azuma K, Harada D, Nosaki K, Hotta K, Nishio M, Kurata T, Fukuhara T, Akamatsu H, Goto K, Shimose T, Kishimoto J, Nakanishi Y, Nishio K, Okamoto I. Exploration of resistance mechanisms for epidermal growth factor receptor-tyrosine kinase inhibitors based on plasma analysis by digital polymerase chain reaction and next-generation sequencing. Cancer Sci 2018;109:3921-33. [PMID: 30289575 DOI: 10.1111/cas.13820] [Cited by in Crossref: 13] [Cited by in F6Publishing: 18] [Article Influence: 3.3] [Reference Citation Analysis]
347 Bui KT, Cooper WA, Kao S, Boyer M. Targeted Molecular Treatments in Non-Small Cell Lung Cancer: A Clinical Guide for Oncologists. J Clin Med 2018;7:E192. [PMID: 30065223 DOI: 10.3390/jcm7080192] [Cited by in Crossref: 18] [Cited by in F6Publishing: 18] [Article Influence: 4.5] [Reference Citation Analysis]
348 Morin-Ben Abdallah S, Hirsh V. Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Treatment of Metastatic Non-Small Cell Lung Cancer, with a Focus on Afatinib. Front Oncol 2017;7:97. [PMID: 28560182 DOI: 10.3389/fonc.2017.00097] [Cited by in Crossref: 6] [Cited by in F6Publishing: 8] [Article Influence: 1.2] [Reference Citation Analysis]
349 Shen YW, Zhang XM, Li ST, Lv M, Yang J, Wang F, Chen ZL, Wang BY, Li P, Chen L, Yang J. Efficacy and safety of icotinib as first-line therapy in patients with advanced non-small-cell lung cancer. Onco Targets Ther 2016;9:929-35. [PMID: 26966381 DOI: 10.2147/OTT.S98363] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
350 Van Assche K, Ferdinande L, Lievens Y, Vandecasteele K, Surmont V. EGFR Mutation Positive Stage IV Non-Small-Cell Lung Cancer: Treatment Beyond Progression. Front Oncol 2014;4:350. [PMID: 25538894 DOI: 10.3389/fonc.2014.00350] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 0.9] [Reference Citation Analysis]
351 Ko R, Shukuya T, Imamura CK, Tokito T, Shimada N, Koyama R, Yamada K, Ishii H, Azuma K, Takahashi K. Phase I study of afatinib plus bevacizumab in patients with advanced non-squamous non-small cell lung cancer harboring EGFR mutations. Transl Lung Cancer Res 2021;10:183-92. [PMID: 33569303 DOI: 10.21037/tlcr-20-824] [Reference Citation Analysis]
352 Ferrara MG, Di Noia V, D'Argento E, Vita E, Damiano P, Cannella A, Ribelli M, Pilotto S, Milella M, Tortora G, Bria E. Oncogene-Addicted Non-Small-Cell Lung Cancer: Treatment Opportunities and Future Perspectives. Cancers (Basel) 2020;12:E1196. [PMID: 32397295 DOI: 10.3390/cancers12051196] [Cited by in Crossref: 19] [Cited by in F6Publishing: 16] [Article Influence: 9.5] [Reference Citation Analysis]
353 Reita D, Pabst L, Pencreach E, Guérin E, Dano L, Rimelen V, Voegeli AC, Vallat L, Mascaux C, Beau-Faller M. Molecular Mechanism of EGFR-TKI Resistance in EGFR-Mutated Non-Small Cell Lung Cancer: Application to Biological Diagnostic and Monitoring. Cancers (Basel) 2021;13:4926. [PMID: 34638411 DOI: 10.3390/cancers13194926] [Reference Citation Analysis]
354 You R, Liu J, Wu DB, Qian X, Lyu B, Zhang Y, Luo N. Cost-Effectiveness Analysis Of EGFR Mutation Testing And Afatinib Versus Gemcitabine-Cisplatin As First-Line Therapy For Advanced Non-Small-Cell Lung Cancer In China. Cancer Manag Res. 2019;11:10239-10248. [PMID: 31824194 DOI: 10.2147/cmar.s219722] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 1.7] [Reference Citation Analysis]
355 Zhou J, Zhao C, Zhao J, Wang Q, Chu X, Li J, Zhou F, Ren S, Li X, Su C, Zhou C. Re-biopsy and liquid biopsy for patients with non-small cell lung cancer after EGFR-tyrosine kinase inhibitor failure. Thorac Cancer 2019;10:957-65. [PMID: 30887673 DOI: 10.1111/1759-7714.13035] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 2.7] [Reference Citation Analysis]
356 Mitsudomi T, Kobayashi Y. Afatinib in lung cancer harboring EGFR mutation in the LUX-Lung trials: six plus three is greater than seven? Transl Lung Cancer Res 2016;5:446-9. [PMID: 27650363 DOI: 10.21037/tlcr.2016.07.06] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.7] [Reference Citation Analysis]
357 Clay TD, Russell PA, Do H, Sundararajan V, Conron M, Wright GM, Solomon B, Dobrovic A, McLachlan SA, Moore MM. EGFR and KRAS mutations do not enrich for the activation of IL-6, JAK1 or phosphorylated STAT3 in resected lung adenocarcinoma. Med Oncol 2017;34:175. [PMID: 28879441 DOI: 10.1007/s12032-017-1031-1] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
358 Liao BC, Lin CC, Yang JC. Novel EGFR Inhibitors in Non-small Cell Lung Cancer: Current Status of Afatinib. Curr Oncol Rep 2017;19:4. [PMID: 28138934 DOI: 10.1007/s11912-017-0560-2] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 1.2] [Reference Citation Analysis]
359 Xu R, Zhong G, Huang T, He W, Kong C, Zhang X, Wang Y, Liu M, Xu M, Chen S. Sequencing of circulating tumor DNA for dynamic monitoring of gene mutations in advanced non-small cell lung cancer. Oncol Lett 2018;15:3726-34. [PMID: 29556275 DOI: 10.3892/ol.2018.7808] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
360 Salvador-Coloma C, Lorente D, Palanca S, Simarro J, Mancheño N, Sandoval J, Lahoz A, Juan Ó. Early radiological response as predictor of overall survival in non-small cell lung cancer (NSCLC) patients with epidermal growth factor receptor mutations. J Thorac Dis 2018;10:1386-93. [PMID: 29707288 DOI: 10.21037/jtd.2018.02.30] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
361 Igawa S, Fukui T, Kasajima M, Ono T, Ozawa T, Kakegawa M, Kusuhara S, Sato T, Nakahara Y, Hisashi M, Sasaki J, Naoki K. First-line osimertinib for poor performance status patients with EGFR mutation-positive non-small cell lung cancer: A prospective observational study. Invest New Drugs 2021. [PMID: 34807331 DOI: 10.1007/s10637-021-01195-2] [Reference Citation Analysis]
362 Melosky B, Blais N, Cheema P, Couture C, Juergens R, Kamel-Reid S, Tsao MS, Wheatley-Price P, Xu Z, Ionescu DN. Standardizing biomarker testing for Canadian patients with advanced lung cancer. Curr Oncol 2018;25:73-82. [PMID: 29507487 DOI: 10.3747/co.25.3867] [Cited by in Crossref: 4] [Cited by in F6Publishing: 11] [Article Influence: 1.0] [Reference Citation Analysis]
363 Rajan A, Schrump DS. Precision Therapy for Lung Cancer: Tyrosine Kinase Inhibitors and Beyond. Semin Thorac Cardiovasc Surg 2015;27:36-48. [PMID: 26074108 DOI: 10.1053/j.semtcvs.2015.04.002] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 1.1] [Reference Citation Analysis]
364 Cho JH, Lim SH, An HJ, Kim KH, Park KU, Kang EJ, Choi YH, Ahn MS, Lee MH, Sun JM, Lee SH, Ahn JS, Park K, Ahn MJ. Osimertinib for Patients With Non-Small-Cell Lung Cancer Harboring Uncommon EGFR Mutations: A Multicenter, Open-Label, Phase II Trial (KCSG-LU15-09).J Clin Oncol. 2020;38:488-495. [PMID: 31825714 DOI: 10.1200/JCO.19.00931] [Cited by in Crossref: 73] [Cited by in F6Publishing: 44] [Article Influence: 24.3] [Reference Citation Analysis]
365 Chen YC, Tsai MJ, Lee MH, Kuo CY, Shen MC, Tsai YM, Chen HC, Hung JY, Huang MS, Chong IW, Yang CJ. Lower starting dose of afatinib for the treatment of metastatic lung adenocarcinoma harboring exon 21 and exon 19 mutations. BMC Cancer 2021;21:495. [PMID: 33941115 DOI: 10.1186/s12885-021-08235-3] [Reference Citation Analysis]
366 Yufen X, Binbin S, Wenyu C, Jialiang L, Xinmei Y. The role of EGFR-TKI for leptomeningeal metastases from non-small cell lung cancer. Springerplus 2016;5:1244. [PMID: 27536527 DOI: 10.1186/s40064-016-2873-2] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.2] [Reference Citation Analysis]
367 Zago G, Muller M, van den Heuvel M, Baas P. New targeted treatments for non-small-cell lung cancer - role of nivolumab. Biologics 2016;10:103-17. [PMID: 27536062 DOI: 10.2147/BTT.S87878] [Cited by in Crossref: 4] [Cited by in F6Publishing: 11] [Article Influence: 0.7] [Reference Citation Analysis]
368 Kobayashi Y, Mitsudomi T. Not all epidermal growth factor receptor mutations in lung cancer are created equal: Perspectives for individualized treatment strategy. Cancer Sci 2016;107:1179-86. [PMID: 27323238 DOI: 10.1111/cas.12996] [Cited by in Crossref: 152] [Cited by in F6Publishing: 151] [Article Influence: 25.3] [Reference Citation Analysis]
369 Lee Y, Lee KH, Lee GK, Lee SH, Lim KY, Joo J, Go YJ, Lee JS, Han JY. Randomized Phase II Study of Afatinib Plus Simvastatin Versus Afatinib Alone in Previously Treated Patients with Advanced Nonadenocarcinomatous Non-small Cell Lung Cancer. Cancer Res Treat 2017;49:1001-11. [PMID: 28111428 DOI: 10.4143/crt.2016.546] [Cited by in Crossref: 21] [Cited by in F6Publishing: 21] [Article Influence: 4.2] [Reference Citation Analysis]
370 Xu Z, Qiao Y, Tu J. Microfluidic Technologies for cfDNA Isolation and Analysis. Micromachines (Basel) 2019;10:E672. [PMID: 31623361 DOI: 10.3390/mi10100672] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
371 Cao Y, Qiu X, Xiao G, Hu H, Lin T. Effectiveness and safety of osimertinib in patients with metastatic EGFR T790M-positive NSCLC: An observational real-world study. PLoS One 2019;14:e0221575. [PMID: 31442277 DOI: 10.1371/journal.pone.0221575] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 2.3] [Reference Citation Analysis]
372 Hanna NH, Dahlberg SE, Kolesar JM, Aggarwal C, Hirsch FR, Ramalingam SS, Schiller JH. Three-arm, randomized, phase 2 study of carboplatin and paclitaxel in combination with cetuximab, cixutumumab, or both for advanced non-small cell lung cancer (NSCLC) patients who will not receive bevacizumab-based therapy: An Eastern Cooperative Oncology Group (ECOG) study (E4508). Cancer 2015;121:2253-61. [PMID: 25740387 DOI: 10.1002/cncr.29308] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 2.1] [Reference Citation Analysis]
373 Graham DM, Leighl NB. Economic Impact of Tissue Testing and Treatments of Metastatic NSCLC in the Era of Personalized Medicine. Front Oncol 2014;4:258. [PMID: 25295228 DOI: 10.3389/fonc.2014.00258] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
374 Gu W, Zhu Y, Ye D. Beyond chemotherapy for advanced disease-the role of EGFR and PD-1 inhibitors. Transl Androl Urol 2017;6:848-54. [PMID: 29184782 DOI: 10.21037/tau.2017.03.92] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
375 Bertran-Alamillo J, Cattan V, Schoumacher M, Codony-Servat J, Giménez-Capitán A, Cantero F, Burbridge M, Rodríguez S, Teixidó C, Roman R, Castellví J, García-Román S, Codony-Servat C, Viteri S, Cardona AF, Karachaliou N, Rosell R, Molina-Vila MA. AURKB as a target in non-small cell lung cancer with acquired resistance to anti-EGFR therapy. Nat Commun 2019;10:1812. [PMID: 31000705 DOI: 10.1038/s41467-019-09734-5] [Cited by in Crossref: 39] [Cited by in F6Publishing: 41] [Article Influence: 13.0] [Reference Citation Analysis]
376 Vu TH, Nguyen HTT, Dao LK, Duong CK, Nguyen CV, Doan TT, Nguyen HTT, Hoang HH, Dinh DK, Le GV, Vu TT, Truong MC, Nguyen LT. Effectiveness and Tolerability of First-Line Afatinib for Advanced EGFR-Mutant Non-Small Cell Lung Cancer in Vietnam. Asian Pac J Cancer Prev 2021;22:1581-90. [PMID: 34048189 DOI: 10.31557/APJCP.2021.22.5.1581] [Reference Citation Analysis]
377 Kasahara N, Imai H, Naruse I, Tsukagoshi Y, Kotake M, Sunaga N, Kaira K, Maeno T, Asao T, Hisada T. Glasgow prognostic score predicts efficacy and prognosis in patients with advanced non-small cell lung cancer receiving EGFR-TKI treatment. Thorac Cancer 2020;11:2188-95. [PMID: 32495520 DOI: 10.1111/1759-7714.13526] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
378 Chen YH, Chen YF, Chen CY, Shih JY, Yu CJ. Clinical factors associated with treatment outcomes in EGFR mutant non-small cell lung cancer patients with brain metastases: a case-control observational study. BMC Cancer 2019;19:1006. [PMID: 31655564 DOI: 10.1186/s12885-019-6140-0] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
379 Hirsh V. Turning EGFR mutation-positive non-small-cell lung cancer into a chronic disease: optimal sequential therapy with EGFR tyrosine kinase inhibitors. Ther Adv Med Oncol 2018;10:1758834017753338. [PMID: 29383041 DOI: 10.1177/1758834017753338] [Cited by in Crossref: 33] [Cited by in F6Publishing: 34] [Article Influence: 8.3] [Reference Citation Analysis]
380 Mogenet A, Greillier L, Tomasini P. The Value of Population Screening in Advancing Personalized Medicine in the Field of Lung Cancer. Pharmgenomics Pers Med 2021;14:987-96. [PMID: 34429632 DOI: 10.2147/PGPM.S267437] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
381 Ichiki M, Wataya H, Yamada K, Tsuruta N, Takeoka H, Okayama Y, Sasaki J, Hoshino T. Preventive effect of kampo medicine (hangeshashin-to, TJ-14) plus minocycline against afatinib-induced diarrhea and skin rash in patients with non-small cell lung cancer. Onco Targets Ther 2017;10:5107-13. [PMID: 29123409 DOI: 10.2147/OTT.S145613] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 1.8] [Reference Citation Analysis]
382 Pan Y, Gao G, Chen X, Tian Q, Wu F, Liu Q, Wang Y, Jiang T, Liu Y, Li X, Yang S, Xu C, Su C, Zhou F, Ren S, Zhou C. Larger tumors are associated with inferior progression-free survival of first-line EGFR-tyrosine kinase inhibitors and a lower abundance of EGFR mutation in patients with advanced non-small cell lung cancer. Thorac Cancer 2019;10:686-94. [PMID: 30793872 DOI: 10.1111/1759-7714.12986] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
383 Seebacher NA, Stacy AE, Porter GM, Merlot AM. Clinical development of targeted and immune based anti-cancer therapies. J Exp Clin Cancer Res 2019;38:156. [PMID: 30975211 DOI: 10.1186/s13046-019-1094-2] [Cited by in Crossref: 58] [Cited by in F6Publishing: 50] [Article Influence: 19.3] [Reference Citation Analysis]
384 Mountzios G. Making progress in epidermal growth factor receptor (EGFR)-mutant non-small cell lung cancer by surpassing resistance: third-generation EGFR tyrosine kinase inhibitors (EGFR-TKIs). Ann Transl Med 2018;6:140. [PMID: 29862229 DOI: 10.21037/atm.2017.10.04] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 2.8] [Reference Citation Analysis]
385 Wang X, Li X, Guo H, Zhu L, Peng Z, Wang J, Yang F, Guo Y. Highly Sensitive Droplet Digital PCR Method for Detection of de novo EGFR T790M Mutation in Patients with Non-Small Cell Lung Cancer. Onco Targets Ther 2020;13:10621-30. [PMID: 33116639 DOI: 10.2147/OTT.S267677] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
386 Gao X, Zhao Y, Bao Y, Yin W, Liu L, Liu R, Yu Z, Zhou X, Shuai J. Poor Prognosis With Coexistence Of EGFR T790M Mutation And Common EGFR-Activating Mutation In Non- Small Cell Lung Cancer. Cancer Manag Res 2019;11:9621-30. [PMID: 32009817 DOI: 10.2147/CMAR.S216721] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
387 Lin CC, Huang WL, Wei F, Su WC, Wong DT. Emerging platforms using liquid biopsy to detect EGFR mutations in lung cancer. Expert Rev Mol Diagn 2015;15:1427-40. [PMID: 26420338 DOI: 10.1586/14737159.2015.1094379] [Cited by in Crossref: 23] [Cited by in F6Publishing: 21] [Article Influence: 3.3] [Reference Citation Analysis]
388 Khrystolubova N, Shieh M, Patel AJ, Bailey R. Pharmacist-led patient education and adverse event management in patients with non-small cell lung cancer receiving afatinib in a community-based, real-world clinical setting. J Oncol Pharm Pract 2020;26:13-22. [PMID: 30832554 DOI: 10.1177/1078155219833441] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.3] [Reference Citation Analysis]
389 Qiao L, Wang J, Long G, Jiang Y. Sequential treatment of tyrosine kinase inhibitor and platinum-based doublet chemotherapy on EGFR mutant non-small cell lung cancer: a meta-analysis of randomized controlled clinical trials. Onco Targets Ther 2017;10:1279-84. [PMID: 28280362 DOI: 10.2147/OTT.S128187] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
390 Fujita K, Nakayama M, Sata M, Nagai Y, Hisata S, Mato N, Suzuki T, Bando M, Hizawa N, Hagiwara K. Highly sensitive detection of driver mutations from cytological samples and cfDNA in lung cancer. Cancer Med 2021;10:8595-603. [PMID: 34617674 DOI: 10.1002/cam4.4330] [Reference Citation Analysis]
391 Li S, Li J, Peng L, Li Y, Wan X. Cost-Effectiveness of Lorlatinib as a First-Line Therapy for Untreated Advanced Anaplastic Lymphoma Kinase-Positive Non-Small Cell Lung Cancer. Front Oncol 2021;11:684073. [PMID: 34136409 DOI: 10.3389/fonc.2021.684073] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
392 Liu Z, Xu L. UBE2S promotes the proliferation and survival of human lung adenocarcinoma cells. BMB Rep 2018;51:642-7. [PMID: 30545437 [PMID: 30545437 DOI: 10.5483/bmbrep.2018.51.12.138] [Cited by in Crossref: 10] [Article Influence: 3.3] [Reference Citation Analysis]
393 Sarcar B, Gimbrone NT, Wright G, Remsing Rix LL, Gordian ER, Rix U, Chiappori AA, Reuther GW, Santiago-Cardona PG, Muñoz-Antonia T, Cress WD. Characterization of epidermal growth factor receptor (EGFR) P848L, an unusual EGFR variant present in lung cancer patients, in a murine Ba/F3 model. FEBS Open Bio 2019;9:1689-704. [PMID: 31314158 DOI: 10.1002/2211-5463.12702] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
394 Melosky B. Rapidly changing treatment algorithms for metastatic nonsquamous non-small-cell lung cancer. Curr Oncol 2018;25:S68-76. [PMID: 29910649 DOI: 10.3747/co.25.3839] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.8] [Reference Citation Analysis]
395 Wiebe S, Schnell D, Külzer R, Gansser D, Weber A, Wallenstein G, Halabi A, Conrad A, Wind S. Influence of Renal Impairment on the Pharmacokinetics of Afatinib: An Open-Label, Single-Dose Study. Eur J Drug Metab Pharmacokinet 2017;42:461-9. [PMID: 27436099 DOI: 10.1007/s13318-016-0359-9] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 3.0] [Reference Citation Analysis]
396 Inoue A. Progress in individualized treatment for EGFR-mutated advanced non-small cell lung cancer. Proc Jpn Acad Ser B Phys Biol Sci 2020;96:266-72. [PMID: 32788550 DOI: 10.2183/pjab.96.020] [Reference Citation Analysis]
397 Ho GF, Chai CS, Alip A, Wahid MIA, Abdullah MM, Foo YC, How SH, Zaatar A, Lam KS, Leong KW, Low JS, Yusof MM, Lee EC, Toh YY, Liam CK. Real-world experience of first-line afatinib in patients with EGFR-mutant advanced NSCLC: a multicenter observational study. BMC Cancer. 2019;19:896. [PMID: 31500587 DOI: 10.1186/s12885-019-6107-1] [Cited by in Crossref: 13] [Cited by in F6Publishing: 14] [Article Influence: 4.3] [Reference Citation Analysis]
398 Chao TT, Wang CY, Chen YL, Lai CC, Chang FY, Tsai YT, Chao CH, Shiau CW, Huang YC, Yu CJ, Chen KF. Afatinib induces apoptosis in NSCLC without EGFR mutation through Elk-1-mediated suppression of CIP2A. Oncotarget 2015;6:2164-79. [PMID: 25537503 DOI: 10.18632/oncotarget.2941] [Cited by in Crossref: 29] [Cited by in F6Publishing: 30] [Article Influence: 4.1] [Reference Citation Analysis]
399 Ding X, Wang L, Liu X, Sun X, Yu J, Meng X. Genetic characterization drives personalized therapy for early-stage non-small-cell lung cancer (NSCLC) patients and survivors with metachronous second primary tumor (MST): A case report. Medicine (Baltimore). 2017;96:e6221. [PMID: 28272214 DOI: 10.1097/md.0000000000006221] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 0.8] [Reference Citation Analysis]
400 Karachaliou N, Rosell R. Targeted treatment of mutated EGFR-expressing non-small-cell lung cancer: focus on erlotinib with companion diagnostics. Lung Cancer (Auckl) 2014;5:73-9. [PMID: 28210145 DOI: 10.2147/LCTT.S50671] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
401 Bai W, Zhen C, Zhang R, Yu W, Zhou Z. Clinicopathological features of patients with transformation from EGFR mutant lung adenocarcinoma to small cell lung cancer. Transl Cancer Res 2021;10:3694-704. [PMID: 35116670 DOI: 10.21037/tcr-21-653] [Reference Citation Analysis]
402 Fan Y, Xu X, Xie C. EGFR-TKI therapy for patients with brain metastases from non-small-cell lung cancer: a pooled analysis of published data. Onco Targets Ther 2014;7:2075-84. [PMID: 25419145 DOI: 10.2147/OTT.S67586] [Cited by in Crossref: 9] [Cited by in F6Publishing: 26] [Article Influence: 1.1] [Reference Citation Analysis]
403 de Gramont A, Watson S, Ellis LM, Rodón J, Tabernero J, de Gramont A, Hamilton SR. Pragmatic issues in biomarker evaluation for targeted therapies in cancer. Nat Rev Clin Oncol 2015;12:197-212. [PMID: 25421275 DOI: 10.1038/nrclinonc.2014.202] [Cited by in Crossref: 126] [Cited by in F6Publishing: 98] [Article Influence: 15.8] [Reference Citation Analysis]
404 Pinsolle J, McLeer-Florin A, Giaj Levra M, de Fraipont F, Emprou C, Gobbini E, Toffart AC. Translating Systems Medicine Into Clinical Practice: Examples From Pulmonary Medicine With Genetic Disorders, Infections, Inflammations, Cancer Genesis, and Treatment Implication of Molecular Alterations in Non-small-cell Lung Cancers and Personalized Medicine. Front Med (Lausanne) 2019;6:233. [PMID: 31737634 DOI: 10.3389/fmed.2019.00233] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
405 Bhandari S, Dunlap N, Kloecker G. Radiotherapy in brain metastases from EGFR-mutated non-small cell lung cancer. J Thorac Dis 2021;13:3230-4. [PMID: 34164215 DOI: 10.21037/jtd-2019-rbmlc-04] [Reference Citation Analysis]
406 Nishimura T, Okano T, Naito M, Iwanaka S, Ohiwa A, Sakakura Y, Yasuma T, Fujimoto H, D'Alessandro-Gabazza CN, Oomoto Y, Kobayashi T, Gabazza EC, Ibata H. Second-line therapy with first- or second-generation tyrosine kinase inhibitors in EGFR-mutated non-small cell lung cancer patients with T790M-negative or unidentified mutation. Thorac Cancer 2021;12:1067-73. [PMID: 33586356 DOI: 10.1111/1759-7714.13870] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
407 Zhu J, Zhang Y, Wang M, Zhang Z, Yue D, Liu S, Pan Y, Wang C. Outcomes in 36 Patients with Stage IIIA-N2 Squamous Cell Carcinoma of the Lung Treated with Nab-Paclitaxel Plus Carboplatin as Neoadjuvant Therapy: A Prospective Study from a Single Center. Med Sci Monit 2021;27:e930738. [PMID: 34376631 DOI: 10.12659/MSM.930738] [Reference Citation Analysis]
408 Zhang Y, Zhang Y, Niu W, Ge X, Huang F, Pang J, Li X, Wang Y, Gao W, Fan F, Li S, Liu H. Experimental Study of Almonertinib Crossing the Blood-Brain Barrier in EGFR-Mutant NSCLC Brain Metastasis and Spinal Cord Metastasis Models. Front Pharmacol 2021;12:750031. [PMID: 34630120 DOI: 10.3389/fphar.2021.750031] [Reference Citation Analysis]
409 Cheng X, Chen H. Tumor heterogeneity and resistance to EGFR-targeted therapy in advanced nonsmall cell lung cancer: challenges and perspectives. Onco Targets Ther 2014;7:1689-704. [PMID: 25285017 DOI: 10.2147/OTT.S66502] [Cited by in Crossref: 44] [Cited by in F6Publishing: 30] [Article Influence: 5.5] [Reference Citation Analysis]
410 Rajurkar S, Mambetsariev I, Pharaon R, Leach B, Tan T, Kulkarni P, Salgia R. Non-Small Cell Lung Cancer from Genomics to Therapeutics: A Framework for Community Practice Integration to Arrive at Personalized Therapy Strategies. J Clin Med 2020;9:E1870. [PMID: 32549358 DOI: 10.3390/jcm9061870] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
411 Russo A, Franchina T, Ricciardi GR, Picone A, Ferraro G, Zanghì M, Toscano G, Giordano A, Adamo V. A decade of EGFR inhibition in EGFR-mutated non small cell lung cancer (NSCLC): Old successes and future perspectives. Oncotarget 2015;6:26814-25. [PMID: 26308162 DOI: 10.18632/oncotarget.4254] [Cited by in Crossref: 107] [Cited by in F6Publishing: 104] [Article Influence: 17.8] [Reference Citation Analysis]
412 Chu QS. Targeting non-small cell lung cancer: driver mutation beyond epidermal growth factor mutation and anaplastic lymphoma kinase fusion. Ther Adv Med Oncol 2020;12:1758835919895756. [PMID: 32047535 DOI: 10.1177/1758835919895756] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 5.5] [Reference Citation Analysis]
413 To C, Beyett TS, Jang J, Feng WW, Bahcall M, Haikala HM, Shin BH, Heppner DE, Rana JK, Leeper BA, Soroko KM, Poitras MJ, Gokhale PC, Kobayashi Y, Wahid K, Kurppa KJ, Gero TW, Cameron MD, Ogino A, Mushajiang M, Xu C, Zhang Y, Scott DA, Eck MJ, Gray NS, Jänne PA. An allosteric inhibitor against the therapy-resistant mutant forms of EGFR in non-small cell lung cancer. Nat Cancer 2022;3:402-17. [PMID: 35422503 DOI: 10.1038/s43018-022-00351-8] [Cited by in Crossref: 6] [Cited by in F6Publishing: 2] [Article Influence: 6.0] [Reference Citation Analysis]
414 Lee JY, Qing X, Xiumin W, Yali B, Chi S, Bak SH, Lee HY, Sun JM, Lee SH, Ahn JS, Cho EK, Kim DW, Kim HR, Min YJ, Jung SH, Park K, Mao M, Ahn MJ. Longitudinal monitoring of EGFR mutations in plasma predicts outcomes of NSCLC patients treated with EGFR TKIs: Korean Lung Cancer Consortium (KLCC-12-02). Oncotarget 2016;7:6984-93. [PMID: 26755650 DOI: 10.18632/oncotarget.6874] [Cited by in Crossref: 89] [Cited by in F6Publishing: 95] [Article Influence: 14.8] [Reference Citation Analysis]
415 Hung MS, Lung JH, Lin YC, Fang YH, Huang SY, Jiang YY, Hsieh MJ, Tsai YH. Comparative Analysis of Two Methods for the Detection of EGFR Mutations in Plasma Circulating Tumor DNA from Lung Adenocarcinoma Patients. Cancers (Basel) 2019;11:E803. [PMID: 31185703 DOI: 10.3390/cancers11060803] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 0.7] [Reference Citation Analysis]
416 Sa H, Song P, Ma K, Gao Y, Zhang L, Wang D. Perioperative Targeted Therapy Or Immunotherapy In Non-Small-Cell Lung Cancer. Onco Targets Ther 2019;12:8151-9. [PMID: 31632066 DOI: 10.2147/OTT.S222412] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]
417 Hung MH, Wang CY, Chen YL, Chu PY, Hsiao YJ, Tai WT, Chao TT, Yu HC, Shiau CW, Chen KF. SET antagonist enhances the chemosensitivity of non-small cell lung cancer cells by reactivating protein phosphatase 2A. Oncotarget 2016;7:638-55. [PMID: 26575017 DOI: 10.18632/oncotarget.6313] [Cited by in Crossref: 23] [Cited by in F6Publishing: 22] [Article Influence: 3.8] [Reference Citation Analysis]
418 Bahleda R, Varga A, Bergé Y, Soria JC, Schnell D, Tschoepe I, Uttenreuther-Fischer M, Delord JP. Phase I open-label study of afatinib plus vinorelbine in patients with solid tumours overexpressing EGFR and/or HER2. Br J Cancer 2018;118:344-52. [PMID: 29337963 DOI: 10.1038/bjc.2017.436] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
419 Lu D, Wang Z, Liu X, Feng S, Dong X, Shi X, Wang H, Wu H, Xiong G, Wang H, Cai K. Differential effects of adjuvant EGFR tyrosine kinase inhibitors in patients with different stages of non-small-cell lung cancer after radical resection: an updated meta-analysis. Cancer Manag Res 2019;11:2677-90. [PMID: 31037035 DOI: 10.2147/CMAR.S187940] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
420 Igarashi T, Teramoto K, Ishida M, Hanaoka J, Daigo Y. Scoring of PD-L1 expression intensity on pulmonary adenocarcinomas and the correlations with clinicopathological factors. ESMO Open 2016;1:e000083. [PMID: 27843633 DOI: 10.1136/esmoopen-2016-000083] [Cited by in Crossref: 38] [Cited by in F6Publishing: 40] [Article Influence: 6.3] [Reference Citation Analysis]
421 Kim YJ, Oremus M, Chen HH, McFarlane T, Fearon D, Horton S. Cost-Effectiveness Analysis of Afatinib, Erlotinib, and Gefitinib as First-Line Treatments for EGFR Mutation-Positive Non-Small-Cell Lung Cancer in Ontario, Canada. Pharmacoeconomics 2021;39:537-48. [PMID: 33786799 DOI: 10.1007/s40273-021-01022-9] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
422 Russo A, Franchina T, Ricciardi G, Battaglia A, Picciotto M, Adamo V. Heterogeneous Responses to Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitors (TKIs) in Patients with Uncommon EGFR Mutations: New Insights and Future Perspectives in this Complex Clinical Scenario. Int J Mol Sci 2019;20:E1431. [PMID: 30901844 DOI: 10.3390/ijms20061431] [Cited by in Crossref: 22] [Cited by in F6Publishing: 27] [Article Influence: 7.3] [Reference Citation Analysis]
423 Zhu WY, Li HF, Fang KX, Zhang BJ, Zhou SQ, Zhang YK, Le HB, Hu XF. Epidermal Growth Factor Receptor Mutations and Their Prognostic Value with Carcinoembryonic Antigen in Pathological T1 Lung Adenocarcinoma. Dis Markers 2018;2018:2942618. [PMID: 29849818 DOI: 10.1155/2018/2942618] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
424 Ariyasu R, Uchibori K, Sasaki T, Tsukahara M, Kiyotani K, Yoshida R, Ono Y, Kitazono S, Ninomiya H, Ishikawa Y, Mizukami Y, Yanagitani N, Fujita N, Nishio M, Katayama R. Monitoring epidermal growth factor receptor C797S mutation in Japanese non-small cell lung cancer patients with serial cell-free DNA evaluation using digital droplet PCR. Cancer Sci 2021;112:2371-80. [PMID: 33686722 DOI: 10.1111/cas.14879] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
425 Sundar R, Chénard-Poirier M, Collins DC, Yap TA. Imprecision in the Era of Precision Medicine in Non-Small Cell Lung Cancer. Front Med (Lausanne) 2017;4:39. [PMID: 28443282 DOI: 10.3389/fmed.2017.00039] [Cited by in Crossref: 8] [Cited by in F6Publishing: 12] [Article Influence: 1.6] [Reference Citation Analysis]
426 Amelia T, Kartasasmita RE, Ohwada T, Tjahjono DH. Structural Insight and Development of EGFR Tyrosine Kinase Inhibitors. Molecules 2022;27:819. [PMID: 35164092 DOI: 10.3390/molecules27030819] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
427 Boolell V, Alamgeer M, Watkins DN, Ganju V. The Evolution of Therapies in Non-Small Cell Lung Cancer. Cancers (Basel) 2015;7:1815-46. [PMID: 26371045 DOI: 10.3390/cancers7030864] [Cited by in Crossref: 67] [Cited by in F6Publishing: 71] [Article Influence: 9.6] [Reference Citation Analysis]
428 Moll HP, Pranz K, Musteanu M, Grabner B, Hruschka N, Mohrherr J, Aigner P, Stiedl P, Brcic L, Laszlo V, Schramek D, Moriggl R, Eferl R, Moldvay J, Dezso K, Lopez-Casas PP, Stoiber D, Hidalgo M, Penninger J, Sibilia M, Győrffy B, Barbacid M, Dome B, Popper H, Casanova E. Afatinib restrains K-RAS-driven lung tumorigenesis. Sci Transl Med 2018;10:eaao2301. [PMID: 29925635 DOI: 10.1126/scitranslmed.aao2301] [Cited by in Crossref: 51] [Cited by in F6Publishing: 47] [Article Influence: 17.0] [Reference Citation Analysis]
429 Wu D, Duan C, Wu F, Chen L, Chen S. Which treatment is preferred for advanced non-small-cell lung cancer with wild-type epidermal growth factor receptor in second-line therapy? A meta-analysis comparing immune checkpoint inhibitor, tyrosine kinase inhibitor and chemotherapy. Oncotarget 2017;8:66491-503. [PMID: 29029530 DOI: 10.18632/oncotarget.20281] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
430 Maarof NNN, Alsalahi A, Abdulmalek E, Fakurazi S, Tejo BA, Abdul Rahman MB. Efficacy of Afatinib in the Treatment of Patients with Non-Small Cell Lung Cancer and Head and Neck Squamous Cell Carcinoma: A Systematic Review and Meta-Analysis. Cancers (Basel) 2021;13:688. [PMID: 33567737 DOI: 10.3390/cancers13040688] [Reference Citation Analysis]
431 Zheng H, Liu QX, Hou B, Zhou D, Li JM, Lu X, Wu QP, Dai JG. Clinical outcomes of WBRT plus EGFR-TKIs versus WBRT or TKIs alone for the treatment of cerebral metastatic NSCLC patients: a meta-analysis. Oncotarget 2017;8:57356-64. [PMID: 28915676 DOI: 10.18632/oncotarget.19054] [Cited by in Crossref: 8] [Cited by in F6Publishing: 11] [Article Influence: 1.6] [Reference Citation Analysis]
432 Pisapia P, Malapelle U, Troncone G. Liquid Biopsy and Lung Cancer. Acta Cytol 2019;63:489-96. [PMID: 30566947 DOI: 10.1159/000492710] [Cited by in Crossref: 38] [Cited by in F6Publishing: 39] [Article Influence: 9.5] [Reference Citation Analysis]
433 Hotta T, Nakashima K, Hata K, Tsubata Y, Isobe T. High serum C-reactive protein levels predict survival in patients with treated advanced lung adenocarcinoma. J Thorac Dis 2021;13:1476-84. [PMID: 33841940 DOI: 10.21037/jtd-20-3123] [Reference Citation Analysis]
434 Yao S, Gu Y, Zhang Y. [Efficacy and Toxicity of Metronomic Oral Vinorelbinen in Advanced Non-small Cell Lung Cancer after Failure to Multiple-lines Treatments]. Zhongguo Fei Ai Za Zhi 2017;20:737-40. [PMID: 29167002 DOI: 10.3779/j.issn.1009-3419.2017.11.03] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
435 Gristina V, La Mantia M, Galvano A, Cutaia S, Barraco N, Castiglia M, Perez A, Bono M, Iacono F, Greco M, Calcara K, Calò V, Rizzo S, Incorvaia L, Lisanti MC, Santanelli G, Sardo D, Inguglia S, Insalaco L, Castellana L, Cusenza S, Pantuso G, Russo A, Bazan V. Non-Small Cell Lung Cancer Harboring Concurrent EGFR Genomic Alterations: A Systematic Review and Critical Appraisal of the Double Dilemma. JMP 2021;2:173-96. [DOI: 10.3390/jmp2020016] [Cited by in Crossref: 4] [Article Influence: 4.0] [Reference Citation Analysis]
436 Lin JJ, Cardarella S, Lydon CA, Dahlberg SE, Jackman DM, Jänne PA, Johnson BE. Five-Year Survival in EGFR-Mutant Metastatic Lung Adenocarcinoma Treated with EGFR-TKIs. J Thorac Oncol 2016;11:556-65. [PMID: 26724471 DOI: 10.1016/j.jtho.2015.12.103] [Cited by in Crossref: 125] [Cited by in F6Publishing: 144] [Article Influence: 17.9] [Reference Citation Analysis]
437 Passaro A, de Marinis F, Tu HY, Laktionov KK, Feng J, Poltoratskiy A, Zhao J, Tan EH, Gottfried M, Lee V, Kowalski D, Yang CT, Srinivasa BJ, Clementi L, Jalikop T, Huang DCL, Cseh A, Park K, Wu YL. Afatinib in EGFR TKI-Naïve Patients with Locally Advanced or Metastatic EGFR Mutation-Positive Non-Small Cell Lung Cancer: A Pooled Analysis of Three Phase IIIb Studies. Front Oncol 2021;11:709877. [PMID: 34307179 DOI: 10.3389/fonc.2021.709877] [Reference Citation Analysis]
438 Lee IH, Yang CY, Shih JY, Yu CJ. Tyrosine Kinase Inhibitors Improved Survival of Critically Ill EGFR-Mutant Lung Cancer Patients Undergoing Mechanical Ventilation. Biomedicines 2021;9:1416. [PMID: 34680533 DOI: 10.3390/biomedicines9101416] [Reference Citation Analysis]
439 Schou M, Varnäs K. PET microdosing of CNS drugs. Clin Transl Imaging 2017;5:291-8. [DOI: 10.1007/s40336-017-0226-y] [Cited by in Crossref: 1] [Article Influence: 0.2] [Reference Citation Analysis]
440 Piscitelli J, Chen J, LaBadie RR, Salageanu J, Chung CH, Tan W. The Effect of Hepatic Impairment on the Pharmacokinetics of Dacomitinib. Clin Drug Investig 2022. [PMID: 35195881 DOI: 10.1007/s40261-022-01125-x] [Reference Citation Analysis]
441 Dugger SA, Platt A, Goldstein DB. Drug development in the era of precision medicine. Nat Rev Drug Discov 2018;17:183-96. [PMID: 29217837 DOI: 10.1038/nrd.2017.226] [Cited by in Crossref: 147] [Cited by in F6Publishing: 113] [Article Influence: 29.4] [Reference Citation Analysis]
442 Ansari J, Yun JW, Kompelli AR, Moufarrej YE, Alexander JS, Herrera GA, Shackelford RE. The liquid biopsy in lung cancer. Genes Cancer 2016;7:355-67. [PMID: 28191282 DOI: 10.18632/genesandcancer.127] [Cited by in Crossref: 17] [Cited by in F6Publishing: 20] [Article Influence: 3.4] [Reference Citation Analysis]
443 Schnell D, Buschke S, Fuchs H, Gansser D, Goeldner RG, Uttenreuther-Fischer M, Stopfer P, Wind S, Petersen-Sylla M, Halabi A, Koenen R. Pharmacokinetics of afatinib in subjects with mild or moderate hepatic impairment. Cancer Chemother Pharmacol 2014;74:267-75. [PMID: 24906422 DOI: 10.1007/s00280-014-2484-y] [Cited by in Crossref: 30] [Cited by in F6Publishing: 26] [Article Influence: 3.8] [Reference Citation Analysis]
444 Chen C, Liu SM, Chen Y, Ou Q, Bao H, Xu L, Zhang Y, Zhong W, Zhou Q, Yang XN, Shao Y, Wu YL, Liu SY, Li Y. Predictive value of TCR Vβ-Jβ profile for adjuvant gefitinib in EGFR mutant NSCLC from ADJUVANT-CTONG 1104 trial. JCI Insight 2022;7:e152631. [PMID: 35014626 DOI: 10.1172/jci.insight.152631] [Reference Citation Analysis]
445 Seto T, Nogami N, Yamamoto N, Atagi S, Tashiro N, Yoshimura Y, Yabuki Y, Saka H. Real-World EGFR T790M Testing in Advanced Non-Small-Cell Lung Cancer: A Prospective Observational Study in Japan. Oncol Ther 2018;6:203-15. [PMID: 32700028 DOI: 10.1007/s40487-018-0064-8] [Cited by in Crossref: 21] [Cited by in F6Publishing: 18] [Article Influence: 5.3] [Reference Citation Analysis]
446 Harada D, Isozaki H, Kozuki T, Yokoyama T, Yoshioka H, Bessho A, Hosokawa S, Takata I, Takigawa N, Hotta K, Kiura K; Okayama Lung Cancer Study Group. Crizotinib for recurring non-small-cell lung cancer with EML4-ALK fusion genes previously treated with alectinib: A phase II trial. Thorac Cancer 2021;12:643-9. [PMID: 33470536 DOI: 10.1111/1759-7714.13825] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
447 Wang Y, He Y, Tian P, Wang W, Wang K, Chuai S, Li Y, Zhao S, Wang Y, Li W. Low T790M relative allele frequency indicates concurrent resistance mechanisms and poor responsiveness to osimertinib. Transl Lung Cancer Res 2020;9:1952-62. [PMID: 33209615 DOI: 10.21037/tlcr-20-915] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
448 Rajagopalan K, Govindan R. Epidermal growth factor receptor tyrosine kinase inhibitors in non-small cell lung cancer: a decade of progress and hopeful future. J Thorac Dis 2015;7:217-9. [PMID: 25922693 DOI: 10.3978/j.issn.2072-1439.2015.01.53] [Reference Citation Analysis]
449 Paludan-Müller AS, Créquit P, Boutron I. Reporting of harms in oncological clinical study reports submitted to the European Medicines Agency compared to trial registries and publications-a methodological review. BMC Med 2021;19:88. [PMID: 33827569 DOI: 10.1186/s12916-021-01955-0] [Reference Citation Analysis]
450 Ricciuti B. Osimertinib for EGFR-mutant non-small cell lung cancer: place in therapy and future perspectives. J Thorac Dis 2019;11:S249-52. [PMID: 30997189 DOI: 10.21037/jtd.2019.01.104] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
451 Zhang W, Gong C, Chen Z, Li M, Li Y, Gao J. Tumor microenvironment-activated cancer cell membrane-liposome hybrid nanoparticle-mediated synergistic metabolic therapy and chemotherapy for non-small cell lung cancer. J Nanobiotechnology 2021;19:339. [PMID: 34689761 DOI: 10.1186/s12951-021-01085-y] [Reference Citation Analysis]
452 Ninomiya K, Teraoka S, Zenke Y, Kenmotsu H, Nakamura Y, Okuma Y, Tamiya A, Nosaki K, Morise M, Aokage K, Oya Y, Kozuki T, Sakamoto T, Tanaka K, Tanaka H, Tanizaki J, Miura S, Mizutani H, Miyauchi E, Yamaguchi O, Ebi N, Goto Y, Sasaki T, Daga H, Morita S, Yamanaka T, Amano S, Hasegawa K, Imamura CK, Suzuki K, Nakajima K, Nishimoto H, Oizumi S, Hida T, Hotta K, Takiguchi Y. Japanese Lung Cancer Society Guidelines for Stage IV NSCLC With EGFR Mutations. JTO Clin Res Rep 2021;2:100107. [PMID: 34589972 DOI: 10.1016/j.jtocrr.2020.100107] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
453 Takahashi T, Terazono H, Suetsugu T, Sugawara H, Arima J, Nitta M, Tanabe T, Okutsu K, Ikeda R, Mizuno K, Inoue H, Takeda Y. High-Trough Plasma Concentration of Afatinib Is Associated with Dose Reduction. Cancers (Basel) 2021;13:3425. [PMID: 34298637 DOI: 10.3390/cancers13143425] [Reference Citation Analysis]
454 Passiglia F, Raez LE, Rolfo C. Moving osimertinib to first-line: the right "strategy" in the chessboard of epidermal growth factor receptor-mutated non-small cell lung cancer? J Thorac Dis 2018;10:S1076-80. [PMID: 29849216 DOI: 10.21037/jtd.2018.03.92] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
455 Kim ES, Halmos B, Kohut IF, Patel T, Rostorfer RD, Spira AI, Cseh A, McKay J, Wallenstein G, Mileham KF. Efficacy and Safety Results of the Afatinib Expanded Access Program. Oncol Ther 2017;5:103-10. [PMID: 28680960 DOI: 10.1007/s40487-017-0043-5] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
456 Jiang T, Luo Y, Wang B. Almonertinib-induced interstitial lung disease: A case report. Medicine (Baltimore) 2021;100:e24393. [PMID: 33546082 DOI: 10.1097/MD.0000000000024393] [Cited by in Crossref: 2] [Article Influence: 2.0] [Reference Citation Analysis]
457 Xu C, Offin M, Paik PK, Li BT. Liquid biopsy guided precision therapy for lung cancers. J Thorac Dis 2018;10:S4173-5. [PMID: 30631586 DOI: 10.21037/jtd.2018.11.02] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
458 Liu X, Ma B, Li T, Zhao L. Case Report: Afatinib-Induced Interstitial Pneumonia: Experiences and Lessons From Two Patients. Front Pharmacol 2021;12:698447. [PMID: 34721009 DOI: 10.3389/fphar.2021.698447] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
459 Lasala R, Santoleri F, Romagnoli A, Musicco F, Costantini A. Dosage adjustments in pivotal clinical trials with oral targeted therapies in solid tumors conducted in Europe. Eur J Clin Pharmacol 2019;75:697-706. [PMID: 30617511 DOI: 10.1007/s00228-018-02621-w] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
460 Huang AC, Huang CH, Ju JS, Chiu TH, Tung PH, Wang CC, Liu CY, Chung FT, Fang YF, Guo YK, Kuo CS, Yang CT. First- or second-generation epidermal growth factor receptor tyrosine kinase inhibitors in a large, real-world cohort of patients with non-small cell lung cancer. Ther Adv Med Oncol 2021;13:17588359211035710. [PMID: 34377157 DOI: 10.1177/17588359211035710] [Reference Citation Analysis]
461 Moaddel R, Ubaida-Mohien C, Tanaka T, Lyashkov A, Basisty N, Schilling B, Semba RD, Franceschi C, Gorospe M, Ferrucci L. Proteomics in aging research: A roadmap to clinical, translational research. Aging Cell 2021;20:e13325. [PMID: 33730416 DOI: 10.1111/acel.13325] [Cited by in Crossref: 10] [Cited by in F6Publishing: 5] [Article Influence: 10.0] [Reference Citation Analysis]
462 Kato Y, Hosomi Y, Watanabe K, Yomota M, Kawai S, Okuma Y, Kubota K, Seike M, Gemma A, Okamura T. Impact of clinical features on the efficacy of osimertinib therapy in patients with T790M-positive non-small cell lung cancer and acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors. J Thorac Dis 2019;11:2350-60. [PMID: 31372272 DOI: 10.21037/jtd.2019.06.03] [Cited by in Crossref: 8] [Cited by in F6Publishing: 19] [Article Influence: 2.7] [Reference Citation Analysis]
463 Rulli E, Ghilotti F, Biagioli E, Porcu L, Marabese M, D'Incalci M, Bellocco R, Torri V. Assessment of proportional hazard assumption in aggregate data: a systematic review on statistical methodology in clinical trials using time-to-event endpoint. Br J Cancer 2018;119:1456-63. [PMID: 30420618 DOI: 10.1038/s41416-018-0302-8] [Cited by in Crossref: 14] [Cited by in F6Publishing: 11] [Article Influence: 3.5] [Reference Citation Analysis]
464 Vigarios E, Epstein JB, Sibaud V. Oral mucosal changes induced by anticancer targeted therapies and immune checkpoint inhibitors. Support Care Cancer 2017;25:1713-39. [PMID: 28224235 DOI: 10.1007/s00520-017-3629-4] [Cited by in Crossref: 65] [Cited by in F6Publishing: 51] [Article Influence: 13.0] [Reference Citation Analysis]
465 Kwok WC, Ho JCM, Tam TCC, Ip MSM, Lam DCL. Survival benefits from afatinib compared with gefitinib and erlotinib among patients with common EGFR mutation in first-line setting. Thorac Cancer 2022. [PMID: 35668712 DOI: 10.1111/1759-7714.14528] [Reference Citation Analysis]
466 Ng TL, Camidge DR. AURA 3: the last word on chemotherapy as a control arm in EGFR mutant NSCLC? Ann Transl Med 2017;5:S14. [PMID: 28567396 DOI: 10.21037/atm.2017.03.73] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
467 Ye X, Xie G, Liu Z, Tang J, Cui M, Wang C, Guo C, Tang J. TNNC1 Reduced Gemcitabine Sensitivity of Nonsmall-Cell Lung Cancer by Increasing Autophagy. Med Sci Monit 2020;26:e922703. [PMID: 32946432 DOI: 10.12659/MSM.922703] [Cited by in Crossref: 2] [Article Influence: 1.0] [Reference Citation Analysis]
468 Jian H, Li W, Ma Z, Huang J, Feng J, Song Y, Gao B, Zhu H, Tao M, Bai C, Ma S, Pan H, Qin S, Hua D, Yu Y, Lu S. Intercalating and maintenance gefitinib plus chemotherapy vs chemotherapy alone in selected advanced non-small cell lung cancer with unknown EGFR status. Sci Rep. 2017;7:8483. [PMID: 28814805 DOI: 10.1038/s41598-017-08399-8] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
469 Dai LJ, Wang C, Ding ZY. A Case-control Study Supporting the Use of Liquid Biopsy in the Targeted Therapy for Lung Cancer. Asian Pac J Cancer Prev 2018;19:1761-6. [PMID: 30049184 DOI: 10.22034/APJCP.2018.19.7.1761] [Cited by in F6Publishing: 4] [Reference Citation Analysis]
470 Esposito A, Criscitiello C, Trapani D, Curigliano G. The Emerging Role of "Liquid Biopsies," Circulating Tumor Cells, and Circulating Cell-Free Tumor DNA in Lung Cancer Diagnosis and Identification of Resistance Mutations. Curr Oncol Rep. 2017;19:1. [PMID: 28110461 DOI: 10.1007/s11912-017-0564-y] [Cited by in Crossref: 28] [Cited by in F6Publishing: 28] [Article Influence: 5.6] [Reference Citation Analysis]
471 Chu Q, Agha A, Devost N, Walton RN, Ghosh S, Ho C. Biopsy on progression in patients with EGFR mutation-positive advanced non-small-cell lung cancer-a Canadian experience. Curr Oncol 2020;27:27-33. [PMID: 32218657 DOI: 10.3747/co.27.5347] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
472 Huang CY, Chen BH, Chou WC, Yang CT, Chang JW. Factors associated with the prognosis and long-term survival of patients with metastatic lung adenocarcinoma: a retrospective analysis. J Thorac Dis 2018;10:2070-8. [PMID: 29850110 DOI: 10.21037/jtd.2018.03.143] [Cited by in Crossref: 4] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
473 Nagano T, Tachihara M, Nishimura Y. Mechanism of Resistance to Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitors and a Potential Treatment Strategy. Cells 2018;7:E212. [PMID: 30445769 DOI: 10.3390/cells7110212] [Cited by in Crossref: 77] [Cited by in F6Publishing: 85] [Article Influence: 19.3] [Reference Citation Analysis]
474 Feng W, Xie Q, Liu S, Ji Y, Li C, Wang C, Jin L. Krüppel-like factor 4 promotes c-Met amplification-mediated gefitinib resistance in non-small-cell lung cancer. Cancer Sci 2018;109:1775-86. [PMID: 29624806 DOI: 10.1111/cas.13601] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 1.5] [Reference Citation Analysis]
475 Jiang X, Wu H, Zhao W, Ding X, You Q, Zhu F, Qian M, Yu P. Lycopene improves the efficiency of anti-PD-1 therapy via activating IFN signaling of lung cancer cells. Cancer Cell Int 2019;19:68. [PMID: 30948928 DOI: 10.1186/s12935-019-0789-y] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]
476 Kitadai R, Okuma Y. Treatment Strategies for Non-Small Cell Lung Cancer Harboring Common and Uncommon EGFR Mutations: Drug Sensitivity Based on Exon Classification, and Structure-Function Analysis. Cancers 2022;14:2519. [DOI: 10.3390/cancers14102519] [Reference Citation Analysis]
477 Westover D, Zugazagoitia J, Cho BC, Lovly CM, Paz-Ares L. Mechanisms of acquired resistance to first- and second-generation EGFR tyrosine kinase inhibitors. Ann Oncol. 2018;29:i10-i19. [PMID: 29462254 DOI: 10.1093/annonc/mdx703] [Cited by in Crossref: 157] [Cited by in F6Publishing: 160] [Article Influence: 52.3] [Reference Citation Analysis]
478 O'Kane GM, Barnes TA, Leighl NB. Resistance to epidermal growth factor receptor tyrosine kinase inhibitors, T790M, and clinical trials. Curr Oncol 2018;25:S28-37. [PMID: 29910645 DOI: 10.3747/co.25.3796] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 2.8] [Reference Citation Analysis]
479 Bansal P, Osman D, Gan GN, Simon GR, Boumber Y. Recent Advances in Targetable Therapeutics in Metastatic Non-Squamous NSCLC. Front Oncol 2016;6:112. [PMID: 27200298 DOI: 10.3389/fonc.2016.00112] [Cited by in Crossref: 3] [Cited by in F6Publishing: 17] [Article Influence: 0.5] [Reference Citation Analysis]
480 Westerink L, Nicolai JLJ, Samuelsen C, Smit HJM, Postmus PE, Griebsch I, Postma MJ. Budget impact of sequential treatment with first-line afatinib versus first-line osimertinib in non-small-cell lung cancer patients with common EGFR mutations. Eur J Health Econ 2020;21:931-43. [PMID: 32328874 DOI: 10.1007/s10198-020-01186-9] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
481 Li J, Kwok HF. Current Strategies for Treating NSCLC: From Biological Mechanisms to Clinical Treatment. Cancers (Basel) 2020;12:E1587. [PMID: 32549388 DOI: 10.3390/cancers12061587] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 3.0] [Reference Citation Analysis]
482 Melosky B. Treatment algorithms for patients with metastatic non-small cell, non-squamous lung cancer. Front Oncol 2014;4:256. [PMID: 25325013 DOI: 10.3389/fonc.2014.00256] [Cited by in Crossref: 8] [Cited by in F6Publishing: 12] [Article Influence: 1.0] [Reference Citation Analysis]
483 Iwama E, Takayama K, Harada T, Okamoto I, Ookubo F, Kishimoto J, Baba E, Oda Y, Nakanishi Y. Highly sensitive and quantitative evaluation of the EGFR T790M mutation by nanofluidic digital PCR. Oncotarget 2015;6:20466-73. [PMID: 26015401 DOI: 10.18632/oncotarget.4058] [Cited by in Crossref: 17] [Cited by in F6Publishing: 20] [Article Influence: 2.8] [Reference Citation Analysis]
484 Wind S, Schnell D, Ebner T, Freiwald M, Stopfer P. Clinical Pharmacokinetics and Pharmacodynamics of Afatinib. Clin Pharmacokinet 2017;56:235-50. [PMID: 27470518 DOI: 10.1007/s40262-016-0440-1] [Cited by in Crossref: 60] [Cited by in F6Publishing: 54] [Article Influence: 12.0] [Reference Citation Analysis]
485 Sheng M, Wang F, Zhao Y, Li S, Wang X, Shou T, Luo Y, Tang W. Comparison of clinical outcomes of patients with non-small-cell lung cancer harbouring epidermal growth factor receptor exon 19 or exon 21 mutations after tyrosine kinase inhibitors treatment: a meta-analysis. Eur J Clin Pharmacol 2016;72:1-11. [PMID: 26490356 DOI: 10.1007/s00228-015-1966-0] [Cited by in Crossref: 31] [Cited by in F6Publishing: 33] [Article Influence: 5.2] [Reference Citation Analysis]
486 Laurila N, Koivunen JP. EGFR inhibitor and chemotherapy combinations for acquired TKI resistance in EGFR-mutant NSCLC models. Med Oncol 2015;32:205. [PMID: 26081015 DOI: 10.1007/s12032-015-0627-6] [Cited by in Crossref: 15] [Cited by in F6Publishing: 19] [Article Influence: 2.1] [Reference Citation Analysis]
487 Cui J, Li L, Yuan S. The Value of Radiotherapy for Advanced Non-Small Cell Lung Cancer With Oncogene Driver-Mutation. Front Oncol 2022;12:863715. [DOI: 10.3389/fonc.2022.863715] [Reference Citation Analysis]
488 Englmeier F, Bleckmann A, Brückl W, Griesinger F, Fleitz A, Nagels K. Clinical benefit and cost-effectiveness analysis of liquid biopsy application in patients with advanced non-small cell lung cancer (NSCLC): a modelling approach. J Cancer Res Clin Oncol. [DOI: 10.1007/s00432-022-04034-w] [Reference Citation Analysis]
489 Lu Z, Cai J, Zeng Z, Liu A. [Management of Drug Therapy for Leptomeningeal Metastasis of Sensitive Driver Gene Positive Non-small Cell Lung Cancer]. Zhongguo Fei Ai Za Zhi 2020;23:710-8. [PMID: 32758347 DOI: 10.3779/j.issn.1009-3419.2020.102.18] [Reference Citation Analysis]
490 Jung HA, Park S, Sun JM, Lee SH, Ahn JS, Ahn MJ, Park K. Treatment and Outcomes of Metastatic Non-Small-Cell Lung Cancer Harboring Uncommon EGFR Mutations: Are They Different from Those with Common EGFR Mutations? Biology (Basel) 2020;9:E326. [PMID: 33036377 DOI: 10.3390/biology9100326] [Reference Citation Analysis]
491 Berardi R, Santoni M, Rinaldi S, Nunzi E, Smerilli A, Caramanti M, Morgese F, Torniai M, Savini A, Fiordoliva I, Onofri A, Pistelli M, Taccaliti A, Cascinu S. Risk of Hyponatraemia in Cancer Patients Treated with Targeted Therapies: A Systematic Review and Meta-Analysis of Clinical Trials. PLoS One 2016;11:e0152079. [PMID: 27167519 DOI: 10.1371/journal.pone.0152079] [Cited by in Crossref: 25] [Cited by in F6Publishing: 20] [Article Influence: 4.2] [Reference Citation Analysis]
492 Watanabe H, Tamura T, Shiozawa T, Ohara G, Kagohashi K, Kawaguchi M, Kurishima K, Satoh H, Hizawa N. Response to alectinib after one year of discontinuation of crizotinib in anaplastic lymphoma kinase-positive non-small-cell lung cancer: A case report. Mol Clin Oncol 2015;3:889-91. [PMID: 26171201 DOI: 10.3892/mco.2015.531] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
493 Van Der Weijst L, Lievens Y, Schrauwen W, Surmont V. Health-Related Quality of Life in Advanced Non-small Cell Lung Cancer: A Methodological Appraisal Based on a Systematic Literature Review. Front Oncol 2019;9:715. [PMID: 31456938 DOI: 10.3389/fonc.2019.00715] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
494 Del Re M, Cucchiara F, Petrini I, Fogli S, Passaro A, Crucitta S, Attili I, De Marinis F, Chella A, Danesi R. erbB in NSCLC as a molecular target: current evidences and future directions. ESMO Open 2020;5:e000724. [PMID: 32820012 DOI: 10.1136/esmoopen-2020-000724] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 8.0] [Reference Citation Analysis]
495 Deng W, Lei Y, Liu S, Yang J, Tu H, Yan H, Wu Y. Comparing overall survival between first generation EGFR-TKIs and chemotherapy in lung cancer patients with Del19/L858R. Chin J Cancer Res 2016;28:339-47. [PMID: 27478319 DOI: 10.21147/j.issn.1000-9604.2016.03.08] [Cited by in Crossref: 7] [Cited by in F6Publishing: 9] [Article Influence: 1.2] [Reference Citation Analysis]
496 Aran V, Omerovic J. Current Approaches in NSCLC Targeting K-RAS and EGFR. Int J Mol Sci 2019;20:E5701. [PMID: 31739412 DOI: 10.3390/ijms20225701] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 5.0] [Reference Citation Analysis]
497 Peng Z, Lin H, Zhou K, Deng S, Mei J. Predictive value of pretreatment PD-L1 expression in EGFR-mutant non-small cell lung cancer: a meta-analysis. World J Surg Oncol 2021;19:145. [PMID: 33964931 DOI: 10.1186/s12957-021-02254-x] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
498 Almeida SBD, Spencer AS, Santos CLD, Fernandes G, Simões P, Silva S, Domingues TD, Honório M. Switch to EGFR-TKI after upfront platinum doublet induction therapy in non-small cell lung cancer (NSCLC) patients with EGFR (Epidermal Growth Factor Receptor) mutation: A multicentre retrospective study. Cancer Treatment and Research Communications 2022;31:100526. [DOI: 10.1016/j.ctarc.2022.100526] [Reference Citation Analysis]
499 Asaka S, Yoshizawa A, Nakata R, Negishi T, Yamamoto H, Shiina T, Shigeto S, Matsuda K, Kobayashi Y, Honda T. Utility of bronchial lavage fluids for epithelial growth factor receptor mutation assay in lung cancer patients: Comparison between cell pellets, cell blocks and matching tissue specimens. Oncol Lett 2018;15:1469-74. [PMID: 29399190 DOI: 10.3892/ol.2017.7464] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
500 Qian J, Zhang X, Zhang B, Yan B, Wang L, Gu P, Wang W, Wang H, Han B. Tyrosine Kinase Inhibitor-Related Hepatotoxicity in Patients with Advanced Lung Adenocarcinoma: A Real-World Retrospective Study. Cancer Manag Res 2020;12:3293-9. [PMID: 32494193 DOI: 10.2147/CMAR.S237968] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
501 Troiani T, Napolitano S, Della Corte CM, Martini G, Martinelli E, Morgillo F, Ciardiello F. Therapeutic value of EGFR inhibition in CRC and NSCLC: 15 years of clinical evidence. ESMO Open 2016;1:e000088. [PMID: 27843640 DOI: 10.1136/esmoopen-2016-000088] [Cited by in Crossref: 56] [Cited by in F6Publishing: 54] [Article Influence: 9.3] [Reference Citation Analysis]
502 Canale M, Pasini L, Bronte G, Delmonte A, Cravero P, Crinò L, Ulivi P. Role of liquid biopsy in oncogene-addicted non-small cell lung cancer. Transl Lung Cancer Res 2019;8:S265-79. [PMID: 31857950 DOI: 10.21037/tlcr.2019.09.15] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 2.7] [Reference Citation Analysis]
503 Liang S, Xu Y, Tan F, Ding L, Ma Y, Wang M. Efficacy of icotinib in advanced lung squamous cell carcinoma. Cancer Med 2018;7:4456-66. [PMID: 30109777 DOI: 10.1002/cam4.1736] [Cited by in Crossref: 5] [Cited by in F6Publishing: 7] [Article Influence: 1.3] [Reference Citation Analysis]
504 Waqar SN, Bonomi PD, Govindan R, Hirsch FR, Riely GJ, Papadimitrakopoulou V, Kazandjian D, Khozin S, Larkins E, Dickson DJ, Malik S, Horn L, Ferris A, Shaw AT, Jänne PA, Mok TS, Herbst R, Keegan P, Pazdur R, Blumenthal GM. Clinician Perspectives on Current Issues in Lung Cancer Drug Development. J Thorac Oncol 2016;11:1387-96. [PMID: 27401214 DOI: 10.1016/j.jtho.2016.05.009] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
505 Chen RL, Chen HJ, Jiang BY, Zhang XC, Zhou Q, Tu HY, Zhong WZ, Wu YL, Yang JJ. Bevacizumab plus chemotherapy for patients with advanced pulmonary adenocarcinoma harboring EGFR mutations. Clin Transl Oncol 2018;20:243-52. [PMID: 28702789 DOI: 10.1007/s12094-017-1714-2] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
506 Tominaga T, Tsuchiya T, Mochinaga K, Arai J, Yamasaki N, Matsumoto K, Miyazaki T, Nagasaki T, Nanashima A, Tsukamoto K, Nagayasu T. Epidermal growth factor signals regulate dihydropyrimidine dehydrogenase expression in EGFR-mutated non-small-cell lung cancer. BMC Cancer 2016;16:354. [PMID: 27268079 DOI: 10.1186/s12885-016-2392-0] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
507 Xiong L, Cui S, Ding J, Sun Y, Zhang L, Zhao Y, Gu A, Chu T, Wang H, Zhong H, Ye X, Gu Y, Zhang X, Hu M, Jiang L. Dynamics of EGFR mutations in plasma recapitulates the clinical response to EGFR-TKIs in NSCLC patients. Oncotarget 2017;8:63846-56. [PMID: 28969034 DOI: 10.18632/oncotarget.19139] [Cited by in Crossref: 16] [Cited by in F6Publishing: 17] [Article Influence: 3.2] [Reference Citation Analysis]
508 Lau SCM, Batra U, Mok TSK, Loong HH. Dacomitinib in the Management of Advanced Non-Small-Cell Lung Cancer. Drugs 2019;79:823-31. [PMID: 31069718 DOI: 10.1007/s40265-019-01115-y] [Cited by in Crossref: 9] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
509 Tan J, Hu C, Deng P, Wan R, Cao L, Li M, Yang H, Gu Q, An J, Jiang J. The Predictive Values of Advanced Non-Small Cell Lung Cancer Patients Harboring Uncommon EGFR Mutations-The Mutation Patterns, Use of Different Generations of EGFR-TKIs, and Concurrent Genetic Alterations. Front Oncol 2021;11:646577. [PMID: 34513661 DOI: 10.3389/fonc.2021.646577] [Reference Citation Analysis]
510 Xie T, Zou Z, Liu C, Zhu Y, Xu Z, Wang L, Li J, Xing P. Front-Line Therapy in EGFR Exon 19 Deletion and 21 Leu858Arg Mutations in Advanced Non-Small Cell Lung Cancer: A Network Meta-Analysis. Evid Based Complement Alternat Med 2021;2021:9311875. [PMID: 34938345 DOI: 10.1155/2021/9311875] [Reference Citation Analysis]
511 Ikeuchi H, Hirose T, Ikegami M, Takamochi K, Suzuki K, Mano H, Kohsaka S. Preclinical assessment of combination therapy of EGFR tyrosine kinase inhibitors in a highly heterogeneous tumor model. Oncogene 2022. [PMID: 35304574 DOI: 10.1038/s41388-022-02263-4] [Reference Citation Analysis]
512 Simons MJHG, Retèl VP, Ramaekers BLT, Butter R, Mankor JM, Paats MS, Aerts JGJV, Mfumbilwa ZA, Roepman P, Coupé VMH, Uyl-de Groot CA, van Harten WH, Joore MA. Early Cost Effectiveness of Whole-Genome Sequencing as a Clinical Diagnostic Test for Patients with Inoperable Stage IIIB,C/IV Non-squamous Non-small-Cell Lung Cancer. Pharmacoeconomics 2021. [PMID: 34405371 DOI: 10.1007/s40273-021-01073-y] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
513 Vitale MG, Scagliarini S, Riccardi F, Barbato C, Otero M, Mocerino C, Ambrosio F, Cartenì G. Long progression-free survival with afatinib in a patient with EGFR-unknown lung adenocarcinoma after erlotinib failure: a case report. Tumori 2015;101:e64-6. [PMID: 25702672 DOI: 10.5301/tj.5000261] [Cited by in Crossref: 2] [Article Influence: 0.3] [Reference Citation Analysis]
514 Morgillo F, Della Corte CM, Fasano M, Ciardiello F. Mechanisms of resistance to EGFR-targeted drugs: lung cancer. ESMO Open 2016;1:e000060. [PMID: 27843613 DOI: 10.1136/esmoopen-2016-000060] [Cited by in Crossref: 182] [Cited by in F6Publishing: 185] [Article Influence: 30.3] [Reference Citation Analysis]
515 Yang Y, Wu B, Huang L, Shi M, Liu Y, Zhao Y, Wang L, Lu S, Chen G, Li B, Xie C, Fang J, Yang N, Zhang Y, Cui J, Song Y, Zhang C, Mei X, Cao B, Yang L, Cheng Y, Ying K, Sun T, Ren B, Yu Q, Liao Z, Pei Z, Wang M, Zhou J, Yu S, Feng G, Wan H, Wang H, Gao S, Wang J, An G, Geng Y, Ji Y, Yuan Y, Ma S, Jia Z, Hu M, Zhou H, Yu J, Sun X, Zhang L. Biosimilar candidate IBI305 plus paclitaxel/carboplatin for the treatment of non-squamous non-small cell lung cancer. Transl Lung Cancer Res 2019;8:989-99. [PMID: 32010577 DOI: 10.21037/tlcr.2019.12.23] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 2.7] [Reference Citation Analysis]
516 Zhou F, Zhou C. Lung cancer in never smokers-the East Asian experience. Transl Lung Cancer Res 2018;7:450-63. [PMID: 30225210 DOI: 10.21037/tlcr.2018.05.14] [Cited by in Crossref: 28] [Cited by in F6Publishing: 35] [Article Influence: 7.0] [Reference Citation Analysis]
517 Zhong W, Yang X, Yan H, Zhang X, Su J, Chen Z, Liao R, Nie Q, Dong S, Zhou Q, Yang J, Tu H, Wu YL. Phase II study of biomarker-guided neoadjuvant treatment strategy for IIIA-N2 non-small cell lung cancer based on epidermal growth factor receptor mutation status. J Hematol Oncol 2015;8:54. [PMID: 25981169 DOI: 10.1186/s13045-015-0151-3] [Cited by in Crossref: 34] [Cited by in F6Publishing: 45] [Article Influence: 4.9] [Reference Citation Analysis]
518 Califano R, Morgillo F, De Mello RA, Mountzios G. Role of mesenchymal-epithelial transition amplification in resistance to anti-epidermal growth factor receptor agents. Ann Transl Med 2015;3:81. [PMID: 25992380 DOI: 10.3978/j.issn.2305-5839.2015.03.44] [Cited by in F6Publishing: 9] [Reference Citation Analysis]
519 Melosky B. Review of EGFR TKIs in Metastatic NSCLC, Including Ongoing Trials. Front Oncol 2014;4:244. [PMID: 25309870 DOI: 10.3389/fonc.2014.00244] [Cited by in Crossref: 28] [Cited by in F6Publishing: 41] [Article Influence: 3.5] [Reference Citation Analysis]
520 Xie X, Wang X, Wu S, Yang H, Liu J, Chen H, Ding Y, Ling L, Lin H. Fatal toxic effects related to EGFR tyrosine kinase inhibitors based on 53 cohorts with 9,569 participants. J Thorac Dis 2020;12:4057-69. [PMID: 32944317 DOI: 10.21037/jtd-19-4000A] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
521 Li CL, Hsia TC, Yang ST, Chao KC, Tu CY, Chen HJ, Li CH. Efficacy of Prophylactic Traditional Chinese Medicine on Skin Toxicity of Afatinib in EGFR Mutation-Positive Advanced Lung Adenocarcinoma: A Single-Center, Prospective, Double-Blinded, Randomized-Controlled Pilot Trial. Integr Cancer Ther 2022;21:15347354221086663. [PMID: 35297709 DOI: 10.1177/15347354221086663] [Reference Citation Analysis]
522 Que D, Xiao H, Zhao B, Zhang X, Wang Q, Xiao H, Wang G. EGFR mutation status in plasma and tumor tissues in non-small cell lung cancer serves as a predictor of response to EGFR-TKI treatment. Cancer Biol Ther 2016;17:320-7. [PMID: 26785777 DOI: 10.1080/15384047.2016.1139238] [Cited by in Crossref: 15] [Cited by in F6Publishing: 21] [Article Influence: 2.5] [Reference Citation Analysis]
523 Takahashi A, Seike M, Chiba M, Takahashi S, Nakamichi S, Matsumoto M, Takeuchi S, Minegishi Y, Noro R, Kunugi S, Kubota K, Gemma A. Ankyrin Repeat Domain 1 Overexpression is Associated with Common Resistance to Afatinib and Osimertinib in EGFR-mutant Lung Cancer. Sci Rep 2018;8:14896. [PMID: 30291293 DOI: 10.1038/s41598-018-33190-8] [Cited by in Crossref: 12] [Cited by in F6Publishing: 14] [Article Influence: 3.0] [Reference Citation Analysis]
524 D'Incecco A, Andreozzi M, Ludovini V, Rossi E, Capodanno A, Landi L, Tibaldi C, Minuti G, Salvini J, Coppi E, Chella A, Fontanini G, Filice ME, Tornillo L, Incensati RM, Sani S, Crinò L, Terracciano L, Cappuzzo F. PD-1 and PD-L1 expression in molecularly selected non-small-cell lung cancer patients. Br J Cancer 2015;112:95-102. [PMID: 25349974 DOI: 10.1038/bjc.2014.555] [Cited by in Crossref: 340] [Cited by in F6Publishing: 367] [Article Influence: 42.5] [Reference Citation Analysis]
525 Kashima J, Kitadai R, Okuma Y. Molecular and Morphological Profiling of Lung Cancer: A Foundation for "Next-Generation" Pathologists and Oncologists. Cancers (Basel) 2019;11:E599. [PMID: 31035693 DOI: 10.3390/cancers11050599] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 4.0] [Reference Citation Analysis]
526 Kato S, Krishnamurthy N, Banks KC, De P, Williams K, Williams C, Leyland-Jones B, Lippman SM, Lanman RB, Kurzrock R. Utility of Genomic Analysis In Circulating Tumor DNA from Patients with Carcinoma of Unknown Primary. Cancer Res 2017;77:4238-46. [PMID: 28642281 DOI: 10.1158/0008-5472.CAN-17-0628] [Cited by in Crossref: 57] [Cited by in F6Publishing: 36] [Article Influence: 11.4] [Reference Citation Analysis]
527 Greenhalgh J, Boland A, Bates V, Vecchio F, Dundar Y, Chaplin M, Green JA. First-line treatment of advanced epidermal growth factor receptor (EGFR) mutation positive non-squamous non-small cell lung cancer. Cochrane Database Syst Rev 2021;3:CD010383. [PMID: 33734432 DOI: 10.1002/14651858.CD010383.pub3] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
528 Choi H, Lee JK, Oh HJ, Kim MS, Kho BG, Park CK, Oh IJ, Kim YC. Efficacy and dose of afatinib in patients with non-small cell lung cancer after failure of prior gefitinib or erlotinib treatment. Thorac Cancer 2021;12:1598-604. [PMID: 33811467 DOI: 10.1111/1759-7714.13957] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
529 Isaka T, Ito H, Nakayama H, Yokose T, Katayama K, Yamada K, Masuda M. Efficacy of Platinum-Based Adjuvant Chemotherapy on Prognosis of Pathological Stage II/III Lung Adenocarcinoma based on EGFR Mutation Status: A Propensity Score Matching Analysis. Mol Diagn Ther 2019;23:657-65. [PMID: 31347029 DOI: 10.1007/s40291-019-00419-9] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
530 Soffietti R, Ahluwalia M, Lin N, Rudà R. Management of brain metastases according to molecular subtypes. Nat Rev Neurol 2020;16:557-74. [PMID: 32873927 DOI: 10.1038/s41582-020-0391-x] [Cited by in Crossref: 21] [Cited by in F6Publishing: 20] [Article Influence: 10.5] [Reference Citation Analysis]
531 Ito K, Hataji O. Osimertinib therapy as first-line treatment before acquiring T790M mutation: from AURA1 trial. J Thorac Dis 2018;10:S3071-7. [PMID: 30430025 DOI: 10.21037/jtd.2018.07.52] [Reference Citation Analysis]
532 Zhang H, Zhang S. [Research Progress of Targeted Therapy for EGFR Gene in Non-small Cell Lung Cancer]. Zhongguo Fei Ai Za Zhi 2017;20:61-5. [PMID: 28103975 DOI: 10.3779/j.issn.1009-3419.2017.01.09] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
533 Haura EB, Rix U. Deploying ibrutinib to lung cancer: another step in the quest towards drug repurposing. J Natl Cancer Inst 2014;106:dju250. [PMID: 25214562 DOI: 10.1093/jnci/dju250] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 0.9] [Reference Citation Analysis]
534 Hung MS, Lung JH, Lin YC, Fang YH, Hsieh MJ, Tsai YH. The content of mutant EGFR DNA correlates with response to EGFR-TKIs in lung adenocarcinoma patients with common EGFR mutations. Medicine (Baltimore) 2016;95:e3991. [PMID: 27368002 DOI: 10.1097/MD.0000000000003991] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.4] [Reference Citation Analysis]
535 Derman BA, Mileham KF, Bonomi PD, Batus M, Fidler MJ. Treatment of advanced squamous cell carcinoma of the lung: a review. Transl Lung Cancer Res 2015;4:524-32. [PMID: 26629421 DOI: 10.3978/j.issn.2218-6751.2015.06.07] [Cited by in F6Publishing: 36] [Reference Citation Analysis]
536 Krawczyk P, Kowalski DM, Ramlau R, Kalinka-Warzocha E, Winiarczyk K, Stencel K, Powrózek T, Reszka K, Wojas-Krawczyk K, Bryl M, Wójcik-Superczyńska M, Głogowski M, Barinow-Wojewódzki A, Milanowski J, Krzakowski M. Comparison of the effectiveness of erlotinib, gefitinib, and afatinib for treatment of non-small cell lung cancer in patients with common and rare EGFR gene mutations. Oncol Lett 2017;13:4433-44. [PMID: 28599445 DOI: 10.3892/ol.2017.5980] [Cited by in Crossref: 24] [Cited by in F6Publishing: 24] [Article Influence: 4.8] [Reference Citation Analysis]
537 Koyama K, Miura S, Watanabe S, Shoji S, Koshio J, Hayashi Y, Ishikawa D, Sato K, Miyabayashi T, Okajima M, Ota T, Tanaka T, Matsumoto N, Kuriyama H, Abe T, Nozaki K, Ichikawa K, Kondo R, Tanaka H, Kikuchi T. Observational study of rebiopsy in EGFR-TKI-resistant patients with EGFR mutation-positive advanced NSCLC. Sci Rep 2022;12. [DOI: 10.1038/s41598-022-10288-8] [Reference Citation Analysis]
538 Xu ZY, Li JL. Comparative review of drug-drug interactions with epidermal growth factor receptor tyrosine kinase inhibitors for the treatment of non-small-cell lung cancer. Onco Targets Ther 2019;12:5467-84. [PMID: 31371986 DOI: 10.2147/OTT.S194870] [Cited by in Crossref: 15] [Cited by in F6Publishing: 8] [Article Influence: 5.0] [Reference Citation Analysis]
539 Kallergi G, Kontopodis E, Ntzifa A, Jordana-ariza N, Karachaliou N, Pantazaka E, Charalambous HA, Psyrri A, Tsaroucha E, Boukovinas I, Koumarianou A, Hatzidaki D, Lianidou E, Georgoulias V, Rosell R, Kotsakis A. Effect of Osimertinib on CTCs and ctDNA in EGFR Mutant Non-Small Cell Lung Cancer Patients: The Prognostic Relevance of Liquid Biopsy. Cancers 2022;14:1574. [DOI: 10.3390/cancers14061574] [Reference Citation Analysis]
540 Kishikawa T, Kasai T, Okada M, Nakachi I, Soda S, Arai R, Takigami A, Sata M. Osimertinib, a third-generation EGFR tyrosine kinase inhibitor: A retrospective multicenter study of its real-world efficacy and safety in advanced/recurrent non-small cell lung carcinoma. Thorac Cancer 2020;11:935-42. [PMID: 32129931 DOI: 10.1111/1759-7714.13378] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 2.5] [Reference Citation Analysis]
541 Cuppens K, Lodewyckx L, Demedts I, Decoster L, Colinet B, Deschepper K, Janssens A, Galdermans D, Pieters T; REVEAL Study Group. Real-World Treatment Patterns, Epidermal Growth Factor Receptor (EGFR) Testing and Outcomes in EGFR-Mutated Advanced Non-small Cell Lung Cancer Patients in Belgium: Results from the REVEAL Study. Drugs Real World Outcomes 2021;8:141-52. [PMID: 33710523 DOI: 10.1007/s40801-021-00243-w] [Reference Citation Analysis]
542 Wang Z, Du X, Chen K, Li S, Yu Z, Wu Z, Yang L, Chen D, Liu W. Impact of Dose Reduction of Afatinib Used in Patients With Non-Small Cell Lung Cancer: A Systematic Review and Meta-Analysis. Front Pharmacol 2021;12:781084. [PMID: 34912228 DOI: 10.3389/fphar.2021.781084] [Reference Citation Analysis]
543 Minami S, Ogata Y, Ihara S, Yamamoto S, Komuta K. Neutrophil-to-Lymphocyte Ratio Predicts Overall Survival of Advanced Non-Small Cell Lung Cancer Harboring Mutant Epidermal Growth Factor Receptor. World J Oncol 2017;8:180-7. [PMID: 29317963 DOI: 10.14740/wjon1069w] [Cited by in Crossref: 11] [Cited by in F6Publishing: 16] [Article Influence: 2.2] [Reference Citation Analysis]
544 Socinski MA, Villaruz LC, Ross J. Understanding Mechanisms of Resistance in the Epithelial Growth Factor Receptor in Non-Small Cell Lung Cancer and the Role of Biopsy at Progression. Oncologist 2017;22:3-11. [PMID: 27821794 DOI: 10.1634/theoncologist.2016-0285] [Cited by in Crossref: 23] [Cited by in F6Publishing: 24] [Article Influence: 3.8] [Reference Citation Analysis]
545 Merinda V, Soegiarto G, Wulandari L. T790M mutations identified by circulating tumor DNA test in lung adenocarcinoma patients who progressed on first-line epidermal growth factor receptor-tyrosine kinase inhibitors. Lung India 2020;37:13-8. [PMID: 31898615 DOI: 10.4103/lungindia.lungindia_182_19] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
546 Ma W, Zeng J, Chen S, Lyu Y, Toomey KA, Phan CT, Yoneda KY, Li T. Small molecule tyrosine kinase inhibitors modulated blood immune cell counts in patients with oncogene-driven NSCLC. Biomark Res 2021;9:69. [PMID: 34488906 DOI: 10.1186/s40364-021-00324-6] [Reference Citation Analysis]
547 Haeussler K, Wang X, Winfree KB, D'yachkova Y, Traore S, Puri T, Thom H, Papagiannopoulos C, Nassim M, Taipale K. Efficacy and safety of first-line therapies in EGFR-mutated advanced non-small-cell lung cancer: a network meta-analysis. Future Oncol 2022. [PMID: 35187947 DOI: 10.2217/fon-2021-0885] [Reference Citation Analysis]
548 Schuler M, Yang JC, Park K, Kim JH, Bennouna J, Chen YM, Chouaid C, De Marinis F, Feng JF, Grossi F, Kim DW, Liu X, Lu S, Strausz J, Vinnyk Y, Wiewrodt R, Zhou C, Wang B, Chand VK, Planchard D; LUX-Lung 5 Investigators. Afatinib beyond progression in patients with non-small-cell lung cancer following chemotherapy, erlotinib/gefitinib and afatinib: phase III randomized LUX-Lung 5 trial. Ann Oncol 2016;27:417-23. [PMID: 26646759 DOI: 10.1093/annonc/mdv597] [Cited by in Crossref: 81] [Cited by in F6Publishing: 87] [Article Influence: 11.6] [Reference Citation Analysis]
549 Schenk EL, Patil T, Pacheco J, Bunn PA Jr. 2020 Innovation-Based Optimism for Lung Cancer Outcomes. Oncologist 2021;26:e454-72. [PMID: 33179378 DOI: 10.1002/onco.13590] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
550 Kim TM, Lee KW, Oh DY, Lee JS, Im SA, Kim DW, Han SW, Kim YJ, Kim TY, Kim JH, Han H, Kim WH, Bang YJ. Phase 1 Studies of Poziotinib, an Irreversible Pan-HER Tyrosine Kinase Inhibitor in Patients with Advanced Solid Tumors. Cancer Res Treat 2018;50:835-42. [PMID: 28859471 DOI: 10.4143/crt.2017.303] [Cited by in Crossref: 34] [Cited by in F6Publishing: 35] [Article Influence: 6.8] [Reference Citation Analysis]
551 Ikeuchi T, Tokuyasu H, Ishikawa S. Successful Treatment of Lung Adenocarcinoma with Epidermal Growth Factor Receptor Compound Mutations Involving Exon 19 Deletion and Exon 20 Insertion by Afatinib. Intern Med 2019;58:101-4. [PMID: 30606938 DOI: 10.2169/internalmedicine.0927-18] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
552 Ernani V, Ganti AK. Immunotherapy in treatment naïve advanced non-small cell lung cancer. J Thorac Dis 2018;10:S412-21. [PMID: 29593887 DOI: 10.21037/jtd.2017.12.94] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 1.5] [Reference Citation Analysis]
553 Zhang L, Luo Y, Chen J, Cheng T, Yang H, Pan C, Li H, Jiang Z. Efficacy and Safety of Afatinib in the Treatment of Advanced Non-Small-Cell Lung Cancer with EGFR Mutations: A Meta-Analysis of Real-World Evidence. J Oncol 2021;2021:8736288. [PMID: 34961817 DOI: 10.1155/2021/8736288] [Reference Citation Analysis]
554 Chen M, Huang W, Yang D, Huang J, Li G, Wang X, Xiao N, Zhang W, Guan J, Wang S, Liu L. ΔCT Value of Amplified Refractory Mutation System Predicts Efficacy of EGFR-TKIs in Advanced Non-Small-Cell Lung Cancer: A Multi-Center Retrospective Study. Front Mol Biosci 2021;8:684661. [PMID: 34692766 DOI: 10.3389/fmolb.2021.684661] [Reference Citation Analysis]
555 Burotto M, Manasanch EE, Wilkerson J, Fojo T. Gefitinib and erlotinib in metastatic non-small cell lung cancer: a meta-analysis of toxicity and efficacy of randomized clinical trials. Oncologist 2015;20:400-10. [PMID: 25795635 DOI: 10.1634/theoncologist.2014-0154] [Cited by in Crossref: 71] [Cited by in F6Publishing: 72] [Article Influence: 10.1] [Reference Citation Analysis]
556 Hopkins AM, Shahnam A, Zhang S, Karapetis CS, Rowland A, Sorich MJ. Prognostic model of survival outcomes in non-small cell lung cancer patients initiated on afatinib: pooled analysis of clinical trial data. Cancer Biol Med 2019;16:341-9. [PMID: 31516754 DOI: 10.20892/j.issn.2095-3941.2018.0474] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
557 Sun H, Wang H, Shi L, Wang M, Li J, Shi J, Ni M, Hu X, Chen Y. Physician preferences for chemotherapy in the treatment of non-small cell lung cancer in China: evidence from multicentre discrete choice experiments. BMJ Open 2020;10:e032336. [PMID: 32051302 DOI: 10.1136/bmjopen-2019-032336] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 2.5] [Reference Citation Analysis]
558 Popescu C, Mazilu L, Suceveanu AI, Grigorescu A. How specific molecular-targeted agents can make obsolete a 'one size fits all' approach in EGFR-mutated NSCLC treatment (Review). Exp Ther Med 2021;22:1150. [PMID: 34504595 DOI: 10.3892/etm.2021.10584] [Reference Citation Analysis]
559 Le AD, Alzghari SK, Jean GW, La-Beck NM. Update on targeted therapies for advanced non-small cell lung cancer: nivolumab in context. Ther Clin Risk Manag 2017;13:223-36. [PMID: 28260909 DOI: 10.2147/TCRM.S104343] [Cited by in Crossref: 13] [Cited by in F6Publishing: 7] [Article Influence: 2.6] [Reference Citation Analysis]
560 Yang CJ, Tsai MJ, Hung JY, Lee MH, Tsai YM, Tsai YC, Hsu JF, Liu TC, Huang MS, Chong IW. The clinical efficacy of Afatinib 30 mg daily as starting dose may not be inferior to Afatinib 40 mg daily in patients with stage IV lung Adenocarcinoma harboring exon 19 or exon 21 mutations. BMC Pharmacol Toxicol 2017;18:82. [PMID: 29237484 DOI: 10.1186/s40360-017-0190-1] [Cited by in Crossref: 16] [Cited by in F6Publishing: 17] [Article Influence: 3.2] [Reference Citation Analysis]
561 Lu HY, Qin J, Han N, Lei L, Xie F, Li C. EGFR, KRAS, BRAF, PTEN, and PIK3CA mutation in plasma of small cell lung cancer patients. Onco Targets Ther 2018;11:2217-26. [PMID: 29720878 DOI: 10.2147/OTT.S159612] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 2.3] [Reference Citation Analysis]
562 Melosky B. Current Treatment Algorithms for Patients with Metastatic Non-Small Cell, Non-Squamous Lung Cancer. Front Oncol 2017;7:38. [PMID: 28373963 DOI: 10.3389/fonc.2017.00038] [Cited by in Crossref: 10] [Cited by in F6Publishing: 12] [Article Influence: 2.0] [Reference Citation Analysis]
563 Xu Y, Ding VW, Zhang H, Zhang X, Jablons D, He B. Spotlight on afatinib and its potential in the treatment of squamous cell lung cancer: the evidence so far. Ther Clin Risk Manag 2016;12:807-16. [PMID: 27307741 DOI: 10.2147/TCRM.S92996] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
564 Liang Q, Gu WM, Huang K, Luo MY, Zou JH, Zhuang GL, Lei HM, Chen HZ, Zhu L, Zhou L, Shen Y. HKB99, an allosteric inhibitor of phosphoglycerate mutase 1, suppresses invasive pseudopodia formation and upregulates plasminogen activator inhibitor-2 in erlotinib-resistant non-small cell lung cancer cells. Acta Pharmacol Sin 2021;42:115-9. [PMID: 32404981 DOI: 10.1038/s41401-020-0399-1] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 6.0] [Reference Citation Analysis]
565 Lopes GL, Vattimo EF, Castro Junior Gd. Identifying activating mutations in the EGFR gene: prognostic and therapeutic implications in non-small cell lung cancer. J Bras Pneumol 2015;41:365-75. [PMID: 26398757 DOI: 10.1590/S1806-37132015000004531] [Cited by in Crossref: 20] [Cited by in F6Publishing: 10] [Article Influence: 3.3] [Reference Citation Analysis]
566 Zhang J, Ren Y, Wang Q, Jia YM. Thoughts and suggestions on the fact that dacomitinib reduction did not affect its efficacy in the Archer 1050 study. Future Oncol 2022. [PMID: 35048746 DOI: 10.2217/fon-2021-0983] [Reference Citation Analysis]
567 Nonagase Y, Takeda M, Azuma K, Hayashi H, Haratani K, Tanaka K, Yonesaka K, Ishii H, Hoshino T, Nakagawa K. Tumor tissue and plasma levels of AXL and GAS6 before and after tyrosine kinase inhibitor treatment in EGFR-mutated non-small cell lung cancer. Thorac Cancer 2019;10:1928-35. [PMID: 31419057 DOI: 10.1111/1759-7714.13166] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
568 Jiang T, Zhou C. Clinical activity of the mutant-selective EGFR inhibitor AZD9291 in patients with EGFR inhibitor-resistant non-small cell lung cancer. Transl Lung Cancer Res. 2014;3:370-372. [PMID: 25806323 DOI: 10.3978/j.issn.2218-6751.2014.08.02] [Cited by in F6Publishing: 27] [Reference Citation Analysis]
569 Iida Y, Kumasawa F, Shimizu T, Shintani Y, Takahashi N, Gon Y. Successful treatment of an elderly patient with an uncommon L861Q epidermal growth factor receptor mutation with low-dose afatinib: A case report. Thorac Cancer 2020;11:447-50. [PMID: 31779047 DOI: 10.1111/1759-7714.13269] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
570 Vavalà T. Role of afatinib in the treatment of advanced lung squamous cell carcinoma. Clin Pharmacol 2017;9:147-57. [PMID: 29225480 DOI: 10.2147/CPAA.S112715] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
571 Du W, Wo Y, Lu T, Wang Y, Jiao W. [A Review of EGFR-TKIs Therapy of Non-small Cell Lung Cancer
with Uncommon EGFR Mutations]. Zhongguo Fei Ai Za Zhi 2019;22:590-9. [PMID: 31526464 DOI: 10.3779/j.issn.1009-3419.2019.09.07] [Reference Citation Analysis]
572 Imai H, Saijo K, Komine K, Otsuki Y, Ohuchi K, Sato Y, Okita A, Takahashi M, Takahashi S, Shirota H, Takahashi M, Ishioka C. Antibiotic therapy augments the efficacy of gemcitabine-containing regimens for advanced cancer: a retrospective study. Cancer Manag Res 2019;11:7953-65. [PMID: 31686910 DOI: 10.2147/CMAR.S215697] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
573 Zhao L, Wang Z, Du H, Chen S, Wang P. Lung Adenocarcinoma Patient Harboring EGFR-KDD Achieve Durable Response to Afatinib: A Case Report and Literature Review. Front Oncol 2021;11:605853. [PMID: 33898306 DOI: 10.3389/fonc.2021.605853] [Reference Citation Analysis]
574 Joshi M, Rizvi SM, Belani CP. Afatinib for the treatment of metastatic non-small cell lung cancer. Cancer Manag Res 2015;7:75-82. [PMID: 25733926 DOI: 10.2147/CMAR.S51808] [Cited by in Crossref: 24] [Cited by in F6Publishing: 9] [Article Influence: 3.4] [Reference Citation Analysis]
575 Passaro A, Pochesci A, Spitaleri G, Catania C, Noberasco C, Del Signore E, de Marinis F. Afatinib in first-line setting for NSCLC harbouring common EGFR mutations: new light after the preliminary results of LUX-Lung 7? J Thorac Dis 2016;8:E217-20. [PMID: 27076973 DOI: 10.21037/jtd.2016.02.21] [Cited by in Crossref: 3] [Cited by in F6Publishing: 6] [Article Influence: 0.5] [Reference Citation Analysis]
576 Gu Y, Lai S, Dong Y, Fu H, Song L, Chen T, Duan Y, Zhang Z. AZD9291 Resistance Reversal Activity of a pH-Sensitive Nanocarrier Dual-Loaded with Chloroquine and FGFR1 Inhibitor in NSCLC. Adv Sci (Weinh) 2021;8:2002922. [PMID: 33511016 DOI: 10.1002/advs.202002922] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 9.0] [Reference Citation Analysis]
577 Yan H, Li Q, Wang W, Zhen H, Cao B. Systems assessment of intercalated combination of chemotherapy and EGFR TKIs versus chemotherapy or EGFR TKIs alone in advanced NSCLC patients. Sci Rep 2015;5:15355. [PMID: 26481697 DOI: 10.1038/srep15355] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.4] [Reference Citation Analysis]
578 Zhou F, Ma W, Li W, Ni H, Gao G, Chen X, Zhang J, Shi J. Thick-wall cavity predicts worse progression-free survival in lung adenocarcinoma treated with first-line EGFR-TKIs. BMC Cancer 2018;18:1033. [PMID: 30352571 DOI: 10.1186/s12885-018-4938-9] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.8] [Reference Citation Analysis]
579 Kato Y, Tanaka Y, Hino M, Gemma A. ProGRP as early predictive marker of non-small-cell lung cancer to small-cell lung cancer transformation after EGFR-TKI treatment. Respir Med Case Rep. 2019;27:100837. [PMID: 31016132 DOI: 10.1016/j.rmcr.2019.100837] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.7] [Reference Citation Analysis]
580 Soldera SV, Leighl NB. Update on the Treatment of Metastatic Squamous Non-Small Cell Lung Cancer in New Era of Personalized Medicine. Front Oncol 2017;7:50. [PMID: 28396848 DOI: 10.3389/fonc.2017.00050] [Cited by in Crossref: 15] [Cited by in F6Publishing: 16] [Article Influence: 3.0] [Reference Citation Analysis]
581 Dong ZY, Zhai HR, Hou QY, Su J, Liu SY, Yan HH, Li YS, Chen ZY, Zhong WZ, Wu YL. Mixed Responses to Systemic Therapy Revealed Potential Genetic Heterogeneity and Poor Survival in Patients with Non-Small Cell Lung Cancer. Oncologist 2017;22:61-9. [PMID: 28126915 DOI: 10.1634/theoncologist.2016-0150] [Cited by in Crossref: 14] [Cited by in F6Publishing: 15] [Article Influence: 3.5] [Reference Citation Analysis]
582 Liu SY, Zhou JY, Li WF, Sun H, Zhang YC, Yan HH, Chen ZH, Chen CX, Ye JY, Yang JJ, Zhou Q, Zhang XC, Wu YL. Concomitant genetic alterations having greater impact on the clinical benefit of EGFR-TKIs in EGFR-mutant advanced NSCLC than BIM deletion polymorphism. Clin Transl Med 2020;10:337-45. [PMID: 32508032 DOI: 10.1002/ctm2.12] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
583 Yamaguchi T, Gotoh Y, Hattori H, Katsuno H, Imaizumi K. Gastrointestinal perforation during treatment with erlotinib plus bevacizumab in two patients with non-small cell lung cancer exhibiting epidermal growth factor receptor mutations: A case report. Oncol Lett 2018;16:1046-50. [PMID: 29963181 DOI: 10.3892/ol.2018.8708] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
584 Sullivan I, Planchard D. Next-Generation EGFR Tyrosine Kinase Inhibitors for Treating EGFR-Mutant Lung Cancer beyond First Line. Front Med (Lausanne) 2016;3:76. [PMID: 28149837 DOI: 10.3389/fmed.2016.00076] [Cited by in Crossref: 25] [Cited by in F6Publishing: 35] [Article Influence: 5.0] [Reference Citation Analysis]
585 Shi J, Yang H, Jiang T, Li X, Zhao C, Zhang L, Zhao S, Liu X, Jia Y, Wang Y, Xi L, Zhang S, Su C, Ren S, Zhou C. Uncommon EGFR mutations in a cohort of Chinese NSCLC patients and outcomes of first-line EGFR-TKIs and platinum-based chemotherapy. Chin J Cancer Res 2017;29:543-52. [PMID: 29353977 DOI: 10.21147/j.issn.1000-9604.2017.06.09] [Cited by in Crossref: 10] [Cited by in F6Publishing: 12] [Article Influence: 2.0] [Reference Citation Analysis]
586 Zhang H, Yang X, Qin N, Li X, Yang H, Nong J, Lv J, Wu Y, Zhang Q, Zhang X, Wang J, Su D, Zhang S. [Detection and Analysis of EGFR and KRAS Mutations 
in the Patients with Lung Squamous Cell Carcinomas]. Zhongguo Fei Ai Za Zhi 2015;18:621-5. [PMID: 26483334 DOI: 10.3779/j.issn.1009-3419.2015.10.04] [Cited by in F6Publishing: 6] [Reference Citation Analysis]
587 Saad N, Poudel A, Basnet A, Gajra A. Epidermal growth factor receptor T790M mutation-positive metastatic non-small-cell lung cancer: focus on osimertinib (AZD9291). Onco Targets Ther 2017;10:1757-66. [PMID: 28367058 DOI: 10.2147/OTT.S100650] [Cited by in Crossref: 13] [Cited by in F6Publishing: 10] [Article Influence: 2.6] [Reference Citation Analysis]
588 Shan X, Zhang Y, Chen H, Dong L, Wu B, Xu T, Hu J, Liu Z, Wang W, Wu L, Feng Z, Liang G. Inhibition of epidermal growth factor receptor attenuates LPS-induced inflammation and acute lung injury in rats. Oncotarget 2017;8:26648-61. [PMID: 28460454 DOI: 10.18632/oncotarget.15790] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.5] [Reference Citation Analysis]
589 Xu T, Yan S, Wang M, Jiang L, Ma P, Lu B, Chen Q, Wei C, Wang Z. LncRNA UCA1 Induces Acquired Resistance to Gefitinib by Epigenetically Silencing CDKN1A Expression in Non-small-Cell Lung Cancer. Front Oncol 2020;10:656. [PMID: 32477939 DOI: 10.3389/fonc.2020.00656] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
590 Wang S, Li J. Second-generation EGFR and ErbB tyrosine kinase inhibitors as first-line treatments for non-small cell lung cancer. Onco Targets Ther 2019;12:6535-48. [PMID: 31496745 DOI: 10.2147/OTT.S198945] [Cited by in Crossref: 12] [Cited by in F6Publishing: 6] [Article Influence: 4.0] [Reference Citation Analysis]
591 Sotelo MJ, Luis García J, Torres-Mattos C, Milián H, Carracedo C, González-Ruiz MÁ, Mielgo-Rubio X, Trujillo-Reyes JC, Couñago F. Recent advances and new insights in the management of early-stage epidermal growth factor receptor-mutated non-small-cell lung cancer. World J Clin Oncol 2021; 12(10): 912-925 [PMID: 34733613 DOI: 10.5306/wjco.v12.i10.912] [Reference Citation Analysis]
592 Zang SZ, Yang YR, Zhao SS, Li YX, Gao XY, Zhong CL. In silico insight into EGFR treatment in patients with lung carcinoma and T790M mutations. Exp Ther Med 2017;13:1735-40. [PMID: 28565760 DOI: 10.3892/etm.2017.4168] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
593 Imamura F, Inoue T, Kunimasa K, Kubota A, Kuhara H, Tamiya M, Nishino K, Kimura M, Kuno K, Kawachi H, Kumagai T. Switching from first or second generation EGFR-TKI to osimertinib in EGFR mutation-positive NSCLC. Lung Cancer Manag 2020;9:LMT29. [PMID: 32346403 DOI: 10.2217/lmt-2020-0005] [Reference Citation Analysis]
594 Zhang Y, Xiang C, Wang Y, Duan Y, Liu C, Zhang Y. PD-L1 promoter methylation mediates the resistance response to anti-PD-1 therapy in NSCLC patients with EGFR-TKI resistance. Oncotarget 2017;8:101535-44. [PMID: 29254184 DOI: 10.18632/oncotarget.21328] [Cited by in Crossref: 21] [Cited by in F6Publishing: 23] [Article Influence: 4.2] [Reference Citation Analysis]
595 Lv F, Sun L, Yang Q, Pan Z, Zhang Y. Prognostic Value of BIM Deletion in EGFR-Mutant NSCLC Patients Treated with EGFR-TKIs: A Meta-Analysis. Biomed Res Int 2021;2021:3621828. [PMID: 34722761 DOI: 10.1155/2021/3621828] [Reference Citation Analysis]
596 Chang WY, Wu YL, Su PL, Yang SC, Lin CC, Su WC. The impact of EGFR mutations on the incidence and survival of stages I to III NSCLC patients with subsequent brain metastasis. PLoS One 2018;13:e0192161. [PMID: 29447182 DOI: 10.1371/journal.pone.0192161] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 3.5] [Reference Citation Analysis]
597 Xu J, Wang J, Zhang S. Mechanisms of resistance to irreversible epidermal growth factor receptor tyrosine kinase inhibitors and therapeutic strategies in non-small cell lung cancer. Oncotarget 2017;8:90557-78. [PMID: 29163853 DOI: 10.18632/oncotarget.21164] [Cited by in Crossref: 24] [Cited by in F6Publishing: 23] [Article Influence: 4.8] [Reference Citation Analysis]
598 Holleman MS, van Tinteren H, Groen HJ, Al MJ, Uyl-de Groot CA. First-line tyrosine kinase inhibitors in EGFR mutation-positive non-small-cell lung cancer: a network meta-analysis. Onco Targets Ther 2019;12:1413-21. [PMID: 30863108 DOI: 10.2147/OTT.S189438] [Cited by in Crossref: 22] [Cited by in F6Publishing: 13] [Article Influence: 7.3] [Reference Citation Analysis]
599 Bhateja P, Sharma N. Afatinib plus chemotherapy versus chemotherapy alone after progression on afatinib: new insights on old question? Ann Transl Med 2016;4:S31. [PMID: 27867999 DOI: 10.21037/atm.2016.09.45] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
600 Yuan G, Wang L, Li J, Feng H, Ji J, Gu W, Shan B. Complexity in Clinical Trials: Blind Spots, Misleading Criteria, Winners and Losers. CCAND 2020;7:3-15. [DOI: 10.2174/2212697x06666191021125423] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
601 Yang L, Tang C, Xu B, Wang W, Li J, Li X, Qin H, Gao H, He K, Song S, Liu X. Classification of Epidermal Growth Factor Receptor Gene Mutation Status Using Serum Proteomic Profiling Predicts Tumor Response in Patients with Stage IIIB or IV Non-Small-Cell Lung Cancer. PLoS One 2015;10:e0128970. [PMID: 26047516 DOI: 10.1371/journal.pone.0128970] [Cited by in Crossref: 5] [Cited by in F6Publishing: 7] [Article Influence: 0.7] [Reference Citation Analysis]
602 Cheng Y, Zhang T, Xu Q. Therapeutic advances in non-small cell lung cancer: Focus on clinical development of targeted therapy and immunotherapy. MedComm (2020) 2021;2:692-729. [PMID: 34977873 DOI: 10.1002/mco2.105] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
603 Wakelee H, Kelly K, Edelman MJ. 50 Years of progress in the systemic therapy of non-small cell lung cancer. Am Soc Clin Oncol Educ Book 2014;:177-89. [PMID: 24857075 DOI: 10.14694/EdBook_AM.2014.34.177] [Cited by in Crossref: 52] [Cited by in F6Publishing: 40] [Article Influence: 7.4] [Reference Citation Analysis]
604 Awasthi S, Maity T, Oyler BL, Qi Y, Zhang X, Goodlett DR, Guha U. Quantitative targeted proteomic analysis of potential markers of tyrosine kinase inhibitor (TKI) sensitivity in EGFR mutated lung adenocarcinoma. J Proteomics 2018;189:48-59. [PMID: 29660496 DOI: 10.1016/j.jprot.2018.04.005] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 1.3] [Reference Citation Analysis]
605 Lee J, Lee D, Kim Y. Mathematical model of STAT signalling pathways in cancer development and optimal control approaches. R Soc Open Sci 2021;8:210594. [PMID: 34631119 DOI: 10.1098/rsos.210594] [Reference Citation Analysis]
606 Saran F, Welsh L, James A, McBain C, Gattamaneni R, Jefferies S, Harris F, Pemberton K, Schaible J, Bender S, Cseh A, Brada M. Afatinib and radiotherapy, with or without temozolomide, in patients with newly diagnosed glioblastoma: results of a phase I trial. J Neurooncol 2021;155:307-17. [PMID: 34787778 DOI: 10.1007/s11060-021-03877-6] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
607 Jiang H, Zhu M, Li Y, Li Q. Association between EGFR exon 19 or exon 21 mutations and survival rates after first-line EGFR-TKI treatment in patients with non-small cell lung cancer. Mol Clin Oncol 2019;11:301-8. [PMID: 31384460 DOI: 10.3892/mco.2019.1881] [Cited by in Crossref: 3] [Cited by in F6Publishing: 8] [Article Influence: 1.0] [Reference Citation Analysis]
608 Park K, Kim JS, Kim JH, Kim YC, Kim HG, Cho EK, Jin JY, Kim M, Märten A, Kang JH. An open-label expanded access program of afatinib in EGFR tyrosine kinase inhibitor-naïve patients with locally advanced or metastatic non-small cell lung cancer harboring EGFR mutations. BMC Cancer 2021;21:802. [PMID: 34253172 DOI: 10.1186/s12885-021-08445-9] [Reference Citation Analysis]
609 Decoster L, Giron P, Mignon S, De Grève J. The evolving first-line treatment of advanced non-small cell lung cancer harbouring epidermal growth factor receptor mutations. Transl Lung Cancer Res 2018;7:S134-7. [PMID: 29780706 DOI: 10.21037/tlcr.2018.03.08] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
610 Pereira I, Gaspar C, Pina M, Azevedo I, Rodrigues A. Real-World T790M Mutation Frequency and Impact of Rebiopsy in Patients With EGFR-Mutated Advanced Non-Small Cell Lung Cancer. Cureus 2020;12:e12128. [PMID: 33489541 DOI: 10.7759/cureus.12128] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
611 Zheng D, Hu M, Bai Y, Zhu X, Lu X, Wu C, Wang J, Liu L, Wang Z, Ni J, Yang Z, Xu J. EGFR G796D mutation mediates resistance to osimertinib. Oncotarget 2017;8:49671-9. [PMID: 28572531 DOI: 10.18632/oncotarget.17913] [Cited by in Crossref: 49] [Cited by in F6Publishing: 56] [Article Influence: 12.3] [Reference Citation Analysis]
612 Kelly WJ, Shah NJ, Subramaniam DS. Management of Brain Metastases in Epidermal Growth Factor Receptor Mutant Non-Small-Cell Lung Cancer. Front Oncol 2018;8:208. [PMID: 30018881 DOI: 10.3389/fonc.2018.00208] [Cited by in Crossref: 30] [Cited by in F6Publishing: 33] [Article Influence: 7.5] [Reference Citation Analysis]
613 Dorantes-Heredia R, Ruiz-Morales JM, Cano-García F. Histopathological transformation to small-cell lung carcinoma in non-small cell lung carcinoma tumors. Transl Lung Cancer Res 2016;5:401-12. [PMID: 27652204 DOI: 10.21037/tlcr.2016.07.10] [Cited by in Crossref: 29] [Cited by in F6Publishing: 24] [Article Influence: 4.8] [Reference Citation Analysis]
614 Hung MS, Chen IC, Lung JH, Lin PY, Li YC, Tsai YH. Epidermal Growth Factor Receptor Mutation Enhances Expression of Cadherin-5 in Lung Cancer Cells. PLoS One 2016;11:e0158395. [PMID: 27362942 DOI: 10.1371/journal.pone.0158395] [Cited by in Crossref: 10] [Cited by in F6Publishing: 13] [Article Influence: 1.7] [Reference Citation Analysis]
615 Tan WL, Tan DSW. Targeting the metastatic niche through anti-angiogenic approaches in epidermal growth factor receptor mutant non-small cell lung cancer. Transl Lung Cancer Res 2018;7:S13-8. [PMID: 29531897 DOI: 10.21037/tlcr.2017.11.12] [Reference Citation Analysis]
616 Tu HY, Wu YL. Effect of Dose Adjustments on the Safety and Efficacy of Afatinib in Chinese Patients with EGFR-Mutated Non-Small Cell Lung Cancer Who Participated in the LUX-Lung Clinical Trial Program. Onco Targets Ther 2020;13:12539-47. [PMID: 33324072 DOI: 10.2147/OTT.S273866] [Reference Citation Analysis]
617 Tamiya M, Kunimasa K, Nishino K, Matsumoto S, Kawachi H, Kuno K, Inoue T, Kuhara H, Imamura F, Goto K, Kumagai T. Successful treatment of an osimertinib-resistant lung adenocarcinoma with an exon 18 EGFR mutation (G719S) with afatinib plus bevacizumab. Invest New Drugs 2021;39:232-6. [PMID: 32556898 DOI: 10.1007/s10637-020-00966-7] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
618 Kuiper JL, Hashemi SM, Thunnissen E, Snijders PJ, Grünberg K, Bloemena E, Sie D, Postmus PE, Heideman DA, Smit EF. Non-classic EGFR mutations in a cohort of Dutch EGFR-mutated NSCLC patients and outcomes following EGFR-TKI treatment. Br J Cancer 2016;115:1504-12. [PMID: 27875527 DOI: 10.1038/bjc.2016.372] [Cited by in Crossref: 24] [Cited by in F6Publishing: 29] [Article Influence: 4.0] [Reference Citation Analysis]
619 Fjaellegaard K, Koefod Petersen J, Andersen G, Biagini M, Bhatnagar R, Laursen CB, Clementsen PF, Bodtger U. The prevalence of tumour markers in malignant pleural effusions associated with primary pulmonary adenocarcinoma: a retrospective study. Eur Clin Respir J 2021;8:1984375. [PMID: 34745460 DOI: 10.1080/20018525.2021.1984375] [Reference Citation Analysis]
620 Wang W, Wang H, Lu P, Yu Z, Xu C, Zhuang W, Song Z. Crizotinib with or without an EGFR-TKI in treating EGFR-mutant NSCLC patients with acquired MET amplification after failure of EGFR-TKI therapy: a multicenter retrospective study. J Transl Med 2019;17:52. [PMID: 30791921 DOI: 10.1186/s12967-019-1803-9] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 4.0] [Reference Citation Analysis]
621 Yang JJ, Zhou Q, Yan HH, Zhang XC, Chen HJ, Tu HY, Wang Z, Xu CR, Su J, Wang BC, Jiang BY, Bai XY, Zhong WZ, Yang XN, Wu YL. A phase III randomised controlled trial of erlotinib vs gefitinib in advanced non-small cell lung cancer with EGFR mutations. Br J Cancer 2017;116:568-74. [PMID: 28103612 DOI: 10.1038/bjc.2016.456] [Cited by in Crossref: 94] [Cited by in F6Publishing: 97] [Article Influence: 18.8] [Reference Citation Analysis]
622 Hung MS, Chuang MC, Chen YC, Lee CP, Yang TM, Chen PC, Tsai YH, Yang YH. Metformin Prolongs Survival in Type 2 Diabetes Lung Cancer Patients With EGFR-TKIs. Integr Cancer Ther 2019;18:1534735419869491. [PMID: 31409137 DOI: 10.1177/1534735419869491] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
623 Christofyllakis K, Monteiro AR, Cetin O, Kos IA, Greystoke A, Luciani A. Biomarker guided treatment in oncogene-driven advanced non-small cell lung cancer in older adults: A Young International Society of Geriatric Oncology Report. J Geriatr Oncol 2022:S1879-4068(22)00105-9. [PMID: 35525790 DOI: 10.1016/j.jgo.2022.04.013] [Reference Citation Analysis]
624 Yang H, Liang SQ, Schmid RA, Peng RW. New Horizons in KRAS-Mutant Lung Cancer: Dawn After Darkness. Front Oncol 2019;9:953. [PMID: 31612108 DOI: 10.3389/fonc.2019.00953] [Cited by in Crossref: 37] [Cited by in F6Publishing: 37] [Article Influence: 12.3] [Reference Citation Analysis]
625 Gao D, Chen Y. Organoid development in cancer genome discovery. Curr Opin Genet Dev 2015;30:42-8. [PMID: 25796043 DOI: 10.1016/j.gde.2015.02.007] [Cited by in Crossref: 33] [Cited by in F6Publishing: 32] [Article Influence: 4.7] [Reference Citation Analysis]
626 Reinwald M, Boch T, Hofmann WK, Buchheidt D. Risk of Infectious Complications in Hemato-Oncological Patients Treated with Kinase Inhibitors. Biomark Insights 2015;10:55-68. [PMID: 27127405 DOI: 10.4137/BMI.S22430] [Cited by in Crossref: 8] [Cited by in F6Publishing: 13] [Article Influence: 1.3] [Reference Citation Analysis]
627 Kato T, Yoshioka H, Okamoto I, Yokoyama A, Hida T, Seto T, Kiura K, Massey D, Seki Y, Yamamoto N. Afatinib versus cisplatin plus pemetrexed in Japanese patients with advanced non-small cell lung cancer harboring activating EGFR mutations: Subgroup analysis of LUX-Lung 3. Cancer Sci 2015;106:1202-11. [PMID: 26094656 DOI: 10.1111/cas.12723] [Cited by in Crossref: 63] [Cited by in F6Publishing: 61] [Article Influence: 9.0] [Reference Citation Analysis]
628 Park K, Tan DSW, Su WC, Cho BC, Kim SW, Lee KH, Wang CC, Seto T, Huang DC, Jung HH, Hsu MC, Bogenrieder T, Lin CC. Phase 1b Open-Label Trial of Afatinib Plus Xentuzumab (BI 836845) in Patients With EGFR Mutation-Positive NSCLC After Progression on EGFR Tyrosine Kinase Inhibitors. JTO Clin Res Rep 2021;2:100206. [PMID: 34590052 DOI: 10.1016/j.jtocrr.2021.100206] [Reference Citation Analysis]
629 Shea M, Costa DB, Rangachari D. Management of advanced non-small cell lung cancers with known mutations or rearrangements: latest evidence and treatment approaches. Ther Adv Respir Dis. 2016;10:113-129. [PMID: 26620497 DOI: 10.1177/1753465815617871] [Cited by in Crossref: 84] [Cited by in F6Publishing: 87] [Article Influence: 12.0] [Reference Citation Analysis]
630 Friedlaender A, Addeo A, Russo A, Gregorc V, Cortinovis D, Rolfo CD. Targeted Therapies in Early Stage NSCLC: Hype or Hope? Int J Mol Sci 2020;21:E6329. [PMID: 32878298 DOI: 10.3390/ijms21176329] [Cited by in Crossref: 8] [Cited by in F6Publishing: 12] [Article Influence: 4.0] [Reference Citation Analysis]
631 Su VY, Yang KY, Huang TY, Hsu CC, Chen YM, Yen JC, Chou YC, Chang YL, He CH. The efficacy of first-line tyrosine kinase inhibitors combined with co-medications in Asian patients with EGFR mutation non-small cell lung cancer. Sci Rep 2020;10:14965. [PMID: 32917914 DOI: 10.1038/s41598-020-71583-w] [Cited by in Crossref: 3] [Cited by in F6Publishing: 5] [Article Influence: 1.5] [Reference Citation Analysis]
632 Watanabe S, Hayashi H, Nakagawa K. Is afatinib a treatment option for brain metastases in patients with EGFR mutation-positive non-small cell lung cancer? Ann Transl Med 2016;4:225. [PMID: 27385269 DOI: 10.21037/atm.2016.05.48] [Cited by in Crossref: 3] [Cited by in F6Publishing: 6] [Article Influence: 0.5] [Reference Citation Analysis]
633 Song X, Hu Y, Li Y, Shao R, Liu F, Liu Y. Overview of current targeted therapy in gallbladder cancer. Signal Transduct Target Ther 2020;5:230. [PMID: 33028805 DOI: 10.1038/s41392-020-00324-2] [Cited by in Crossref: 7] [Cited by in F6Publishing: 10] [Article Influence: 3.5] [Reference Citation Analysis]
634 Ferro A, Filoni A, Pavan A, Pasello G, Guarneri V, Conte P, Alaibac M, Bonanno L. Subacute Cutaneous Lupus Erythematosus-Like Eruption Induced by EGFR -Tyrosine Kinase Inhibitor in EGFR-Mutated Non-small Cell Lung Cancer: A Case Report. Front Med (Lausanne) 2021;8:570921. [PMID: 34179028 DOI: 10.3389/fmed.2021.570921] [Reference Citation Analysis]
635 Weisberg E, Parent A, Yang PL, Sattler M, Liu Q, Liu Q, Wang J, Meng C, Buhrlage SJ, Gray N, Griffin JD. Repurposing of Kinase Inhibitors for Treatment of COVID-19. Pharm Res 2020;37:167. [PMID: 32778962 DOI: 10.1007/s11095-020-02851-7] [Cited by in Crossref: 39] [Cited by in F6Publishing: 31] [Article Influence: 19.5] [Reference Citation Analysis]
636 Barnes TA, O'Kane GM, Vincent MD, Leighl NB. Third-Generation Tyrosine Kinase Inhibitors Targeting Epidermal Growth Factor Receptor Mutations in Non-Small Cell Lung Cancer. Front Oncol 2017;7:113. [PMID: 28620581 DOI: 10.3389/fonc.2017.00113] [Cited by in Crossref: 31] [Cited by in F6Publishing: 33] [Article Influence: 6.2] [Reference Citation Analysis]
637 Fang S, Wang Z. EGFR mutations as a prognostic and predictive marker in non-small-cell lung cancer. Drug Des Devel Ther 2014;8:1595-611. [PMID: 25302015 DOI: 10.2147/DDDT.S69690] [Cited by in Crossref: 10] [Cited by in F6Publishing: 21] [Article Influence: 1.3] [Reference Citation Analysis]
638 Zhu J, Guan J, Ji X, Song Y, Xu X, Wang Q, Zhang Q, Guo R, Wang R, Zhang R. A two-phase comprehensive NSCLC prognostic study identifies lncRNAs with significant main effect and interaction. Mol Genet Genomics 2022. [PMID: 35218396 DOI: 10.1007/s00438-022-01869-3] [Reference Citation Analysis]
639 Oizumi S, Sugawara S, Minato K, Harada T, Inoue A, Fujita Y, Maemondo M, Watanabe S, Ito K, Gemma A, Demura Y, Fukumoto S, Isobe H, Kinoshita I, Morita S, Kobayashi K, Hagiwara K, Aiba K, Nukiwa T. Updated survival outcomes of NEJ005/TCOG0902: a randomised phase II study of concurrent versus sequential alternating gefitinib and chemotherapy in previously untreated non-small cell lung cancer with sensitive EGFR mutations. ESMO Open 2018;3:e000313. [PMID: 29531840 DOI: 10.1136/esmoopen-2017-000313] [Cited by in Crossref: 21] [Cited by in F6Publishing: 21] [Article Influence: 5.3] [Reference Citation Analysis]
640 Brückl WM, Reck M, Griesinger F, Schäfer H, Kortsik C, Gaska T, Rawluk J, Krüger S, Kokowski K, Budweiser S, Ficker JH, Hoffmann C, Schüler A, Laack E. Afatinib as first-line treatment in patients with EGFR-mutated non-small cell lung cancer in routine clinical practice. Ther Adv Med Oncol 2021;13:17588359211012361. [PMID: 33995597 DOI: 10.1177/17588359211012361] [Reference Citation Analysis]
641 Mountzios G, Lampaki S, Koliou GA, Vozikis A, Kontogiorgos I, Papantoniou P, Koufaki MI, Res E, Boutis A, Christopoulou A, Pastelli N, Grivas A, Aravantinos G, Lalla E, Oikonomopoulos G, Koumarianou A, Spyratos D, Bafaloukos D, Rigakos G, Papakotoulas P, Fountzilas G, Linardou H. An Observational Study to Assess the Molecular Epidemiology and Direct Medical Costs of Epidermal Growth Factor Receptor (EGFR) Mutations in Patients with Advanced EGFR Mutation-Positive Non-Small Cell Lung Cancer Treated with Afatinib in Real-World Clinical Settings in Greece. Lung Cancer (Auckl) 2021;12:93-102. [PMID: 34512058 DOI: 10.2147/LCTT.S318007] [Reference Citation Analysis]
642 Choo JR, Tan CS, Soo RA. Treatment of EGFR T790M-Positive Non-Small Cell Lung Cancer. Target Oncol 2018;13:141-56. [PMID: 29423594 DOI: 10.1007/s11523-018-0554-5] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 3.0] [Reference Citation Analysis]
643 Tu HY, Feng J, Shi M, Zhao J, Wang Y, Chang J, Wang J, Cheng Y, Zhu J, Tan EH, Li K, Zhang Y, Lee V, Yang CT, Su WC, Lam DC, Srinivasa BJ, Rajappa S, Ho CL, Lam KC, Hu Y, Bondarde SA, Liu X, Tian Y, Xue Z, Cseh A, Huang DC, Zhou C, Wu YL. A Phase IIIb Open-Label, Single-Arm Study of Afatinib in EGFR TKI-Naïve Patients with EGFRm+ NSCLC: Final Analysis, with a Focus on Patients Enrolled at Sites in China. Target Oncol 2022. [PMID: 35020119 DOI: 10.1007/s11523-021-00859-6] [Reference Citation Analysis]
644 Hsu PC, Huang CY, Wang CC, Kuo SC, Chu CH, Tung PH, Huang AC, Wang CL, Chiu LC, Fang YF, Yang CT. The Combination of Afatinib and Bevacizumab in Untreated EGFR-Mutated Advanced Lung Adenocarcinoma: A Multicenter Observational Study. Pharmaceuticals (Basel) 2020;13:E331. [PMID: 33113888 DOI: 10.3390/ph13110331] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
645 Yang B, Qin A, Zhang K, Ren H, Liu S, Liu X, Pan X, Yu G. Circulating Tumor Cells Predict Prognosis Following Tyrosine Kinase Inhibitor Treatment in EGFR-Mutant Non-Small Cell Lung Cancer Patients. Oncol Res 2017;25:1601-6. [PMID: 28474575 DOI: 10.3727/096504017X14928634401178] [Cited by in Crossref: 17] [Cited by in F6Publishing: 13] [Article Influence: 3.4] [Reference Citation Analysis]
646 Brat K, Bratova M, Skrickova J, Barinova M, Hurdalkova K, Pesek M, Havel L, Koubkova L, Hrnciarik M, Krejci J, Fischer O, Zemanova M, Coupkova H, Svaton M. Real-life effectiveness of first-line anticancer treatments in stage IIIB/IV NSCLC patients: Data from the Czech TULUNG Registry. Thorac Cancer 2020;11:3346-56. [PMID: 33016001 DOI: 10.1111/1759-7714.13679] [Reference Citation Analysis]
647 Yin ZJ, Tu HY, Fu M, Zhong WZ, An SJ, Yan HH, Chen HJ, Lin HR, Wu YL. Impact of menopausal status and HER-2/neu protein on efficacy of EGFR-TKI in EGFR mutant patients with non-small cell lung cancer. J Cancer 2018;9:2987-93. [PMID: 30210620 DOI: 10.7150/jca.25679] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
648 Ai X, Guo X, Wang J, Stancu AL, Joslin PMN, Zhang D, Zhu S. Targeted therapies for advanced non-small cell lung cancer. Oncotarget 2018;9:37589-607. [PMID: 30680072 DOI: 10.18632/oncotarget.26428] [Cited by in Crossref: 25] [Cited by in F6Publishing: 27] [Article Influence: 6.3] [Reference Citation Analysis]
649 Esteban-Villarrubia J, Soto-Castillo JJ, Pozas J, San Román-Gil M, Orejana-Martín I, Torres-Jiménez J, Carrato A, Alonso-Gordoa T, Molina-Cerrillo J. Tyrosine Kinase Receptors in Oncology. Int J Mol Sci 2020;21:E8529. [PMID: 33198314 DOI: 10.3390/ijms21228529] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
650 Tang N, Zhang Q, Fang S, Han X, Wang Z. Anti-tumor activity of high-dose EGFR tyrosine kinase inhibitor and sequential docetaxel in wild type EGFR non-small cell lung cancer cell nude mouse xenografts. Oncotarget 2017;8:9134-43. [PMID: 27852073 DOI: 10.18632/oncotarget.13327] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
651 Park S, Lee SY, Kim D, Sim YS, Ryu JS, Choi J, Lee SH, Ryu YJ, Lee JH, Chang JH. Comparison of epidermal growth factor receptor tyrosine kinase inhibitors for patients with lung adenocarcinoma harboring different epidermal growth factor receptor mutation types. BMC Cancer 2021;21:52. [PMID: 33430803 DOI: 10.1186/s12885-020-07765-6] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
652 Ding M, Liao H, Zhou N, Yang Y, Guan S, Chen L. B7-H3-Induced Signaling in Lung Adenocarcinoma Cell Lines with Divergent Epidermal Growth Factor Receptor Mutation Patterns. Biomed Res Int 2020;2020:8824805. [PMID: 33426073 DOI: 10.1155/2020/8824805] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
653 Huang WL, Chen YL, Yang SC, Ho CL, Wei F, Wong DT, Su WC, Lin CC. Liquid biopsy genotyping in lung cancer: ready for clinical utility? Oncotarget 2017;8:18590-608. [PMID: 28099915 DOI: 10.18632/oncotarget.14613] [Cited by in Crossref: 36] [Cited by in F6Publishing: 31] [Article Influence: 7.2] [Reference Citation Analysis]
654 Gu J, Xu S, Huang L, Li S, Wu J, Xu J, Feng J, Liu B, Zhou Y. Value of combining serum carcinoembryonic antigen and PET/CT in predicting EGFR mutation in non-small cell lung cancer. J Thorac Dis 2018;10:723-31. [PMID: 29607142 DOI: 10.21037/jtd.2017.12.143] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
655 Xu J, Wu W, Wu C, Mao Y, Qi X, Guo L, Lu R, Xie S, Lou J, Zhang Y, Ding Y, Guo Z, Zhang L, Liang N, Chen P, Zhang C, Tao M, Yu Z, Geng H, Xu M, Shi M, Wang L, Guo W, Zhao J, Li J, Shi L, Zhang Y, Qin Z, Chen J, Liu J, Ren J, Yang Z, Pan X, Lv Z, Dong H, Zhang J, Ou J, Li Z, Kaji K, Wang Y, Wang J, Wang Z. A large-scale, multicentered trial evaluating the sensitivity and specificity of digital PCR versus ARMS-PCR for detecting ctDNA-based EGFR p.T790M in non-small-cell lung cancer patients. Transl Lung Cancer Res 2021;10:3888-901. [PMID: 34858779 DOI: 10.21037/tlcr-21-564] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
656 Peravali M, Wang H, Kim C, Veytsman I. Combined Inhibition of EGFR and VEGF Pathways in Patients with EGFR-Mutated Non-Small Cell Lung Cancer: A Systematic Review and Meta-Analysis. Curr Oncol Rep 2020;22. [DOI: 10.1007/s11912-020-00981-0] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
657 Wu YL, Sequist LV, Hu CP, Feng J, Lu S, Huang Y, Li W, Hou M, Schuler M, Mok T, Yamamoto N, O'Byrne K, Hirsh V, Gibson N, Massey D, Kim M, Yang JC. EGFR mutation detection in circulating cell-free DNA of lung adenocarcinoma patients: analysis of LUX-Lung 3 and 6. Br J Cancer 2017;116:175-85. [PMID: 28006816 DOI: 10.1038/bjc.2016.420] [Cited by in Crossref: 41] [Cited by in F6Publishing: 51] [Article Influence: 6.8] [Reference Citation Analysis]
658 Liang SK, Hsieh MS, Lee MR, Keng LT, Ko JC, Shih JY. Real-world experience of afatinib as a first-line therapy for advanced EGFR mutation-positive lung adenocarcinoma. Oncotarget 2017;8:90430-43. [PMID: 29163842 DOI: 10.18632/oncotarget.19563] [Cited by in Crossref: 37] [Cited by in F6Publishing: 37] [Article Influence: 7.4] [Reference Citation Analysis]
659 Ramlau R, Krawczyk P, Dziadziuszko R, Chmielewska I, Milanowski J, Olszewski W, Stencel K, Ramlau-Piątek K, Segiet A, Skroński M, Grudny J, Chorostowska-Wynimko J. Predictors of EGFR mutation and factors associated with clinical tumor stage at diagnosis: Experience of the INSIGHT study in Poland. Oncol Lett 2017;14:5611-8. [PMID: 29113190 DOI: 10.3892/ol.2017.6907] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 0.4] [Reference Citation Analysis]
660 Singh N. Beyond epidermal growth factor receptor (EGFR) and anaplastic lymphoma kinase (ALK) testing in advanced non-small cell lung cancer: Is the picture as "ROS1" as it appears? Lung India 2017;34:405-8. [PMID: 28869221 DOI: 10.4103/lungindia.lungindia_305_17] [Reference Citation Analysis]
661 Ulivi P, Petracci E, Canale M, Priano I, Capelli L, Calistri D, Chiadini E, Cravero P, Rossi A, Delmonte A, Crinò L, Bronte G. Liquid Biopsy for EGFR Mutation Analysis in Advanced Non-Small-Cell Lung Cancer Patients: Thoughts Drawn from a Real-Life Experience. Biomedicines 2021;9:1299. [PMID: 34680416 DOI: 10.3390/biomedicines9101299] [Reference Citation Analysis]
662 Feng Q, Gai F, Sang Y, Zhang J, Wang P, Wang Y, Liu B, Lin D, Yu Y, Fang J. A comparison of QuantStudio™ 3D Digital PCR and ARMS-PCR for measuring plasma EGFR T790M mutations of NSCLC patients. Cancer Manag Res 2018;10:115-21. [PMID: 29403309 DOI: 10.2147/CMAR.S148134] [Cited by in Crossref: 8] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
663 Laurie SA, Banerji S, Blais N, Brule S, Cheema PK, Cheung P, Daaboul N, Hao D, Hirsh V, Juergens R, Laskin J, Leighl N, MacRae R, Nicholas G, Roberge D, Rothenstein J, Stewart DJ, Tsao MS. Canadian consensus: oligoprogressive, pseudoprogressive, and oligometastatic non-small-cell lung cancer. Curr Oncol. 2019;26:e81-e93. [PMID: 30853813 DOI: 10.3747/co.26.4116] [Cited by in Crossref: 11] [Cited by in F6Publishing: 14] [Article Influence: 3.7] [Reference Citation Analysis]
664 Hochmair M. Medical Treatment Options for Patients with Epidermal Growth Factor Receptor Mutation-Positive Non-Small Cell Lung Cancer Suffering from Brain Metastases and/or Leptomeningeal Disease. Target Oncol 2018;13:269-85. [PMID: 29700687 DOI: 10.1007/s11523-018-0566-1] [Cited by in Crossref: 32] [Cited by in F6Publishing: 30] [Article Influence: 10.7] [Reference Citation Analysis]
665 Satgunaseelan L, Porazinski S, Strbenac D, Istadi A, Willet C, Chew T, Sadsad R, Palme CE, Lee JH, Boyer M, Yang JYH, Clark JR, Pajic M, Gupta R. Oral Squamous Cell Carcinoma in Young Patients Show Higher Rates of EGFR Amplification: Implications for Novel Personalized Therapy. Front Oncol 2021;11:750852. [PMID: 34912708 DOI: 10.3389/fonc.2021.750852] [Reference Citation Analysis]
666 Arrieta O, Anaya P, Morales-Oyarvide V, Ramírez-Tirado LA, Polanco AC. Cost-effectiveness analysis of EGFR mutation testing in patients with non-small cell lung cancer (NSCLC) with gefitinib or carboplatin-paclitaxel. Eur J Health Econ 2016;17:855-63. [PMID: 26338546 DOI: 10.1007/s10198-015-0726-5] [Cited by in Crossref: 16] [Cited by in F6Publishing: 14] [Article Influence: 2.3] [Reference Citation Analysis]
667 Takahashi S, Noro R, Seike M, Zeng C, Matsumoto M, Yoshikawa A, Nakamichi S, Sugano T, Hirao M, Matsuda K, Hamada M, Gemma A. Long Non-Coding RNA CRNDE Is Involved in Resistance to EGFR Tyrosine Kinase Inhibitor in EGFR-Mutant Lung Cancer via eIF4A3/MUC1/EGFR Signaling. Int J Mol Sci 2021;22:4005. [PMID: 33924522 DOI: 10.3390/ijms22084005] [Reference Citation Analysis]
668 Abughanimeh O, Kaur A, Osta BE, Ganti AK. Novel targeted therapies for advanced non-small lung cancer. Seminars in Oncology 2022. [DOI: 10.1053/j.seminoncol.2022.03.003] [Reference Citation Analysis]
669 Xu M, Xie Y, Ni S, Liu H. The latest therapeutic strategies after resistance to first generation epidermal growth factor receptor tyrosine kinase inhibitors (EGFR TKIs) in patients with non-small cell lung cancer (NSCLC). Ann Transl Med 2015;3:96. [PMID: 26015938 DOI: 10.3978/j.issn.2305-5839.2015.03.60] [Cited by in F6Publishing: 14] [Reference Citation Analysis]
670 Wu C, Song W, Wang Z, Wang B. Functions of lncRNA DUXAP8 in non-small cell lung cancer. Mol Biol Rep 2022. [PMID: 35031926 DOI: 10.1007/s11033-021-07066-6] [Reference Citation Analysis]
671 Hu X, Li H, Kang X, Wang X, Pang H, Liu C, Zhang J, Wang Y. First-Line Tyrosine Kinase Inhibitors Combined With Local Consolidative Radiation Therapy for Elderly Patients With Oligometastatic Non-Small Cell Lung Cancer Harboring EGFR Activating Mutations. Front Oncol 2022;12:766066. [DOI: 10.3389/fonc.2022.766066] [Reference Citation Analysis]
672 Chang CH, Lee CH, Ko JC, Chang LY, Lee MC, Zhang JF, Wang JY, Shih JY, Yu CJ. Effect of β-Blocker in Treatment-Naïve Patients With Advanced Lung Adenocarcinoma Receiving First-Generation EGFR-TKIs. Front Oncol 2020;10:583529. [PMID: 33194721 DOI: 10.3389/fonc.2020.583529] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
673 Zhao Y, Liu J, Cai X, Pan Z, Liu J, Yin W, Chen H, Xie Z, Liang H, Wang W, Guo Z, Zhao S, Liang W, He J. Efficacy and safety of first line treatments for patients with advanced epidermal growth factor receptor mutated, non-small cell lung cancer: systematic review and network meta-analysis. BMJ 2019;367:l5460. [PMID: 31591158 DOI: 10.1136/bmj.l5460] [Cited by in Crossref: 33] [Cited by in F6Publishing: 35] [Article Influence: 11.0] [Reference Citation Analysis]
674 Kaneda T, Yoshioka H, Tamiya M, Tamiya A, Hata A, Okada A, Niwa T, Shiroyama T, Kanazu M, Ishida T, Katakami N. Differential efficacy of cisplatin plus pemetrexed between L858R and Del-19 in advanced EGFR-mutant non-squamous non-small cell lung cancer. BMC Cancer 2018;18:6. [PMID: 29291705 DOI: 10.1186/s12885-017-3952-7] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 1.3] [Reference Citation Analysis]
675 Berghmans T, Evison M, Blum TG, Peled N, Cadranel J. New drugs in thoracic oncology: needs and knowledge - an online ERS Lung Cancer Assembly survey. ERJ Open Res 2018;4:00040-2018. [PMID: 30186846 DOI: 10.1183/23120541.00040-2018] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
676 Yamaoka T, Kusumoto S, Ando K, Ohba M, Ohmori T. Receptor Tyrosine Kinase-Targeted Cancer Therapy. Int J Mol Sci 2018;19:E3491. [PMID: 30404198 DOI: 10.3390/ijms19113491] [Cited by in Crossref: 75] [Cited by in F6Publishing: 66] [Article Influence: 18.8] [Reference Citation Analysis]
677 Liu H, Zhang B, Sun Z. Spectrum of EGFR aberrations and potential clinical implications: insights from integrative pan-cancer analysis. Cancer Commun (Lond) 2020;40:43-59. [PMID: 32067422 DOI: 10.1002/cac2.12005] [Cited by in Crossref: 10] [Cited by in F6Publishing: 12] [Article Influence: 5.0] [Reference Citation Analysis]
678 Romanidou O, Landi L, Cappuzzo F, Califano R. Overcoming resistance to first/second generation epidermal growth factor receptor tyrosine kinase inhibitors and ALK inhibitors in oncogene-addicted advanced non-small cell lung cancer. Ther Adv Med Oncol 2016;8:176-87. [PMID: 27239236 DOI: 10.1177/1758834016631531] [Cited by in Crossref: 16] [Cited by in F6Publishing: 19] [Article Influence: 2.7] [Reference Citation Analysis]
679 Carlson JJ, Suh K, Orfanos P, Wong W. Cost Effectiveness of Alectinib vs. Crizotinib in First-Line Anaplastic Lymphoma Kinase-Positive Advanced Non-Small-Cell Lung Cancer. Pharmacoeconomics 2018;36:495-504. [PMID: 29488070 DOI: 10.1007/s40273-018-0625-6] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 4.7] [Reference Citation Analysis]
680 Zhu Y, Du Y, Liu H, Ma T, Shen Y, Pan Y. Study of efficacy and safety of pulsatile administration of high-dose gefitinib or erlotinib for advanced non-small cell lung cancer patients with secondary drug resistance: A single center, single arm, phase II clinical trial. Thorac Cancer. 2016;7:663-669. [PMID: 27755796 DOI: 10.1111/1759-7714.12384] [Cited by in Crossref: 17] [Cited by in F6Publishing: 17] [Article Influence: 2.8] [Reference Citation Analysis]
681 Minegishi Y, Yamaguchi O, Sugawara S, Kuyama S, Watanabe S, Usui K, Mori M, Hataji O, Nukiwa T, Morita S, Kobayashi K, Gemma A. A phase II study of first-line afatinib for patients aged ≥75 years with EGFR mutation-positive advanced non-small cell lung cancer: North East Japan Study Group trial NEJ027. BMC Cancer 2021;21:208. [PMID: 33648453 DOI: 10.1186/s12885-021-07861-1] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
682 Jorge SE, Kobayashi SS, Costa DB. Epidermal growth factor receptor (EGFR) mutations in lung cancer: preclinical and clinical data. Braz J Med Biol Res 2014;47:929-39. [PMID: 25296354 [PMID: 25296354 DOI: 10.1590/1414-431x20144099] [Cited by in Crossref: 56] [Cited by in F6Publishing: 1] [Article Influence: 7.0] [Reference Citation Analysis]
683 Vestergaard HH, Christensen MR, Lassen UN. A systematic review of targeted agents for non-small cell lung cancer. Acta Oncol 2018;57:176-86. [PMID: 29172833 DOI: 10.1080/0284186X.2017.1404634] [Cited by in Crossref: 28] [Cited by in F6Publishing: 21] [Article Influence: 7.0] [Reference Citation Analysis]
684 Hess LM, Brnabic A, Mason O, Lee P, Barker S. Relationship between Progression-free Survival and Overall Survival in Randomized Clinical Trials of Targeted and Biologic Agents in Oncology. J Cancer 2019;10:3717-27. [PMID: 31333789 DOI: 10.7150/jca.32205] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 3.7] [Reference Citation Analysis]
685 Pender A, Popat S. Understanding lung cancer molecular subtypes. Clinical Practice 2014;11:441-53. [DOI: 10.2217/cpr.14.39] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
686 Li W, Qu J, Xu Z. Clinical features and mutation status of EGFR, KRAS, BRAF, EML4-ALK and ROS1 between surgical resection samples and non surgical resection samples in lung cancer. J Thorac Dis. 2015;7:875-880. [PMID: 26101643 DOI: 10.3978/j.issn.2072-1439.2015.04.49] [Cited by in F6Publishing: 6] [Reference Citation Analysis]
687 Kaliks RA. An update on clinical oncology for the non-oncologist. Einstein (Sao Paulo) 2016;14:294-9. [PMID: 27462901 DOI: 10.1590/S1679-45082016MD3550] [Reference Citation Analysis]
688 Lin JZ, Ma SK, Wu SX, Yu SH, Li XY. A network meta-analysis of nonsmall-cell lung cancer patients with an activating EGFR mutation: Should osimertinib be the first-line treatment? Medicine (Baltimore) 2018;97:e11569. [PMID: 30045282 DOI: 10.1097/MD.0000000000011569] [Cited by in Crossref: 14] [Cited by in F6Publishing: 6] [Article Influence: 3.5] [Reference Citation Analysis]
689 Hayama M, Suzuki H, Shiroyama T, Tamiya M, Okamoto N, Tanaka A, Morishita N, Nishida T, Nishihara T, Hirashima T. Chemotherapy for patients with advanced lung cancer receiving long-term oxygen therapy. J Thorac Dis 2016;8:116-23. [PMID: 26904219 DOI: 10.3978/j.issn.2072-1439.2016.01.42] [Reference Citation Analysis]
690 Tong X, Tanino R, Sun R, Tsubata Y, Okimoto T, Takechi M, Isobe T. Protein tyrosine kinase 2: a novel therapeutic target to overcome acquired EGFR-TKI resistance in non-small cell lung cancer. Respir Res 2019;20:270. [PMID: 31791326 DOI: 10.1186/s12931-019-1244-2] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
691 Smolle E, Taucher V, Lindenmann J, Pichler M, Smolle-Juettner FM. Liquid biopsy in non-small cell lung cancer-current status and future outlook-a narrative review. Transl Lung Cancer Res 2021;10:2237-51. [PMID: 34164273 DOI: 10.21037/tlcr-21-3] [Reference Citation Analysis]
692 Yonesaka K, Kudo K, Nishida S, Takahama T, Iwasa T, Yoshida T, Tanaka K, Takeda M, Kaneda H, Okamoto I, Nishio K, Nakagawa K. The pan-HER family tyrosine kinase inhibitor afatinib overcomes HER3 ligand heregulin-mediated resistance to EGFR inhibitors in non-small cell lung cancer. Oncotarget 2015;6:33602-11. [PMID: 26418897 DOI: 10.18632/oncotarget.5286] [Cited by in Crossref: 34] [Cited by in F6Publishing: 27] [Article Influence: 5.7] [Reference Citation Analysis]
693 Solomon BJ, Loong HH, Summers Y, Thomas ZM, French P, Lin BK, Sashegyi A, Wolf J, Yang JC, Drilon A. Correlation between treatment effects on response rate and progression-free survival and overall survival in trials of targeted therapies in molecularly enriched populations. ESMO Open 2022;7:100398. [PMID: 35183043 DOI: 10.1016/j.esmoop.2022.100398] [Reference Citation Analysis]
694 Ono T, Igawa S, Ozawa T, Kasajima M, Ishihara M, Hiyoshi Y, Kusuhara S, Nishinarita N, Fukui T, Kubota M, Sasaki J, Hisashi M, Katagiri M, Naoki K. Evaluation of osimertinib efficacy according to body surface area and body mass index in patients with non-small cell lung cancer harboring an EGFR mutation: A prospective observational study. Thorac Cancer 2019;10:880-9. [PMID: 30821083 DOI: 10.1111/1759-7714.13018] [Cited by in Crossref: 6] [Cited by in F6Publishing: 8] [Article Influence: 2.0] [Reference Citation Analysis]
695 Yamada Y, Imai H, Sugiyama T, Minemura H, Kanazawa K, Kasai T, Minato K, Kaira K, Kaburagi T. Effectiveness and Safety of EGFR-TKI Rechallenge Treatment in Elderly Patients with Advanced Non-Small-Cell Lung Cancer Harboring Drug-Sensitive EGFR Mutations. Medicina (Kaunas) 2021;57:929. [PMID: 34577852 DOI: 10.3390/medicina57090929] [Reference Citation Analysis]
696 Boolell V, Alamgeer M, Watkins DN, Ganju V. The Evolution of Therapies in Non-Small Cell Lung Cancer. Cancers (Basel) 2015;7:1815-46. [PMID: 26371045 DOI: 10.3390/cancers7030864] [Reference Citation Analysis]
697 Yokota H, Sato K, Sakamoto S, Okuda Y, Asano M, Takeda M, Nakayama K, Miura M. Relationship between Plasma Concentrations of Afatinib and the Onset of Diarrhea in Patients with Non-Small Cell Lung Cancer. Biology (Basel) 2021;10:1054. [PMID: 34681153 DOI: 10.3390/biology10101054] [Reference Citation Analysis]
698 Zhang J, Zhang Y, Tang S, Jiang L, He Q, Hamblin LT, He J, Xu Z, Wu J, Chen Y, Liang H, Chen D, Huang Y, Wang X, Deng K, Jiang S, Zhou J, Xu J, Chen X, Liang W, He J. Systematic bias between blinded independent central review and local assessment: literature review and analyses of 76 phase III randomised controlled trials in 45 688 patients with advanced solid tumour. BMJ Open 2018;8:e017240. [PMID: 30206071 DOI: 10.1136/bmjopen-2017-017240] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 2.8] [Reference Citation Analysis]
699 Wu SG, Shih JY. Management of acquired resistance to EGFR TKI-targeted therapy in advanced non-small cell lung cancer. Mol Cancer. 2018;17:38. [PMID: 29455650 DOI: 10.1186/s12943-018-0777-1] [Cited by in Crossref: 154] [Cited by in F6Publishing: 178] [Article Influence: 38.5] [Reference Citation Analysis]
700 Zhu YC, Xu CW, Ye XQ, Yin MX, Zhang JX, Du KQ, Zhang ZH, Hu J. Lung cancer with concurrent EGFR mutation and ROS1 rearrangement: a case report and review of the literature. Onco Targets Ther. 2016;9:4301-4305. [PMID: 27486332 DOI: 10.2147/ott.s109415] [Cited by in Crossref: 13] [Cited by in F6Publishing: 8] [Article Influence: 2.2] [Reference Citation Analysis]
701 Ohe Y, Imamura F, Nogami N, Okamoto I, Kurata T, Kato T, Sugawara S, Ramalingam SS, Uchida H, Hodge R, Vowler SL, Walding A, Nakagawa K. Osimertinib versus standard-of-care EGFR-TKI as first-line treatment for EGFRm advanced NSCLC: FLAURA Japanese subset. Jpn J Clin Oncol 2019;49:29-36. [PMID: 30508196 DOI: 10.1093/jjco/hyy179] [Cited by in Crossref: 41] [Cited by in F6Publishing: 38] [Article Influence: 13.7] [Reference Citation Analysis]
702 Nakao K, Kobuchi S, Marutani S, Iwazaki A, Tamiya A, Isa S, Okishio K, Kanazu M, Tamiya M, Hirashima T, Imai K, Sakaeda T, Atagi S. Population pharmacokinetics of afatinib and exposure-safety relationships in Japanese patients with EGFR mutation-positive non-small cell lung cancer. Sci Rep 2019;9:18202. [PMID: 31796841 DOI: 10.1038/s41598-019-54804-9] [Cited by in Crossref: 9] [Cited by in F6Publishing: 5] [Article Influence: 3.0] [Reference Citation Analysis]
703 Zhou Q, Yang JJ, Chen ZH, Zhang XC, Yan HH, Xu CR, Su J, Chen HJ, Tu HY, Zhong WZ, Yang XN, Wu YL. Serial cfDNA assessment of response and resistance to EGFR-TKI for patients with EGFR-L858R mutant lung cancer from a prospective clinical trial. J Hematol Oncol 2016;9:86. [PMID: 27619632 DOI: 10.1186/s13045-016-0316-8] [Cited by in Crossref: 20] [Cited by in F6Publishing: 29] [Article Influence: 3.3] [Reference Citation Analysis]
704 Heigener DF, Schumann C, Sebastian M, Sadjadian P, Stehle I, Märten A, Lüers A, Griesinger F, Scheffler M; Afatinib Compassionate Use Consortium (ACUC). Afatinib in Non-Small Cell Lung Cancer Harboring Uncommon EGFR Mutations Pretreated With Reversible EGFR Inhibitors. Oncologist 2015;20:1167-74. [PMID: 26354527 DOI: 10.1634/theoncologist.2015-0073] [Cited by in Crossref: 33] [Cited by in F6Publishing: 39] [Article Influence: 4.7] [Reference Citation Analysis]
705 Liang XM, Qin Q, Liu BN, Li XQ, Zeng LL, Wang J, Kong LP, Zhong DS, Sun LL. Targeting DNA-PK overcomes acquired resistance to third-generation EGFR-TKI osimertinib in non-small-cell lung cancer. Acta Pharmacol Sin 2021;42:648-54. [PMID: 33414509 DOI: 10.1038/s41401-020-00577-1] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
706 Hung MS, Fang YH, Lin YC, Lung JH, Hsieh MJ, Tsai YH. Survival-associated factors of first-line EGFR-tyrosine kinase inhibitor responders and non-responders in lung adenocarcinoma patients with common EGFR mutations. Mol Clin Oncol 2018;8:421-8. [PMID: 29456848 DOI: 10.3892/mco.2018.1550] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
707 Chinese Society of Lung Cancer, Chinese Anti-Cancer Association. [EGFR-TKI ADR Management Chinese Expert Consensus]. Zhongguo Fei Ai Za Zhi 2019;22:57-81. [PMID: